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The  success  of  gene  medicine  ultimately  depends  on  the  efficient  intracellular  
delivery  and  sustained  expression  of  nucleic  acid  therapeutics,  yet  nonviral  gene  
delivery  performed  with  cationic  polymer  carriers  has  been  chronically  hindered  by  the  
slow  release  of  nucleic  acid  payloads  at  their  targets,  as  well  as  the  transient  nature  of  
exogenous  transgene  expression.  Polymer-­‐‑nucleic  acid  nanocomplexes  prepared  with  
passive  gene  carriers  using  traditional  bulk  methods  have  proven  inadequate  for  most  
translational  applications.  The  objective  of  this  work  is  to  improve  nonviral  gene  transfer  
through  the  selection,  formulation,  and  application  of  improved  nanoparticulate  
delivery  systems.    
After  screening  a  number  of  number  of  cationic  polymer  delivery  vectors  
ranging  from  natural  to  synthetic,  high  molecular  weight  to  low,  binary  and  ternary,  we  
identified  a  bioreducible  linear  poly(amido  amine)  able  to  give  sustained,  robust  
expression  of  both  DNA  and  RNA  through  serial  dosing.  We  next  turned  our  attention  
to  the  process  of  nanocomplex  assembly.  Traditional  assembly  via  bulk  mixing  is  poorly  
controlled,  and  the  poor  quality  of  these  nanocomplexes  is  a  significant  impediment  to  
the  establishment  of  robust  structure-­‐‑function  relationships  and  the  advancement  of  
efficacious  nonviral  gene  delivery.  So,  we  developed  an  emulsion-­‐‑based  microfluidic  
nanomanufacturing  platform  to  better  control  the  self-­‐‑assembly  process,  and  thus  the  
physical  properties  of  nanocomplexes.  Confined  mixing  within  picoliter  droplets  
  v  
generates  self-­‐‑assembled  nanocomplexes  that  are  more  uniform  and  more  effective.  This  
microfluidic  nanomanufacturing  approach  possesses  broad  utility  in  the  production  of  
polymer-­‐‑nucleic  acid  nanocomplexes;  we  demonstrated  that  its  benefits  extend  to  
multiple  gene  carriers,  a  range  of  nucleic  acid  payloads,  and  translationally  relevant  cell  
types.  Then,  we  applied  the  improved  nanomanufactured  particles  to  begin  to  address  
an  unmet  clinical  need,  namely  the  lack  of  a  safe  and  ethical  source  of  cells  to  treat  
neurodegenerative  diseases.  Nonviral  cellular  reprogramming  strategies  eliminate  the  
integration  of  viral  DNA  sequences  and  represent  a  potentially  safer  alternative  to  viral  
transdifferentiation  methods  to  generate  therapeutic  cells.  Using  nanomanufactured  
polymer-­‐‑nucleic  acid  nanocomplexes,  we  improved  the  efficiency  of  nonviral  cellular  
reprogramming  of  fibroblasts  directly  to  functional  induced  neuronal  cells.    
Nonviral  gene  therapy  will  continue  to  demand  more  sophisticated  delivery  
systems  to  continue  to  progress.  Microfluidic  nanomanufacturing  represents  a  
reproducible  and  scalable  platform  to  synthesize  more  uniform  nanocomplexes  that  not  
only  improves  their  performance  but  may  also  help  establish  clearer  structure-­‐‑function  
relationships  that  will  inform  future  carrier  design.  Complementing  the  innovative  
chemical  and  biological  approaches  to  create  multifunctional  nanoparticles,  this  study  
indicates  that  microfluidic  nanomanufacturing  can  serve  as  a  parallel  physical  strategy  
to  both  optimize  the  properties  of  polymer-­‐‑nucleic  acid  nanocomplexes  and  improve  
their  performance  in  applications  with  important  clinical  implications.  
  vi  
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1. Introduction  
As  advances  in  genomics  continue  to  expand  the  range  of  targets  for  therapeutic  
intervention,  nucleic  acid-­‐‑based  technologies  are  poised  to  play  a  more  prominent  role  
in  the  treatment  of  many  inherited  and  acquired  diseases.  One  approach  to  their  
delivery  has  been  to  use  polymers  to  condense  nucleic  acids  into  nanocomplexes,  
facilitating  cellular  uptake  and  preventing  degradation  en  route  to  target  cells.  However,  
engineering  polymeric  gene  delivery  vectors  to  release  an  intact  nucleic  acid  payload  at  
the  optimal  time  and  place  remains  a  formidable  challenge.  An  ideal  vector  would  
provide  total  protection  of  complexed  cargo  from  degradation  prior  to  releasing  it  
efficiently  near  or  within  the  nucleus  of  a  target  cell.  While  optimization  of  polymer  
properties,  such  as  molecular  weight  and  charge  density,  has  proven  largely  inadequate  
in  addressing  this  challenge,  applying  polymeric  carriers  that  respond  to  temperature,  
light,  pH,  and  redox  environment  to  trigger  a  switch  from  a  tight,  protective  complex  to  
a  more  relaxed  interaction  favoring  release  at  the  appropriate  time  and  place  has  shown  
promise.  After  screening  a  number  of  polymer  delivery  systems  ranging  from  natural  to  
synthetic,  high  molecular  weight  to  low,  binary  and  ternary,  we  identified  a  bioreducible  
linear  poly(amido  amine)  able  to  give  sustained,  robust  expression  of  both  DNA  and  
RNA  through  serial  dosing.  This  work  strives,  through  optimization  of  this  carrier’s  
formulation  and  application,  to  alleviate  the  paucity  of  uniform,  potent,  biocompatible,  
and  reproducibly  generated  gene  carriers  that  are  able  to  satisfy  the  contrary  
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requirements  of  adequate  protection  and  efficient  release,  in  order  to  achieve  the  
primary  goal  of  sustainable  and  robust  transgene  expression.  
While  tremendous  effort  has  been  concentrated  on  carrier  design  and  
optimization,  the  process  of  nanocomplex  assembly  has  been  largely  overlooked.  
Traditional  assembly  via  bulk  mixing  (i.e.  vortex  mixing),  while  convenient,  is  poorly  
controlled  and  results  in  metastable  preparations,  variable  nanocomplex  properties,  and  
inconsistent  results.  The  poor  quality  of  these  nanocomplexes  is  a  significant  
impediment  to  both  the  establishment  of  robust  structure-­‐‑function  relationships  and  the  
translation  of  nonviral  gene  delivery.  So,  we  developed  an  emulsion-­‐‑based  microfluidic  
nanomanufacturing  platform  to  better  control  the  self-­‐‑assembly  process,  and  thus  the  
physical  properties  of  nanocomplexes,  through  confinement  of  the  complexation  
reaction  to  picoliter  droplets.  Confined  mixing  within  droplets  enables  the  charge  
neutralization  between  polyelectrolytes  to  reach  equilibrium,  thereby  generating  self-­‐‑
assembled  nanocomplexes  that  are  more  uniform  and  more  effective.  Nanocomplexes  
produced  by  this  nanomanufacturing  approach  were  smaller,  more  monodispersed,  
lower  in  zeta  potential,  and  more  colloidally  stable  compared  to  their  bulk-­‐‑assembled  
counterparts.  The  amount  of  unreacted  polymer  remaining  following  assembly  was  
reduced,  contributing  to  diminished  cytotoxicity.  Most  importantly,  the  improved  
nanoparticles  consistently  mediated  improved  transfection.  We  applied  a  quantum  dot-­‐‑
FRET  nanosensor  paired  with  flow  cytometric  detection  to  ascribe  the  increased  
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transfection  efficiency  to  specific  changes  in  intracellular  behavior,  such  as  uptake  and  
intracellular  release.  This  microfluidic  nanomanufacturing  approach  possesses  broad  
utility  in  the  production  of  polymer-­‐‑nucleic  acid  nanocomplexes;  we  demonstrated  that  
its  benefits  extend  to  custom  gene  carriers,  a  range  of  nucleic  acid  payloads,  and  
multiple  translationally  relevant  cell  types.    
The  increased  transfection  efficiency  and  diminished  toxicity  of  
nanomanufactured  particles  are  especially  advantageous  in  applications  requiring  high  
levels  of  transgene  expression  and  repeated  administration.  One  such  application  is  the  
nonviral  direct  cellular  reprogramming  of  fibroblasts  to  neurons.  In  an  effort  to  address  
the  lack  of  a  safe  and  ethical  source  of  therapeutic  cells  to  treat  neurodegenerative  
diseases,  we  developed  a  nonviral  transfection  strategy  to  deliver  genes  encoding  the  
transcription  factors  necessary  to  convert  fibroblasts  directly  to  functional  neuronal  cells.  
Nonviral  cellular  reprogramming  strategies  eliminate  the  integration  of  viral  DNA  
sequences  and  represent  a  potentially  safer  alternative  to  viral  transdifferentiation  
methods.  Our  method  produced  neuronal  cells  with  appropriate  morphological  
changes,  activation  and  expression  of  endogenous  neuronal  markers,  and  
electrophysiological  function.  Delivery  of  the  reprogramming  factors  with  microfluidic  
nanomanufactured  particles  significantly  improved  the  efficiency  of  this  nonviral  
neuronal  transdifferentiation,  which  is  a  critical  parameter  in  the  effort  to  generate  a  
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sufficient  supply  cells  for  potential  transplantation  given  the  postmitotic,  non-­‐‑
proliferative  nature  of  neurons.  
The  overall  objective  of  this  work  is  to  improve  nonviral  gene  delivery  through  
the  production  of  polymer-­‐‑nucleic  acid  nanocomplexes  using  advanced  bioprocessing  
and  nanomanufacturing  techniques.  This  dissertation  describes  efforts  to  extend,  
evaluate,  and  apply  a  reliable  and  scalable  microfluidic  platform  to  manufacture  
polymer-­‐‑nucleic  acid  nanocomplexes  with  better-­‐‑controlled  characteristics  and  
improved  functional  performance.  Through  the  results  described  here,  we  have  
contributed  to  the  improvement  of  nonviral  gene  transfer  and  cellular  reprogramming  
by:  1)  selecting  and  synthesizing  a  promising  polymeric  gene  carrier  while  optimizing  
its  delivery  strategy  to  facilitate  serial  dosing  without  compounding  cytotoxicity,  2)  
implementing  emulsion-­‐‑based  microfluidic  nanomanufacturing  techniques  to  improve  
the  physicochemical  characteristics  and  functional  performance  of  the  chosen  
nanoparticles,  and  3)  applying  these  more  potent  nanoparticles  to  increase  the  efficiency  
of  nonviral  cellular  reprogramming  of  fibroblasts  to  functional  induced  neurons.  
Ultimately,  efficacious  nonviral  gene  delivery  will  depend  on  the  combination  of  
intelligent  material  design,  controlled  nanomanufacturing,  innovative  imaging  
techniques,  and  sophisticated  model  systems  to  enable  the  rational  design  and  
advancement  of  polymeric  gene  delivery  systems.  We  addressed  each  of  these  
considerations  through  the  following  specific  aims.  
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1.1 Specific Aim 1 
Screen,  select,  and  synthesize  a  promising  polymeric  gene  carrier  while  
optimizing  its  delivery  scheme  to  facilitate  serial  dosing  without  compounding  
cytotoxicity.  In  this  aim,  we  identified  a  polymer  gene  carrier  with  an  inherent  response  
mechanism  to  changes  in  the  redox  environment  present  in  the  cytoplasm  of  cells.  This  
carrier  is  designed  to  release  its  payload  efficiently  within  cells,  and  then  degrade  to  
minimize  associated  sequelae.  Employing  this  carrier  enabled  us  to  optimize  and  adopt  
serial  dosing  schemes  to  achieve  consistently  high  transgene  expression  levels  without  
compounding  toxicity.    
Hypothesis  1:  By  synthesizing,  screening,  and  selecting  a  responsive  polymeric  gene  
carrier  that  mediates  very  high  transfection  levels  through  the  efficient  release  of  nucleic  acids,  we  
can  deliver  serial  doses  to  mitigate  the  problem  of  transient  expression,  without  prohibitive  
limitations  arising  from  compounding  cytotoxicity.    
1.2 Specific Aim 2  
Develop  and  evaluate  the  benefits  of  microfluidic  nanomanufacturing  with  
select  gene  carrier  systems,  nucleic  acid  payloads,  and  translationally  relevant  cell  
types  to  achieve  improved  nanoparticle  physicochemical  properties  and  functional  
performance.  In  this  aim,  we  proved  the  feasibility  of  improved  nanocomplex  
preparation  using  a  microfluidic  nanomanufacturing  approach  with  multiple  gene  
carriers  loaded  with  either  plasmid  DNA  or  messenger  RNA  payloads.  We  
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characterized  the  physical  and  chemical  properties  of  these  nanomanufactured  products  
and  quantified  their  intracellular  release  using  a  quantum  dot-­‐‑FRET  flow  cytometric  
detection  system.  We  also  tested  the  transfection  capabilities  of  the  improved  particles  in  
primary  cells,  stem  cells,  and  other  difficult-­‐‑to-­‐‑transfect  cell  types.    
Hypothesis  2:  Nanomanufactured  nanoparticles  composed  of  custom  polymeric  gene  
carriers  and  diverse  nucleic  acids  exhibit  consistent  improvements  in  physical  properties  when  
compared  to  their  counterparts  produced  by  conventional  bulk  methods.  These  changes  lead  to  
differences  in  intracellular  release  and  improved  functional  performance,  including  superior  
transfection,  in  a  variety  of  cell  types.    
1.3 Specific Aim 3 
Apply  nanomanufactured  particles  to  increase  the  efficiency  of  nonviral  direct  
cellular  reprogramming  of  fibroblasts  to  functional  induced  neurons.  In  the  final  aim,  
we  applied  the  microfluidic  nanomanufactured  particles  to  improve  nonviral  direct  
cellular  reprogramming.  We  delivered  the  three  transcription  factor  genes  required  to  
directly  convert  fibroblasts  to  functional  induced  neurons,  demonstrating  that  such  
conversion  is  feasible  without  the  use  of  viral  delivery  methods.  The  serial  dosing  
approach  derived  from  Specific  Aim  1,  when  paired  with  the  more-­‐‑potent  microfluidic  
nanomanufactured  particles  derived  from  Specific  Aim  2,  enabled  the  generation  of  
functional  induced  neurons  with  greater  efficiency.    
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Hypothesis  3:  The  increased  transfection  efficiency  and  diminished  toxicity  of  
nanomanufactured  particles  translates  to  an  increase  in  the  cellular  reprogramming  efficiency  of  
fibroblasts  directly  to  functional  neuronal  cells.  
  
  
Figure  1.  Summary  of  Specific  Aims  
To  improve  nonviral  gene  transfer  and  cellular  reprogramming,  we  optimized  the  
formulation  of  a  bioresponsive  polymeric  gene  carrier,  implemented  a  microfluidic  
nanomanufacturing  approach  to  further  improve  the  form  and  function  of  these  
nanoparticles,  and  applied  them  to  enhance  nonviral  direct  cellular  reprogramming.  
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2. Background and Motivation 
  
Some  of  the  material  in  Chapter  2  is  included  in:    
1)  Balancing  protection  and  release  of  DNA:  tools  to  address  a  bottleneck  of  non-­‐‑
viral  gene  delivery.  Grigsby  CL  and  Leong  KW.  2010.  J  R  Soc  Interface.  7  Suppl  1:S67-­‐‑82  
2)  Understanding  nonviral  nucleic  acid  delivery  with  quantum  dot-­‐‑FRET  
nanosensors.  Grigsby  CL,  Ho  YP,  Leong  KW.  2012.  Nanomedicine.  7(4):565-­‐‑77  
  
Gene  therapy  has  the  potential  to  treat  a  wide  variety  of  inherited  and  acquired  
genetic  disorders,  including  diabetes,  cystic  fibrosis,  cancer,  and  hemophilia  [1-­‐‑3].  The  
theoretical  simplicity  of  the  technique,  along  with  the  sequencing  of  the  human  genome,  
gave  rise  to  the  field  amidst  considerable  excitement  in  the  1990’s  [4].  To  treat  diseases  
caused  by  a  missing  or  aberrant  protein,  DNA  encoding  the  desired  gene  is  introduced  
to  the  nucleus  of  a  cell  where  it  is  subsequently  processed  into  a  functional  protein.  In  
practice,  however,  this  has  proven  much  more  difficult  than  predicted.  The  lack  of  safe  
and  effective  gene  delivery  methods  has  hindered  the  clinical  translation  of  gene  
therapy.  Many  potential  barriers  exist  along  the  path  from  the  laboratory  bench  to  the  
nucleus  of  a  cell.  First,  the  DNA  must  reach  the  plasma  membrane  of  a  target  cell  and  be  
taken  up.  The  path  to  target  cells  is  nontrivial,  as  the  extracellular  environment  contains  
many  molecules  able  to  trap  and  degrade  DNA.  Once  inside  the  cell,  the  DNA  
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encounters  a  harsh  enzymatic  environment  that  promotes  its  degradation.  In  most  cases,  
the  administration  of  naked  DNA  results  in  insufficient  amounts  of  intact  coding  
sequence  reaching  the  nucleus.  In  an  effort  to  increase  the  amount  of  intact  DNA  
reaching  the  nucleus,  various  techniques  have  been  used  with  mixed  degrees  of  success.  
Poration  of  the  plasma  membrane  has  been  accomplished  using  electrical  and  
mechanical  means  such  as  electroporation,  ultrasound-­‐‑based  sonoporation,  and  the  gene  
gun.  However,  for  reasons  of  low  efficacy,  tissue  damage,  or  poor  access  to  deep  tissue,  
these  methods  face  significant  barriers  to  translation  in  vivo.  The  bulk  of  current  
research  is  focused  on  the  use  of  vectors  designed  to  package  and  protect  a  DNA  
payload  for  delivery  into  the  cell.  Vectors  commonly  used  today  range  from  virus  to  
lipids,  peptides,  and  polymers.  
The  majority  of  gene  therapy  clinical  trials  have  relied  on  viral  vectors  for  gene  
transduction  due  to  their  high  efficiency.  However,  the  high  transfection  efficiency  of  
viral  vectors  comes  at  a  cost.  Viral  vectors  pose  safety  concerns  stemming  from  their  
immunogenicity  and  toxicity.  Limitations  of  cell  mitosis  for  retrovirus,  contamination  of  
adenovirus,  and  packaging  constraints  of  adeno-­‐‑associated  virus  (AAV)  also  lessen  their  
appeal.  Nonviral  vectors  composed  of  cationic  polymers,  lipids,  and  peptides  able  to  
form  ionic  complexes  with  DNA  currently  achieve  lower  and  transient  transgene  
expression  levels,  but  possess  the  potential  advantages  of  unrestricted  DNA  cargo  size,  
ease  of  synthesis,  low  immunogenicity,  and  potential  for  repeated  administration.  They  
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can  also  address  many  pharmaceutical  considerations  better  than  viral  vectors,  such  as  
scale-­‐‑up,  storage  stability,  and  quality  control.  Still,  nonviral  gene  delivery  remains  
prohibitively  inefficient  for  most  therapeutic  applications.  Development  of  safe  and  
effective  nonviral  gene  carriers  is  critical  to  the  eventual  success  of  gene  therapy.  
Polycationic  polymers  have  been  extensively  investigated  as  gene  delivery  
vectors  because  of  their  versatility.  They  are  able  to  interact  electrostatically  with  
negatively  charged  nucleic  acids  to  form  stable  particles,  termed  polyplexes,  with  
diameters  on  the  order  of  nanometers.  Physical  properties  of  polymers  such  as  rigidity,  
hydrophilicity,  charge  density,  biodegradability,  and  molecular  weight  can  be  tuned  to  
modulate  gene  delivery  properties  such  as  DNA  binding,  colloidal  stability  of  ionic  
complexes,  endosomal  escape,  vector  unpacking,  cytotoxicity,  and  transfection  
efficiency.  Also,  it  is  likely  that  for  different  target  cells  and  tissues,  or  different  routes  of  
administration,  the  optimal  characteristics  of  the  DNA-­‐‑polymer  nanoparticles  would  
differ  in  kind.  For  gene  therapy  to  advance,  rational  design  of  gene  delivery  vectors  able  
to  address  the  individual  rate-­‐‑limiting  steps  identified  along  the  gene  delivery  pathway  
is  necessary.  These  steps  include  cellular  localization  and  binding,  internalization,  
subcellular  trafficking,  endosomal  escape,  unpacking  and  release,  and  nuclear  
translocation  (Figure  2).  Each  must  be  studied  individually  and  in  concert,  as  changes  in  
the  structure  of  a  polymeric  vector  designed  to  increase  unpacking  could  adversely  
influence  its  behavior  during  another  step  up-­‐‑  or  downstream.  Without  considering  each  
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step  independently  and  systematically,  advances  will  remain  phenomenological  and  
stochastic.  Once  each  step  is  understood,  the  knowledge  can  be  integrated  toward  the  
rational  design  of  polymeric  gene  carriers  that  address  multiple  barriers.  
  
Figure  2.  Barriers  to  Nonviral  Gene  Delivery  
After  shuttling  a  DNA  payload  into  the  cell,  a  carrier  must  then  release  it.  This  happens  
either  (i)  in  the  endocytic  vesicle,  (ii)  in  the  cytoplasm  or  (iii)  in  the  nucleus.  Ideally,  the  




One  crux  of  the  nonviral  gene  delivery  pathway  is  the  release  of  intact  nucleic  
acids  from  the  polymer  into  the  cytoplasm  or  nucleus  of  a  target  cell.  If  release  occurs  
too  slowly  or  not  at  all,  the  DNA  will  not  be  accessible  to  the  transcriptional  machinery  
and  will  eventually  be  lost  or  diluted  out  by  processes  including  exocytosis  and  mitosis.  
If  release  occurs  too  readily,  or  if  the  polyplex  is  not  compact  enough  to  resist  enzyme  
penetration,  the  DNA  is  susceptible  to  degradation  prior  to  reaching  the  nucleus.  
Various  vector  design  strategies  have  been  tried  to  achieve  release  at  the  right  time  and  
place.  So  far,  the  competing  functionalities  of  protection  and  efficient  release  have  
proven  difficult  to  engineer  into  polymeric  gene  carriers.  Fortunately,  recent  advances  in  
imaging  modalities,  microscopy,  and  complex  tissue  models  have  begun  to  help  
elucidate  the  barriers  encountered  by  a  polyplex  on  the  path  to  transfection.  Both  live  
and  fixed  cell  imaging  have  advanced  such  that  single  particles  can  be  tracked  
intracellularly  in  the  spatiotemporal  domain.  Polyplexes  can  be  tagged  and  tracked  to  
determine  their  uptake  kinetics  and  subcellular  localization  at  specific  time-­‐‑points,  as  
well  as  their  dissociation  status.  The  ability  to  resolve  structure-­‐‑function  relationships  at  
the  subcellular,  single-­‐‑particle  level  provides  valuable  information  for  the  rational  
design  of  the  next  generation  of  polymeric  gene  carriers.  Sections  2.1  through  2.7  of  this  
chapter  examine  the  current  rational  design  strategies  to  effect  appropriate  DNA  release  
at  the  optimal  time  and  place  while  maintaining  adequate  DNA  protection,  as  well  as  
the  most  important  imaging  techniques  and  engineering  tools  that  allow  for  the  
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characterization  and  evaluation  of  these  gene  carriers.  Systematic  studies  using  state  of  
the  art  imaging  techniques  and  models  will  enable  the  rational  design  of  polymeric  gene  
carriers  that  address  the  tradeoff  between  protection  and  efficient  release  of  DNA,  
helping  to  close  the  gap  between  engineering  phenomena  and  therapeutic  success.  
In  addition  to  gene  carrier  design,  the  means  by  which  polyplexes  are  assembled  
can  also  impact  their  form  and  function.  Bulk  mixing,  the  process  used  by  the  vast  
majority  researchers  to  form  polyplexes  via  electrostatic  self-­‐‑assembly,  introduces  
significant  variability  to  the  quality  of  polyplexes  because  of  their  metastable  
preparation  and  non-­‐‑equilibrium  composition  [5].  The  heterogeneity  resulting  from  bulk  
synthesis  impedes  advances  in  nonviral  gene  delivery  with  respect  to  rational  carrier  
design,  mechanistic  understanding,  and  optimization.  The  final  properties  and  
composition  of  the  product  depend  on  how  the  polyelectrolytes  initially  encounter  one  
another,  which  is  determined  by  chaotic  mixing  and  operator  inputs.  Irreproducibility  is  
rampant,  as  slight  perturbations  of  mixing  protocols  are  known  to  produce  particles  of  
differing  qualities.  The  resulting  heterogeneity  is  an  impediment  to  the  progress  of  
nonviral  gene  delivery  in  multiple  ways:  1)  It  precludes  mechanistic  understandings  of  
the  gene  transfer  process  if  only  a  subpopulation  of  particles  is  responsible  for  an  
observed  behavior;  2)  it  exacerbates  the  challenge  of  establishing  precise  structure-­‐‑
function  relationships;  and  3)  it  hinders  the  translation  of  nonviral  delivery  systems  if  
they  cannot  be  manufactured  in  a  reproducible  and  scalable  manner.  Sections  2.8  
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through  2.10  of  this  chapter  address  the  basis  of  the  manufacturing  issue,  as  well  as  
some  of  the  most  recent  attempts  to  address  the  problem  with  a  range  of  engineering  
approaches.  
  The  primary  objective  of  gene  delivery  is  to  have  a  positive  impact  on  human  
health,  and  one  of  the  most  pressing  unmet  clinical  needs  today  is  the  prevalence  and  
intransigence  of  neurodegenerative  diseases.  Patients  with  Alzheimer’s  or  Parkinson’s 
disease  may  see  temporary  improvements  with  pharmacologic  intervention  or  deep  
brain  stimulation,  but  the  clinical  benefits  inevitably  decline  with  the  progressive  loss  of  
neuronal  function.  Cell  replacement  therapy  has  been  proposed  as  a  long-­‐‑term  solution.  
However,  finding  an  appropriate  cell  source  has  been  a  challenge  while  safety  and  
ethical  concerns  preclude  the  use  of  embryonic  stem  cells.  The  translation  of  therapies  
derived  from  induced  pluripotent  stem  cells  (iPSC)  have  been  slowed  by  concerns  of  
teratogenic  potential.  Recently,  the  reprogramming  of  adult  cells  from  one  type  to  
another  was  reported.  In  2010,  researchers  found  that  expression  of  three  genes  
encoding  transcription  factors  (Ascl1,  Brn2,  Myt1l)  delivered  by  lentivirus  was  sufficient  
to  convert  fibroblasts  to  functional  neurons  [6].  This  exciting  revelation  brings  the  
prospect  of  an  ethical,  practical,  and  safe  neuronal  cell  therapy  one  step  closer  to  reality.  
However,  the  unpredictable  integration  of  viral  DNA  sequences  into  the  genome  of  the  
cells  renders  them  unsuitable  for  transplantation.  So,  there  would  be  significant  benefits  
associated  with  a  non-­‐‑integrative,  nonviral  cellular  reprogramming  approach  to  
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generate  a  source  of  therapeutic  neuronal  cells  directly  from  differentiated  somatic  cells.  
While  such  nonviral  direct  conversion  of  fibroblasts  to  functional  neurons  greatly  
reduces  the  ethical  and  safety  concerns  of  previous  methods,  its  efficiency  must  be  
increased  to  enable  potential  translation.  Sections  2.11  through  2.13  of  this  chapter  
address  aspects  of  cellular  reprogramming  and  relevant  recent  therapeutic  approaches  
for  the  treatment  of  neurodegenerative  diseases.  
2.1 Release as a Rate-Limiting Barrier 
It  is  intuitive  that  polyplexes  must  dissociate  in  order  for  the  bound  DNA  to  be  
processed  within  a  target  cell.  Early  computational  models  of  nonviral  gene  delivery  
using  an  integrative  systems  approach  identified  the  efficient  release  of  DNA  from  its  
carrier  as  a  critical  step  in  the  transfection  process.  A  first-­‐‑order  mass  action  model  
predicted  a  biphasic  dependence  of  transgene  expression  on  the  rate  of  vector  
unpacking,  which  was  validated  with  in  vitro  transfection  data  [7].  An  optimal  
intermediate  value  for  the  release  rate  constant  was  computed  when  the  model  was  
populated  with  values  for  polylysine  gene  carriers  taken  from  the  literature.  The  model  
predicted  a  dissociation  threshold  rate-­‐‑constant  of  10-­‐‑3  minutes-­‐‑1,  above  which  
transfection  efficiency  is  significantly  increased.  A  more  recent  and  comprehensive  
model  arrived  at  the  same  conclusion  [8].  Some  of  the  data  used  to  create  the  model  
were  borrowed  from  an  earlier  report  that  proposed  vector  unpacking  as  a  potential  
rate-­‐‑limiting  barrier  to  nonviral  gene  delivery.  In  that  study,  Schaffer  et  al.  found  that  
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fluorescently  labeled  180-­‐‑residue  polylysine  (MW~28  kDa)  remained  co-­‐‑localized  with  
plasmid  DNA  in  the  nucleus  and  perinuclear  region  of  transfected  fibroblasts  [9]  (Figure  
3).  In  contrast,  36-­‐‑  and  19-­‐‑residue  polylysines  delivered  free  plasmid  to  the  nucleus.  In  
vitro  transcription  assays  showed  that  the  shorter  polycations  freed  plasmid  more  
readily  for  transcription,  and  cell  transfection  studies  showed  that  the  intermediate  
polymer  length  resulted  in  the  highest  transgene  expression  levels.  The  authors  
explained  that  dissociation  might  occur  spontaneously  due  to  thermodynamics,  or  via  
competitive  displacement  of  DNA  by  another  anionic  species.  Genomic  DNA  in  the  cell  
nucleus  can  participate  in  polyplex  destabilization  by  ion  exchange  [9],  but  it  remains  
unknown  precisely  which  dissociative  mechanisms  dominate  for  most  carrier  systems.  
Nuclear  microinjection  of  polyethylenimine  (PEI)-­‐‑DNA  polyplexes  results  in  high  
transgene  expression  levels,  showing  unpacking  can  take  place  in  the  nucleus  [10].  
Again,  chromosomal  DNA  may  be  implicated,  or  polymerases  may  mediate  DNA  
release  similar  to  their  stripping  of  histone  proteins  during  DNA  replication  [11].  
Another  study  demonstrated  that  RNA  found  in  the  cytoplasm  could  also  promote  
DNA  release  by  ion  exchange  [12].  Regardless  of  exactly  where  and  by  which  processes  





Figure  3.  Polymers  Commonly  Used  and  Modified  for  Nonviral  Gene  Delivery  
  
2.2 Modulating Protection and Release with Polymer Properties 
Many  physical,  chemical,  and  structural  features  of  a  polymeric  gene  carrier  
affect  its  ability  to  bind,  condense,  and  protect  a  DNA  payload  from  enzymatic  and  
nonspecific  degradation.  These  same  features  also  play  important  roles  in  determining  
when  and  where  the  DNA  is  released.  With  many  polymeric  systems,  the  abilities  to  
protect  and  efficiently  release  DNA  are  inversely  related.  One  goal  of  carrier  design  
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should  be  to  strike  an  optimal  balance  between  protection  and  release  to  maximize  
transfection  (Figure  4).      
  
  
Figure  4.  Balancing  Protection  and  Release  of  Nonviral  Gene  Carriers  
Vectors  exhibiting  both  strong  protection  of  DNA  and  efficient  intracellular  release  
mediate  the  highest  levels  of  transfection.  Vectors  capable  of  only  one  of  these  qualities  
typically  do  not  perform  as  well.  Vectors  capable  of  neither  are  largely  ineffective.  
  
2.2.1 Polymer Length 
Molecular  weight  or  length  of  the  polymer  chains  is  one  property  known  to  
influence  the  tradeoff  between  protection  and  release.  For  instance,  one  study  
demonstrated  that  polyplexes  based  on  highly  defined  low  molecular  weight  chitosan  
oligomers  (10-­‐‑  to  50-­‐‑mers)  dissociated  more  easily  than  those  derived  from  high  
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molecular  weight  (1000-­‐‑mer)  chitosan  chains  [13].  Below  about  14  monomer  units,  the  
polyplexes  formed  were  weak  and  unstable.  The  more  easily  dissociated  polyplexes  also  
mediated  higher  transgene  expression  levels  in  vitro  and  in  vivo.  However,  the  
polyplexes  needed  to  be  formed  with  a  much  higher  polymer-­‐‑to-­‐‑DNA  ratio  (N:P  charge  
ratio  as  high  as  60:1,  as  opposed  to  5:1  for  the  high  molecular  weight  chitosan)  to  bind  
and  retain  DNA  as  determined  by  gel  retardation  assay.  Lower  mass  ratios  resulted  in  
unstable  polyplexes,  yielding  poor  transfection  results.  The  decreased  ability  of  the  
shorter  polycations  to  effectively  complex  the  anionic  phosphate  groups  of  DNA  can  be  
explained  by  their  lower  binding  valency  combined  with  the  loss  of  the  chain  
entanglement  effect  exhibited  by  the  longer  polymers.  Longer  polymer  chains  more  
easily  entangle  free  DNA  once  the  initial  electrostatic  interaction  occurs,  creating  an  
additional  non-­‐‑ionic,  knot-­‐‑like  binding  component  [14].  Shorter  chains  are  less  able  to  
physically  entangle  molecules  of  DNA,  and  the  requirement  of  additional  molecules  to  
match  the  binding  strength  of  longer  chains  may  be  energetically  unfavorable  to  
polyplex  formation.      
As  discussed  previously,  Schaffer  et  al.  reported  that  polylysine  of  an  
intermediate  length  (36  residues)  possesses  superior  gene  delivery  properties  than  
shorter  (19  residues)  and  longer  (180  residues)  chains  [9].  Dissociation  rates  and  
transcription  levels  were  higher  in  vitro  for  the  smaller  chains,  whereas  longer  polymer  
chains  significantly  inhibited  RNA  synthesis.  However,  once  the  chains  became  too  
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short,  transgene  expression  levels  dropped.  Premature  release  and  degradation  of  the  
plasmid  was  again  the  putative  culprit.  Selecting  the  optimal  chain  length  of  a  polymer  
gene  carrier  is  perhaps  the  most  straightforward  and  established  way  to  change  the  
release  kinetics  and  DNA  protection  properties  of  a  polymeric  gene  carrier,  but  that  
alone  may  not  be  enough  because  the  structural  and  charge  characteristics  of  a  polymer  
are  also  important.    
2.2.2 Charge Density and Structural Rigidity  
There  are  few  published  systematic  studies  investigating  the  effects  of  charge  
density  and  stiffness  of  polymeric  gene  carriers  on  their  DNA  binding  affinity  and  
release  characteristics.  One  such  study  using  a  series  of  linear  poly(amido  amine)s  
(PAAs)  looked  at  how  their  physiochemical  properties  and  colloidal  stability  were  
affected  by  changes  in  charge  density  and  structural  rigidity  [15].  The  authors  reported  
that  the  DNA  binding  behavior  of  the  PAAs  depended  on  their  molecular  structures,  
showing  by  gel  retardation  assays  that  chains  with  a  single  tertiary  amino  group  per  
monomer  bound  DNA  more  weakly  than  those  with  two  tertiary  amino  groups.  
However,  when  the  methylene  linker  in  the  diacrylamide  segment  of  the  polymer  
possessing  two  tertiary  amino  groups  was  substituted  for  a  piperazine  ring,  the  DNA  
binding  affinity  was  greatly  diminished.  The  authors  speculated  that  this  decrease  in  
binding  is  caused  by  the  resultant  increase  in  rigidity  from  the  ring  substitution.  The  
increase  in  rigidity,  despite  a  higher  charge  density,  resulted  in  decreased  colloidal  
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stability  and  transfection  efficiency.  It  is  difficult  to  separate  the  effects  of  decreased  
uptake  of  the  larger  polyplexes  and  premature  degradation  of  plasmid  when  ascribing  
the  blame  for  the  decrease  in  transfection,  but  it  is  likely  that  both  effects  contribute.    
Another  series  of  studies  aimed  to  improve  the  transfection  efficiency  of  PEI  
through  the  optimization  of  charge  density.  Forrest  et  al.  acetylated  primary  and  
secondary  amines  of  PEI  to  varying  degrees,  decreasing  the  number  of  positive  charges  
available  to  bind  DNA  at  neutral  pH  [16].  They  found  that  acetylation  of  43  percent  of  
the  primary  amines  and  23  percent  of  the  secondary  amines  of  25  kDa  branched  PEI  
decreased  the  surface  charge  and  increased  the  size  of  polyplexes,  while  mediating  up  to  
21-­‐‑fold  higher  transgene  expression  compared  to  unmodified  PEI.  The  authors  attribute  
the  increase  in  transfection,  at  least  partially,  to  more  efficient  release  of  DNA  from  the  
acetylated  PEI.  Gabrielson  et  al.  studied  25  kDa  branched  PEI  with  even  higher  degrees  
of  acetylation  [17].  They  found  that  acetylation  of  the  primary  amines  up  to  57%  
increased  transfection,  while  further  acetylation  resulted  in  diminished  efficacy.  This  
time,  the  authors’  speculation  that  the  decrease  in  charge  density  results  in  more  
efficient  intracellular  release  of  DNA  was  confirmed  via  fluorescence  imaging  
techniques.  These  studies  demonstrate  that  an  optimal  charge  density  exists  for  PEI,  and  
that  it  alters  the  polymer-­‐‑DNA  binding  and  release  characteristics.      
A  recently  developed  gene  carrier  is  composed  of  linear  PEI  with  approximately  
20  percent  of  the  secondary  amines  functionalized  with  hydrolysable  methyl  ester,  
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charge-­‐‑shifting  side  chains  [18].  As  ester  hydrolysis  occurs,  negative  charges  are  
gradually  introduced  to  the  polymer,  so  that  the  effective  positive  charge  density  is  
decreased,  weakening  DNA  binding  and  promoting  polyplex  dissociation.  Higher  
degrees  of  side-­‐‑chain  addition  resulted  in  polyplexes  that  dissociated  prematurely,  but  
the  carrier  with  20  percent  substitution  mediated  8-­‐‑fold  higher  transfection  levels  than  
unmodified  linear  PEI.  The  authors  propose  that  20  percent  substitution  results  in  the  
accumulation  of  negative  charges  at  the  proper  rate  to  release  DNA  intracellularly  via  
competition  with  other  anionic  species.  Another  way  of  promoting  DNA  release  is  the  
design  of  biodegradable  vectors,  such  as  polyphosphoesters  including  polyphosphates  
(PPEs)  and  polyphosphoramidates  (PPAs)  [19].  The  rationale  of  using  carriers  that  can  
be  hydrolyzed  over  time  is  derived  from  the  desire  to  promote  DNA  release.  By  
degrading  steadily  over  time,  these  carriers  can  provide  sustained  release  of  DNA,  
improving  the  bioavailability  inside  and  outside  the  cell.  The  release  kinetics  can  be  
adjusted  by  varying  the  polymer-­‐‑to-­‐‑DNA  ratio,  as  well  as  the  composition  of  the  
backbone  and  side  chains.  Polyphosphoesters  also  offer  a  high  degree  of  structural  
versatility,  which  permits  the  tailored  design  of  its  physiochemical  properties.  Their  
efficacy  rivals  PEI,  but  with  much  less  associated  toxicity.  However,  a  steady  
degradation  means  that  control  over  the  spatiotemporal  release  of  DNA  is  lacking.  It  
would  be  advantageous  to  trigger  DNA  release  at  a  specific  time  and  place.  
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2.2.3 Stimuli-Responsive Strategies  
The  ideal  gene  carrier  would  protect  DNA  from  nucleases  and  provide  
unrestricted  access  to  polymerases.  Polymers  able  to  respond  to  biological  or  
environmental  cues  that  signal  the  right  time  and  place  for  DNA  deprotection  and  
release  are  perhaps  better  suited  than  their  unresponsive  counterparts  for  providing  
such  selective  enzymatic  access.  Polyplexes  capable  of  responding  to  environmental  
stimuli  have  the  potential  to  circumvent  barriers  to  delivery  in  ways  that  traditional  
carriers  cannot.  Many  physical  stimuli  have  been  studied,  including  light,  heat,  
sonication,  and  magnetic  fields.  Furthermore,  some  polymers  can  respond  to  chemical  
stimuli  such  as  pH  and  redox  changes.  One  reason  that  viruses  are  such  potent  gene  
carriers  is  their  ability  to  respond  to  physical  and  chemical  cues  in  certain  subcellular  
compartments  to  more  efficiently  complete  the  steps  of  their  replication  cycle.  Many  
researchers  are  trying  to  borrow  viral  response  mechanisms  and  apply  them  to  
polymeric  gene  carrier  designs.    
2.2.3.1  Redox-­‐‑Responsive  Polymers  
One  strategy  to  facilitate  DNA  release  at  the  right  time  and  right  place  is  to  
include  bioreducible  disulfide  linkages  in  the  polymer  chain.  Disulfide  bonds  are  
covalent  linkages  formed  via  the  oxidation  of  sulfhydryl  (-­‐‑SH)  groups.  They  are  quickly  
cleaved  inside  cells,  which  possess  a  reducing  environment  due  to  high  concentrations  
of  reducing  enzymes  such  as  glutathione  reductase  and  sulfhydryl  species  like  
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glutathione  as  compared  to  the  extracellular  spaces.  Consequently,  disulfide  bonds  are  
relatively  stable  in  plasma  and  extracellular  spaces,  but  rapidly  degrade  inside  cells.  This  
rapid  degradation  can  lead  to  the  dissociation  of  a  polyplex  and  DNA  release.  Disulfide  
linkages  added  to  polylysine  and  25  kDa  branched  PEI  resulted  in  improved  gene  
carrier  properties  such  as  higher  transfection  levels  and  diminished  cytotoxicity  when  
compared  to  their  unmodified  analogues  [20,  21].  Lin  et  al.  have  shown  more  recently  
that  a  minimal  number  of  disulfide  linkages  in  the  main  chain  of  poly(amido  amine)s  is  
sufficient  to  allow  efficient  intracellular  DNA  release  [22-­‐‑24].  Again,  a  side  effect  of  the  
polymer  degradation  is  a  marked  decrease  in  cytotoxicity  as  compared  to  the  polymer  
analogues  lacking  disulfide  linkages.  The  ability  of  the  polymer  to  protect  the  DNA  
prior  to  cleavage  of  the  disulfide  bonds  is  unaffected.  Miyata  et  al.  studied  the  addition  
of  thiol  groups  to  a  polylysine  backbone  with  possible  modification  of  its  charge  density  
[25].  Using  the  reagent  that  substituted  positive  charges  for  disulfide  linkages,  they  
created  a  redox  sensitivity  that  led  to  efficient  intracellular  DNA  release  and  50-­‐‑fold  
higher  transfection  efficiency  in  cells,  as  compared  to  the  thiolated  polylysine  with  
unaltered  positive  charges.  The  balance  between  charge  density  and  disulfide  cross-­‐‑
linking  can  both  play  crucial  roles  in  the  mediation  of  efficient  gene  transfer.  These  
reports  demonstrate  that  the  inclusion  of  disulfide  bonds  into  polymer  chains  can  lead  to  
the  fast  intracellular  degradation  of  polyplexes,  efficient  DNA  release,  sufficient  
protection,  improved  transfection,  and  decreased  cytotoxicity.    
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2.2.3.2  pH-­‐‑Sensitive  Polymers  
Polymers  sensitive  to  pH  offer  another  layer  of  biochemical  responsiveness.  
Decreases  in  pH  are  known  to  occur  near  tumors,  sites  of  inflammation,  and  in  the  
endocytic  vesicles  through  which  polyplexes  travel  following  endocytosis.  A  triblock  
copolymer  composed  of  lactosylated  PEG-­‐‑block-­‐‑polysilamine-­‐‑block-­‐‑poly[2-­‐‑(N,N-­‐‑
dimethylamino)ethyl  methacrylate]  (lac-­‐‑PEG-­‐‑PSAO-­‐‑PAMA)  has  been  developed  by  
Oishi  et  al.  to  undergo  pH-­‐‑sensitive  conformational  changes  [26].  When  the  pH  drops  
from  neutral  (~7)  to  slightly  acidic  (~4)  typical  of  endosomal  compartments,  the  PSAO  
segments  of  the  3-­‐‑layer  micelle  swell  and  cause  the  polyplex  to  grow  in  diameter.  This  
conformational  change  may  decrease  the  binding  affinity  of  the  polymer  for  DNA,  
allowing  intracellular  anions  to  compete  with  and  release  the  DNA  more  easily.  Prior  to  
release,  the  tight  conformation  affords  good  protection  to  the  bound  DNA.  The  lactose  
group  was  incorporated  to  promote  receptor-­‐‑mediated  endocytosis  by  hepatocytes.    
To  deliver  genes  specifically  to  the  acidic  interstitium  of  tumors,  PEI-­‐‑DNA  
nanoparticles  have  been  further  functionalized  with  a  pH-­‐‑responsive  poly(methacryloyl  
sulfadimethoxine)  (PSD)-­‐‑block-­‐‑PEG  (PSD-­‐‑b-­‐‑PEG)  [27].  At  a  normal  physiological  pH  of  
7.4,  the  nanoparticles  mediate  very  little  transfection.  The  PSD-­‐‑b-­‐‑PEG  layer  served  to  
shield  the  positive  surface  charges  of  the  PEI-­‐‑based  polyplexes,  decreasing  both  
cytotoxicity  and  the  ability  of  the  polyplexes  to  interact  with  cell  membranes.  However  
at  pH  6.6,  the  polyplexes  shed  the  PSD-­‐‑b-­‐‑PEG  and  exhibited  the  high  transfection  and  
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cytotoxicity  characteristic  of  PEI-­‐‑based  systems.  Such  a  high-­‐‑sensitivity  pH-­‐‑responsive  
system  could  be  used  to  shield  and  protect  polyplexes  at  physiological  pH  until  delivery  
to  an  acidic  environment,  whereupon  stripping  of  the  mask  makes  transfection  possible.  
Despite  the  fact  that  the  PSD-­‐‑b-­‐‑PEG  used  is  not  easily  degraded,  the  principle  shows  
good  promise.  
Another  strategic  alternative  to  shielding  polyplexes  with  pH-­‐‑sensitive  units  and  
the  inclusion  of  polymer  segments  that  switch  conformations  upon  acidification  is  the  
addition  of  acid-­‐‑labile  linkages  within  the  polymer  backbone.  Kim  et  al.  introduced  
imine  linkages  into  a  PEI  backbone  by  crosslinking  low  molecular  weight  PEI  (1.8  kDa)  
with  glutaraldehyde  [28].  The  half-­‐‑life  of  hydrolytic  degradation  of  their  polymer  
decreased  two  orders  of  magnitude  when  the  pH  was  changed  from  7.4  (118  hours)  to  
4.5  (1.1  hours).  A  DNase  protection  assay  confirmed  that  the  carrier  affords  sufficient  
protection  from  nuclease  activity.  The  system  is  designed  such  that  DNA  is  released  
upon  acidification  of  the  endosomal  compartment.  The  acid-­‐‑labile  PEI  polyplexes  
yielded  transgene  expression  levels  similar  to  25  kDa  branched  PEI,  but  with  much  
lower  associated  toxicity  likely  due  to  the  degradation  into  smaller  chains.      
2.2.3.3  Thermo-­‐‑Sensitive  Polymers  
In  contrast  to  the  natural  environmental  stimuli  encountered  by  the  polyplexes  
discussed  above,  a  stimulus  can  also  be  applied  externally  to  trigger  DNA  release.  A  
targeted  increase  in  temperature  is  one  stimulus  frequently  exploited.  Poly(N-­‐‑
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isopropylacrylamide)  (PNIPAm)  is  a  widely-­‐‑used  thermo-­‐‑sensitive  polymer  that  exists  
in  a  water-­‐‑soluble  state  below  its  lower  critical  solution  temperature  (LCST)  of  32˚C.  
Above  its  LCST,  which  can  be  tuned  closer  to  body  temperature  by  varying  its  monomer  
makeup,  it  becomes  hydrophobic.  This  leads  to  phase  transformation  to  a  gel  state,  or  a  
change  in  architecture  if  bound  to  other  molecules.  In  its  hydrophobic  state,  PNIPAm  
can  condense  large  DNA  molecules  and  is  small  enough  to  enter  cells.  When  cooled  
below  its  LCST,  PNIPAm  reverts  to  the  solution  state  to  release  the  DNA  [29,  30].  
PNIPAm  has  also  been  grafted  with  proven  gene  carriers  such  as  PEI  and  chitosan  to  
impart  responsive  properties  and  improve  transfection  [31-­‐‑35].  
Another  class  of  thermo-­‐‑sensitive  polymers  used  for  gene  delivery  is  elastin-­‐‑like  
polypeptides  (ELPs).  These  are  pentapeptide  repeats  Val-­‐‑Pro-­‐‑Gly-­‐‑Xaa-­‐‑Gly  where  Xaa  
specifies  any  amino  acid  residue  except  proline.  These  polymers  exhibit  an  inverse  
phase  transition  with  temperature,  as  well  as  controllable  degradation  [36].  In  contrast  to  
the  conventional  thermosensitive  polymer  PNIPAm,  polyplexes  generated  with  ELPs  
allow  for  hyperthermic  DNA  release  instead  of  release  upon  cooling.  This  can  be  
beneficial  in  certain  cases,  as  hyperthermia  is  already  an  established  targeted  treatment  
for  some  diseases  such  as  cancer.  As  synthetic  polypeptides,  ELPs  can  be  produced  by  
recombinant  methods  to  control  polydispersity  and  expressed  as  fusion  proteins  if  
additional  domains  are  desired.  Chen  et  al.  used  a  recombinant  diblock  copolymer  
consisting  of  cationic  oligolysine  (VGK8G)  and  an  ELP  block  with  60  repeat  units  of  
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VPGXG,  where  X  is  Val,  Ala,  and  Gly  in  a  5:2:3  ratio  for  hyperthermic  gene  delivery  [37].  
While  these  and  other  novel  thermo-­‐‑responsive  polymeric  gene  carriers,  such  as  the  
diblock  copolymer  methoxy  PEG-­‐‑co-­‐‑poly(ε-­‐‑caprolactone)  (mPEG-­‐‑PCL)  [38]  are  being  
explored  and  developed,  temperature-­‐‑sensitive  gene  delivery  vectors  have  obvious  
drawbacks  in  that  a  temperature  gradient  must  be  applied  in  a  site-­‐‑specific  and  non-­‐‑
invasive  manner  for  the  technology  to  be  attractive  to  physicians  and  patients.  The  sol-­‐‑
gel  transition  must  also  be  sharp  since  the  strong  temperature  buffering  capacity  in  vivo  
would  dampen  any  thermal  gradient.  These  challenges  hinder  clinical  translation,  and  
currently  limit  the  technology  primarily  to  the  realm  of  in  vitro  studies.    
2.2.3.4  Light-­‐‑Sensitive  Polymers  
Light  is  a  physical  stimulus  that  can  be  very  convenient,  depending  on  the  
application  and  target  tissue.  It  is  an  appropriate  stimulus  for  targets  located  near  the  
surface  of  the  body,  as  near-­‐‑infrared  (NIR)  light  between  750  nm  and  1000  nm  in  
wavelength  penetrates  the  skin  without  damaging  cells  or  tissues.  This  so-­‐‑called  “water  
window”  is  useful  due  to  the  lack  of  absorption  from  water  or  biological  chromophores.  
Handwerger  et  al.  designed  a  novel  photolabile  monomer  for  gene  delivery.  P25M  
consists  of  three  domains,  a  cationic  domain  of  25  kDa  PEI  to  bind  DNA,  a  
polymerizable  methacrylamide  moiety  for  crosslinking  DNA  within  the  polyplex,  and  a  
photolabile  nitrobenzyl  domain  for  triggered  release  by  365nm  light  [39].  Gel  retardation  
demonstrated  that  P25M  condensed  DNA  at  a  charge  ratio  of  3:4,  and  light  scattering  
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showed  the  polymer  forms  polyplexes  of  <  500  nm  diameter.  This  work  demonstrates  
the  feasibility  of  light-­‐‑responsive  polymeric  gene  carriers  for  the  spatial,  temporal,  and  
metered  delivery  of  DNA.  Few  other  light-­‐‑responsive  polymers  have  been  developed  for  
gene  delivery  applications,  but  some  have  shown  promise  in  the  delivery  of  non-­‐‑nucleic  
acid  cargo  [40-­‐‑42].  
2.2.4 Inclusion of Enzymes and Inhibitors 
Polyplex  systems  need  not  be  limited  to  simple  pairs  of  polymer  and  DNA.  
Other  molecules  such  as  proteins,  enzymes,  and  chemicals  can  also  be  included  into  the  
polyplex  to  enhance  DNA  protection  or  facilitate  release.  In  a  study  of  DNA-­‐‑gelatin  
nanospheres  for  gene  delivery,  Truong  et  al.  observed  incomplete  protection  of  
complexed  DNA  from  nuclease  digestion.  In  an  attempt  to  increase  the  protection  of  
DNA,  they  co-­‐‑encapsulated  inhibitors  of  DNase  I  [43].  The  inclusion  of  sodium  
iodoacetate  and  aurintricarboxylic  acid  each  showed  minor  improvements  in  DNA  
protection,  but  the  benefits  did  not  translate  to  any  improvement  in  transfection  levels.    
A  pair  of  more  recent  studies  examined  the  use  of  chitosanase  to  promote  the  
dissociation  of  chitosan-­‐‑based  polyplexes  [44,  45].  In  the  first  report,  the  enzyme  was  
pre-­‐‑delivered  to  cells  prior  to  transfection.  The  authors  observed  that  radiolabeled  
chitosan  polyplexes  were  able  to  penetrate  cells  twice  as  efficiently  as  commercial  lipid  
transfection  reagents,  but  the  resultant  transgene  expression  was  far  lower.  However,  
upon  pre-­‐‑delivery  of  chitosanase  via  osmotic  lysis,  cells  transfected  with  chitosan  
  30  
polyplexes  containing  a  LacZ  reporter  gene  expressed  twice  as  much  β-­‐‑galactosidase  
activity  as  those  transfected  with  lipid  reagents.  In  the  subsequent  report,  the  
chitosanase  gene  was  co-­‐‑transfected  along  with  the  gene  of  interest  since  pre-­‐‑delivery  
via  osmotic  lysis  is  impractical  in  vivo.  The  rationale  was  that  once  the  chitosanase  gene  
was  processed,  it  would  start  a  positive-­‐‑feedback  cascade  leading  to  the  degradation  of  
all  the  chitosan  and  efficient  release  of  DNA.  In  four  different  cell  lines,  the  authors  
found  that  β-­‐‑galactosidase  and  green  fluorescent  protein  expression  levels  were  similar  
between  lipid-­‐‑mediated  transfections  and  chitosan  polyplex  transfections  using  the  
chitosanase  construct.  Expression  levels  with  an  inactive  mutant  of  the  chitosanase  gene  
were  identical  to  those  with  no  chitosanase  gene  at  all,  barely  above  the  levels  achieved  
by  naked  DNA.  Similar  techniques  have  been  used  to  neutralize  the  threat  of  binding  
and  sequestration  of  nanoparticles  by  extracellular  matrix  (ECM)  components.  The  
functionalization  of  nanoparticles  with  collagenase  resulted  in  the  localized  degradation  
of  matrix  molecules  and  a  less  tortuous  path  leading  to  the  cell  membrane  that  increased  
the  rate  of  polyplex  transport  [46].    
2.3 Imaging Techniques and Engineering Models to Evaluate the 
Protection and Release of DNA from Polyplexes 
Traditionally,  fluorescence  microscopy  has  been  the  method  of  choice  to  image  
molecules  involved  in  gene  delivery.  Fluorescently  labeled  carriers  and  DNA  can  be  
followed  from  the  extracellular  compartment,  through  the  cell,  and  into  the  nucleus.  
However,  co-­‐‑localization  of  fluorescent  signals  and  imaging  at  discrete  time-­‐‑points  can  
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only  give  so  much  information  about  a  carrier’s  function  and  fate.  Recent  advancements  
have  vastly  improved  the  precision  with  which  engineers  can  observe  the  details  of  
polyplex  trafficking  and  dissociation.  Technologies  such  as  time-­‐‑lapse  microscopy,  
multiple  particle  tracking,  fluorescence  correlation  spectroscopy,  quantum  dot  labeling,  
and  fluorescence  energy  resonance  transfer  (FRET)  now  allow  much  finer  details  of  
nonviral  transfection  to  be  observed.  
2.3.1 Determination of Dissociation Status by Fluorescence 
Microscopy 
While  single  fluorescent  markers  affixed  to  polyplexes  allow  their  subcellular  
localization  to  be  determined,  no  information  is  gained  about  their  integrity  or  
dissociation  status.  Packaged  nucleic  acid  cargo  must  be  released  at  the  appropriate  time  
and  place  to  ensure  processing.  One  method  used  to  follow  the  intracellular  unpacking  
fate  of  polyplexes  is  colocalization  of  two  different  fluorescent  markers,  one  attached  to  
the  polymer  and  one  to  the  DNA  [47].  These  approaches  are  limited  by  the  need  for  the  
polymer  and  DNA  to  diffuse  sufficiently  far  enough  from  each  other  to  detect  their  
distinct  signals,  thereby  lacking  the  sensitivity  and  spatial  resolution  to  determine  when  
and  where  the  precise  onset  of  dissociation  occurs.  It  is  conceivable  that  the  fluorescently  
labeled  molecules  could  be  co-­‐‑localized  without  actually  being  associated.  Another  
fluorescent  assay  used  to  study  the  unpacking  of  polyplexes  and  DNA  release  uses  the  
fluorophore  YOYO-­‐‑1.  The  fluorescent  emission  signal  of  the  YOYO  dye  is  three  orders  of  
magnitude  higher  when  bound  to  DNA  than  when  it  is  unbound  in  solution.  When  the  
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YOYO-­‐‑labeled  DNA  is  complexed  with  polymer  and  the  dye  molecules  are  pulled  near  
one  another,  they  interact  with  one  another  to  cause  a  self-­‐‑quenching  effect  that  
decreases  the  emission  signal  [48].  Thus,  the  YOYO  signal  is  high  only  when  bound  to  
free  DNA,  and  can  be  used  to  probe  the  dissociation  status  of  polyplexes.  However,  this  
technique  is  better  suited  for  bulk  measurements  than  single-­‐‑particle  tracking  due  to  the  
lack  of  a  clear  binary  signal  indicating  binding  or  release  for  each  polyplex.      
2.3.2 Förster Resonance Energy Transfer 
Another  technique  used  to  study  the  time-­‐‑dependent  intermolecular  interactions  
of  polyplexes  is  fluorescence  resonance  energy  transfer  (FRET).  In  FRET,  a  fluorescent  
donor  label  has  an  emission  spectral  peak  that  overlaps  the  excitation  peak  of  an  
appropriately  chosen  acceptor  label.  When  energy  is  applied  at  the  excitation  frequency  
of  the  donor,  the  donor  fluorophore  emits  energy  at  an  appropriate  wavelength  to  excite  
the  acceptor  by  non-­‐‑radiative  dipole-­‐‑dipole  interactions  [49,  50].  The  acceptor  then  emits  
at  its  own  emission  wavelength  (Figure  5).  The  result  is  that  the  acceptor  will  only  emit  
if  it  is  close  enough  to  be  excited  by  a  donor.  The  efficiency  of  FRET  falls  off  relative  to  
the  sixth  power  of  the  distance  separating  the  donor-­‐‑acceptor  pair,  with  appreciable  
acceptor  emission  only  occurring  when  the  two  fluorophores  are  less  than  ten  
nanometers  apart  [51].  This  property  makes  FRET  pairs  ideal  to  probe  the  dissociation  
kinetics  of  polyplexes  with  high  sensitivity  and  resolve  distances  below  the  diffraction  




Figure  5:  Förster  Resonance  Energy  Transfer  
When  a  FRET  donor  and  acceptor  are  less  than  10  nm  apart,  energy  transfer  takes  place.  
Otherwise,  the  acceptor  is  not  excited  and  does  not  emit.  When  a  quantum  dot  acceptor  
is  excited,  it  emits  at  a  wavelength  that  overlaps  the  acceptor  absorbance  spectra,  but  not  
the  acceptor  emission  spectra.  
  
Traditionally,  FRET  pairs  consist  of  commercially  available  organic  fluorophores.  
Itaka  et  al.  employed  plasmid  DNA  doubly  labeled  with  fluorescien  and  X-­‐‑rhodamine  as  
a  FRET  pair  to  determine  the  serum  stability  of  poly(L-­‐‑lysine)  (PLL)  polyplexes  in  
physiological  media.  They  observed  that  the  fluorescence  spectra  of  the  labeled  DNA  
changed  drastically  upon  complexation  and  condensation  with  polymer  [52,  53].  In  a  
later  study,  the  same  group  used  a  fluorescein  and  Cy5  FRET  pair  to  probe  the  uptake  
and  release  of  polyplexes  derived  from  linear  (22  kDa)  and  branched  (25  kDa)  PEI  [53].  
They  found  that  linear  PEI  promoted  fast  uptake  and  unpacking,  whereas  branched  PEI  
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resulted  in  retarded  release  of  DNA  as  indicated  by  the  FRET  signal.  Their  results  
correlated  well  with  measures  of  transfection  efficiency  using  each  carrier.  In  another  
report,  PEI-­‐‑DNA  polyplexes  were  labeled  with  Alexa  Fluor  488  and  rhodamine  as  a  
FRET  pair  and  used  to  study  the  effect  of  substrate  stiffness  on  polyplex  uptake  and  
dissociation  [54].  FRET  is  quickly  gaining  popularity  in  the  field  as  its  utility  becomes  
apparent.    
However,  traditional  organic  fluorophores  are  not  without  shortcomings,  as  
most  of  them  have  narrow  excitation  and  broad  emission  spectra.  If  the  emission  
spectrum  of  the  donor  overlaps  that  of  the  acceptor,  crosstalk  will  occur  and  
contaminate  the  FRET  output  signal.  Another  drawback  to  the  use  of  organic  
fluorophores  in  FRET  is  their  susceptibility  to  photobleaching,  which  often  renders  their  
use  incompatible  with  time-­‐‑lapse  and  real-­‐‑time  polyplex  tracking  studies.  One  proposed  
solution  to  address  the  issues  with  organic  fluorophores  is  the  use  of  semiconducting  
nanocrystals  called  quantum  dots  (QD’s)  as  efficient  FRET  donors  [55,  56].  They  are  
characterized  by  broad  absorption,  narrow  emission  spectra,  and  high  photostability,  
which  help  minimize  complications  typical  of  conventional  FRET  such  as  spectral  
crosstalk  and  direct  acceptor  excitation  [55].  A  QD-­‐‑FRET  system  allows  the  tracking  of  a  
single  polyplex  over  an  extended  period  of  time  in  a  living  cell  via  confocal  microscopy  
with  a  high  signal-­‐‑to-­‐‑noise  ratio.  Chen  and  Ho  et  al.  used  such  a  QD-­‐‑FRET  system  to  
elucidate  the  intracellular  fate  of  polyplexes  derived  from  three  different  polymers  [57,  
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58].  Analysis  of  confocal  microscopy  images  taken  in  live  cells  allowed  them  to  construct  
a  three-­‐‑compartment  kinetic  model  describing  the  subcellular  localization  and  
dissociation  status  of  the  three  different  polyplexes  in  either  the  cytosol,  endocytic  
vesicles,  or  the  nucleus  at  various  times.  Their  results  reveal  how  unpacking  kinetics  can  
correlate  with  transfection  efficiency,  a  mechanistic  insight  that  could  lead  to  the  rational  
design  of  better  gene  carriers.  
A  recent  refinement  of  this  technique  is  to  apply  a  two-­‐‑step  or  relay  QD-­‐‑FRET  
approach  to  also  monitor  DNA  degradation  at  the  same  time  [59].  In  this  case,  plasmid  
DNA,  double-­‐‑labeled  with  QD  (525  nm  emission)  and  nucleic  acid  dyes  were  complexed  
with  Cy5-­‐‑labeled  polymeric  gene  carriers.  The  QD  donor  drives  energy  transfer  stepwise  
through  the  intermediate  nucleic  acid  dye  to  the  final  acceptor  Cy5.  At  least  three  
distinct  states  of  DNA  condensation  and  integrity  (complexed  and  intact,  unpacked  and  
intact,  and  unpacked  and  degraded)  were  distinguished  in  a  single-­‐‑particle  manner  and  
within  cells  by  quantitative  ratiometric  analysis  of  energy  transfer  efficiencies.  This  
novel  two-­‐‑step  QD-­‐‑FRET  method  allows  for  more  detailed  assessment  of  the  onset  of  
DNA  release  and  degradation  simultaneously.  
2.3.3 Fluorescence Correlation Spectroscopy 
Another  means  of  detecting  the  dissociation  of  polyplexes  in  the  cell  is  termed  
fluorescence  correlation  spectroscopy  (FCS),  whereby  the  colocalization  of  the  
fluorescent  signals  is  tracked  not  only  spatially,  but  also  temporally  in  the  excitation  
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volume  of  a  confocal  microscope  [60,  61].  The  concentration  of  labeled  molecules  is  kept  
low,  so  that  each  contributes  significantly  to  the  detected  signal.  The  detection  volume  is  
also  very  small  (~  femtoliters),  so  that  only  a  few  fluorophores  are  detected  at  a  given  
time.  Then,  the  diffusion  of  fluorescent  molecules  in  and  out  of  the  detection  volume  
leads  to  fluorescent  fluctuations  that  provide  information  about  the  molecules.  When  
associated,  the  tagged  molecules  move  in  and  out  of  the  fixed  excitation  volume  
simultaneously.  When  dissociated,  they  move  independently.  Based  on  the  measured  
kinetic  properties  of  the  labeled  molecules,  their  diffusion  coefficients  can  be  calculated  
to  determine  if  they  are  bound  or  free.  This  approach  is  convenient  and  powerful,  but  
does  have  limitations.  It  relies  on  the  differences  in  the  diffusive  properties  of  the  
complexed  or  dissociated  molecules,  which  are  likely  to  be  affected  by  associations  with  
other  intracellular  charged  species,  limiting  sensitivity  and  precision.  Lucas  et  al.  
employed  FCS  by  transfecting  cells  with  polyplexes  consisting  of  rhodamine  green  
labeled  nucleotides  and  either  high  molecular  weight  poly-­‐‑DMAEMA  or  low  molecular  
weight  PLL  labeled  with  Cy5  to  determine  if  the  polyplexes  dissociated  before  or  after  
reaching  the  nucleus  [62].  
Image  correlation  spectroscopy  (ICS)  is  an  analogous  technique  also  used  to  track  
polyplex  behavior  intracellularly  over  time.  Again,  polyplexes  are  conjugated  with  
fluorophores  and  excited  by  a  laser  under  a  confocal  microscope.  However,  now  the  
image  of  the  entire  cell  is  used  instead  of  a  smaller  fixed  focal  volume.  The  fluorescent  
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intensities  at  each  pixel  are  used  to  calculate  autocorrelation  functions,  gaining  insight  
into  the  transport  and  aggregation  behavior  of  polyplexes  once  internalized.  Using  ICS,  
Kulkarni  et  al.  found  that  for  short  intervals  (<  10  s),  polyplexes  tend  to  move  along  
distinct  paths  that  perhaps  implicate  microtubules  in  polyplex  transport  [63].  For  longer  
intervals,  the  motion  was  much  more  Brownian,  indicative  of  passive  transport.    
Sometimes,  it  is  advantageous  to  employ  more  than  one  imaging  technique  in  
combination  to  answer  specific  questions  pertaining  to  DNA  protection  and  release.  One  
example  is  the  combination  of  FRET  and  FCS  to  probe  the  stability  of  DNA  delivered  
intracellularly  [64].  Remaut  et  al.  delivered  oligonucleotides  bearing  a  rhodamine  green  
and  a  Cy5  fluorophore  on  its  3’  and  5’  termini,  respectively.  Using  the  two  labels  as  a  
FRET  pair,  the  authors  performed  dual-­‐‑color  FCS  to  monitor  the  red-­‐‑to-­‐‑green  acceptor-­‐‑
to-­‐‑donor  fluorescence  ratio.  They  were  able  to  study  the  degradation  of  the  delivered  
DNA  at  very  low  concentrations  in  cytoplasmic  extract  and  living  cells  by  both  methods  
simultaneously.  Degradation  of  the  DNA  was  indicated  by  the  disappearance  of  the  
FRET  signal,  as  well  as  the  red-­‐‑to-­‐‑green  emission  ratio  and  diffusion  times  calculated  
from  the  autocorrelation  curves.  They  estimated  that  the  cytoplasmic  turnover  time  for  
an  unmodified  40-­‐‑mer  oligonucleotide  was  between  2  and  10  minutes,  underscoring  the  
necessity  of  DNA  protection  until  it  is  delivered  to  its  final  destination.    
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2.4 Unpacking in Extracellular Space 
The  intracellular  barriers  to  nonviral  gene  delivery  are  better  understood  than  
those  encountered  by  polyplexes  prior  to  reaching  the  cell  surface.  It  is  unfortunate  that  
the  consideration  and  characterization  of  these  extracellular  barriers  is  often  neglected.  
Exposure  of  polyplexes  to  serum  or  proteoglycans  often  decreases  their  transfection  
efficiency  by  causing  aggregation  or  premature  DNA  release  [65-­‐‑67].  Just  as  charged  
species  inside  the  cell,  such  as  chromosomal  DNA  and  cytoplasmic  RNA  can  cause  the  
release  of  DNA  via  competitive  ion  exchange,  charged  molecules  found  in  the  
extracellular  compartment  and  on  the  cell  surface  can  also  influence  the  release  process.  
Aggregation  outside  the  cell  results  both  in  premature  unpacking,  as  well  as  the  
formation  of  larger  conglomerates  of  nanoparticles  that  hinder  uptake.  PEGylation,  the  
addition  of  polyethylene  glycol  units,  is  a  common  modification  made  to  polymers  to  
increase  their  salt  and  serum  stability.  However,  studies  have  shown  that  the  addition  of  
PEG  may  actually  result  in  a  less  stable  ionic  complex  outside  the  cell  and  decreased  
transfection  efficiencies  [65,  68-­‐‑72].  The  hydrophilic  PEG  chains  may  induce  swelling  of  
the  polyplexes  and  can  lead  to  either  premature  release  of  DNA  in  the  extracellular  
compartment  or  increased  access  to  nucleases  that  can  degrade  DNA  before  it  reaches  
the  cell.      
DNA  delivered  via  polyplex  is  very  susceptible  to  sequestration  and  degradation  
by  a  variety  of  processes  before  it  ever  reaches  a  target  cell.  To  overcome  these  
  39  
challenges,  accurate  in  vitro  models  must  be  developed  to  recapitulate  the  extracellular  
barriers  found  in  vivo  for  rational  carrier  design.  This  is  a  formidable  challenge,  as  the  
relevant  barriers  vary  greatly  with  the  route  of  administration.  One  route  may  require  
the  balance  of  protection  versus  release  to  be  skewed  far  toward  one  extreme,  while  
another  demands  the  reverse.  For  example,  it  is  known  that  injection  of  naked  DNA  
results  in  substantial  transgene  expression  in  skeletal  muscle  [73,  74].  However,  DNA  
delivered  orally  needs  to  survive  the  acid  and  enzymes  found  in  the  stomach  and  gut  
[75].  It  follows  that  carriers  for  intramuscular  injections  should  be  labile  and  unpack  
rapidly,  whereas  carriers  for  oral  delivery  must  form  tight  complexes  with  DNA  to  
provide  maximum  protection  until  they  reach  their  target.  Other  routes  of  
administration  require  more  intermediate  properties.  The  different  demands  typical  of  
different  routes  of  delivery  complicate  the  considerations  in  designing  systems  to  model  
extracellular  barriers.      
The  study  and  evaluation  of  most  new  gene  carriers  currently  takes  place  
primarily  in  monolayer  cell  culture  systems.  Such  two-­‐‑dimensional  environments  
generally  fail  to  accurately  mimic  the  extracellular  environment  polyplexes  will  
encounter  in  vivo.  When  nanoparticles  are  added  to  the  culture  dish,  they  interact  with  
the  cell  monolayer  from  the  apical  side.  In  two-­‐‑dimensional  (2-­‐‑D)  culture  systems,  the  
amount  of  extracellular  matrix  secreted  by  cells  is  lower  on  the  apical  side  than  the  
basolateral  surfaces  [76,  77].  So,  polyplexes  delivered  to  the  culture  medium  have  a  
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relatively  unimpeded  path,  where  the  reality  of  the  situation  in  vivo  includes  a  far  more  
tortuous  path  through  the  small  pores  of  the  ECM.  Furthermore,  the  molecular  
constituents  of  the  ECM  are  neither  neutral  nor  inert.  For  example,  proteoglycans  are  
negatively  charged  under  physiological  conditions.  They  can  interact  with  polyplexes  
possessing  positive  zeta  potentials,  sequestering  or  disrupting  them  prior  to  their  ever  
reaching  a  target  cell  [65,  78].  As  a  result,  some  groups  are  looking  at  three-­‐‑dimensional  
(3-­‐‑D)  tissue  culture  systems  that  more  accurately  portray  the  conditions  found  in  vivo  in  
terms  of  the  structure,  volume,  and  composition  of  the  extracellular  domain.  More  
accurate  models  could  result  in  more  reliable  assessments  of  gene  carrier  efficiencies  in  
vitro,  bridging  the  gap  in  success  that  often  exists  between  cell  culture  experiments  and  
animal  studies.    
The  sophistication  of  these  3-­‐‑D  models  ranges  from  simple  hydrogels  of  
crosslinked  ECM  molecules  to  multicellular  spheroids,  multilayer  cell  cultures,  and  ex  
vivo  tissue  models  [79].  A  model  as  basic  as  a  hydrogel  of  crosslinked  ECM  molecules,  
such  as  collagen  or  Matrigel,  can  offer  a  great  deal  of  insight  into  the  transport  
properties  and  dynamic  stability  of  polyplexes  in  the  extracellular  domain.  The  effects  of  
polymer  modification  or  functionalization  on  polyplex  behavior  outside  the  cell  can  be  
studied,  as  well  as  the  shape  and  size  restrictions  imposed  on  polyplexes  by  the  ECM  
pore  sizes  [80,  81].  Hydrogel  models  have  been  used  to  demonstrate  that  aggregation  
and  premature  dissociation  of  polyplexes  by  charged  ECM  components  does  indeed  
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take  place  [82].  If  desired,  cells  can  be  added  to  the  hydrogel  to  look  beyond  transport,  at  
the  effect  of  ECM  on  uptake  and  transfection.  More  sophisticated  hydrogel  systems  can  
be  perfused  to  more  accurately  mimic  the  situation  in  vivo  where  fluids  flow  and  
influence  nanoparticle  transport  [83].  Hydrogels  also  allow  real-­‐‑time  nanoparticle  
imaging  in  situ  without  any  significant  processing  required.      
A  more  complex  3-­‐‑D  model  of  spherical  cell  clusters  that  secrete  their  own  ECM  
is  called  the  multicellular  spheroid  [84-­‐‑87].  As  perhaps  the  smallest  approximation  of  
native  tissues,  multicellular  spheroids  are  a  convenient  means  of  probing  polyplex  
transport  and  stability  in  the  intact  spheroid,  and  subsequently  in  the  constituent  cells  
upon  enzymatic  disruption  [88].  They  can  be  grown  to  reach  various  sizes,  up  to  a  few  
millimeters  in  diameter.  They  produce  ECM  in  a  3-­‐‑D  manner  similar  to  native  biological  
tissues,  with  a  composition  more  like  native  tissues  than  hydrogels  made  of  only  a  few  
components  [89].  Small  spheroids  consist  entirely  of  healthy  cells  that  can  be  used  to  
study  polyplex  distribution  and  transport  in  normal  tissues.  Larger  spheroids  more  
closely  resemble  tumor  tissue,  with  distinct  proliferating,  quiescent,  and  necrotic  
regions.  Multicellular  spheroids,  as  with  hydrogels,  can  be  used  to  study  the  effects  of  
polyplex  size,  shape,  charge,  and  functionalization  on  transport  and  transfection.  Data  
collection  is  facile,  often  taking  place  in  the  form  of  confocal  microscopy,  
immunohistochemistry,  or  flow  cytometry  of  the  dissociated  spheroid  cells.  The  use  of  
multicellular  spheroids  is  becoming  more  widespread  as  the  need  to  evaluate  gene  
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carriers  in  3-­‐‑D  systems  becomes  more  apparent.  
Multilayer  cell  cultures  are  another  useful  tool  for  studying  the  transport  and  
stability  of  polyplexes.  Using  transwell  type  culture  plates,  one  layer  of  cells  can  be  
cultured  on  a  semi-­‐‑permeable  membrane  insert.  Beneath  the  membrane  is  a  layer  of  
culture  medium  covering  a  second  layer  of  cells.  Multilayer  systems  are  especially  useful  
for  modeling  scenarios  in  which  polyplexes  must  pass  through  a  layer  of  cells  prior  to  
reaching  their  target  cells.  Such  situations  are  encountered  in  extravasation  through  the  
vascular  endothelium  after  systemic  administration  of  polyplexes,  as  well  as  in  the  
escape  from  the  gut  through  the  intestinal  epithelium  in  oral  gene  delivery.  Similar  
barriers  are  found  in  the  airway  epithelium  encountered  by  polyplexes  delivered  to  the  
respiratory  system.  Multilayer  transwell  culture  models  have  been  developed  to  study  
each  of  these  situations  [90-­‐‑93].  Additionally,  each  layer  in  the  multilayer  system  is  not  
confined  to  a  single  cell  type.  Co-­‐‑cultures  can  be  seeded  on  either  layer  to  more  
accurately  mimic  the  situation  in  vivo.  For  example,  the  intestinal  epithelium  contains  
mucus-­‐‑secreting  goblet  cells  and  M-­‐‑cells  of  the  immune  system  that  continually  shuttle  
particulate  contents  of  the  intestinal  lumen  to  their  basolateral  side  via  transcytosis.  The  
presence  of  mucus  and  transcytotic  activity  could  significantly  alter  the  transport  
characteristics  of  polyplexes  involved  in  oral  gene  delivery,  so  the  inclusion  of  these  cell  
types  in  co-­‐‑culture  multilayer  transwell  models  could  provide  valuable  information  [94-­‐‑
96].  
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The  final  category  of  common  3-­‐‑D  models  is  ex  vivo  tissue  cultures.  By  using  
tissue  directly  from  an  animal  or  patient,  preservation  of  the  native  ECM  structure  and  
composition,  cell  organization,  and  cell  phenotypes  is  possible.  Such  models  have  a  
higher  likelihood  of  predicting  in  vivo  efficacy  accurately.  Ex  vivo  cultures  of  a  wide  
range  of  tissue  types  have  been  successful:  liver,  cartilage,  airway  epithelium  [97],  lung  
[98],  and  intestine  [99].  Imaging,  histology,  and  most  other  standard  assays  are  feasible  
with  ex  vivo  tissue  cultures.  The  drawbacks  of  using  tissue  explants  for  the  evaluation  of  
gene  carriers  include  the  cost  and  ethics  associated  with  the  use  of  primary  tissues,  as  
well  as  the  relative  difficulty  of  maintaining  the  architecture  and  phenotype  of  entire  
tissues  compared  to  more  basic  cell  layers  and  spheroids.  However,  they  still  may  
provide  the  most  accurate  information  about  transfection  capabilities  short  of  testing  in  
animal  models.      
2.5 Cell-Specific Design Requirements 
A  final  consideration  in  carrier  design  is  the  potential  differences  in  the  desired  
protection  and  release  characteristics  of  polyplexes  when  introduced  to  different  cell  
types.  The  transfection  efficiency  of  a  gene  carrier  can  vary  by  orders  of  magnitude  
depending  on  the  cell  type  being  transfected.  One  can  envisage  that  metabolically  active  
cells  favor  a  tilt  towards  protection  whereas  slowly  proliferating  cells  might  favor  more  
rapid  unpacking.  The  proliferation  rate  of  target  cells  can  play  a  major  role  in  whether  or  
not  polyplexes  gain  access  to  the  nucleus  where  some  unpacking  has  been  shown  to  take  
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place.  During  each  iteration  of  the  cell  cycle,  the  nuclear  envelope  is  broken  down  and  
reformed.  While  the  nuclear  envelope  becomes  discontinuous  during  mitosis,  
polyplexes  or  DNA  may  diffuse  into  what  will  become  the  nucleus  of  the  daughter  cells  
and  eventually  be  transcribed.  In  a  non-­‐‑dividing  cell,  they  may  have  been  unable  to  
penetrate  the  nucleus.  This  is  often  the  case  with  primary  cells  and  cells  of  the  immune  
system  that  proliferate  more  slowly  than  transformed  cell  lines,  accounting  for  the  lower  
transfectability  of  the  former.      
Furthermore,  cells  internalize  polyplexes  through  a  variety  of  uptake  pathways,  
including  clathrin-­‐‑mediated  endocytosis,  calveolin-­‐‑mediated  endocytosis,  clathrin-­‐‑  and  
calveolin-­‐‑independent  endocytosis,  macropinocytosis,  and  phagocytosis  [100,  101].  The  
route  ultimately  taken  likely  depends  on  the  target  cell  type,  as  well  as  polyplex  size  and  
vector  physiochemical  properties.  To  maximize  efficacy,  the  anticipated  internalization  
pathway  should  be  considered  during  the  vector  design  process.  Another  difference  
between  cell  types  is  the  amount  and  composition  of  extracellular  matrix  they  secrete.  
Secretion  of  a  large  volume  of  ECM  with  small  pore  sizes  will  certainly  diminish  the  
ability  of  polyplexes  to  reach  and  transfect  cells.  Other  cell  types  pose  unique  challenges,  
such  as  the  macrophage.  Macrophages  are  a  key  component  in  inflammatory  reactions  
and  the  foreign  body  response.  They  also  function  as  antigen-­‐‑presenting  cells  and  
participate  in  B  and  T  lymphocyte  development.  Thus,  they  are  desirable  targets  for  
gene  delivery.  Unfortunately,  macrophages  are  very  active  in  phagocytosis  and  
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degradation  of  particulate  matter  they  consume  [102].  Polyplexes  internalized  by  
macrophages  rarely  escape  the  phagocytic/endocytic  pathway  and  are  usually  degraded.  
However,  these  same  challenges  sometimes  offer  unique  opportunities  to  hijack  cellular  
processes  to  enhance  gene  delivery.  Acid-­‐‑labile  carriers  are  being  developed  to  respond  
to  the  acidic  environments  typical  of  macrophage  phagosomes  [103].  This  is  one  
example  of  the  special  rational  design  considerations  that  will  be  necessary  to  efficiently  
transfect  troublesome  cell  types.  
2.6 Conclusions on Carrier Design and Selection 
Computational  models  and  experimental  evidence  have  shown  that  inadequate  
protection  and  inefficient  release  of  DNA  from  polymeric  vectors  are  both  serious  
obstructions  to  successful  gene  delivery.  A  thorough  understanding  of  the  properties  
and  processes  that  contribute  to  the  protection  and  release  of  DNA  in  polyplex-­‐‑mediated  
gene  delivery  systems  is  indispensable  to  the  rational  design  of  future  vectors.  
Phenomenological  comparisons  of  vectors  based  on  readouts  of  reporter  genes  offer  
only  a  glimpse  into  the  complex  systems  involved  in  transfection  of  cells  and  transport  
through  tissues.  The  rate-­‐‑limiting  barriers  are  undoubtedly  multifactorial,  so  a  
systematic  engineering  approach  is  the  only  way  to  gain  an  understanding  of  why,  how,  
where,  and  when  one  carrier  is  superior  to  another.        
Researchers  have  now  begun  to  study  and  isolate  each  step,  and  each  molecule,  
of  the  nonviral  gene  delivery  process.  The  accumulation  of  knowledge  from  both  the  life  
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sciences  and  physical  sciences  has  made  such  an  interdisciplinary  approach  to  the  
problem  possible.  When  changing  polymer  properties  such  as  the  molecular  weight  and  
charge  density  is  insufficient  to  provide  optimal  protection  and  release,  some  polymers  
can  be  made  to  respond  to  environmental  or  applied  stimuli.  Changes  in  temperature,  
light,  pH,  and  redox  potential  can  be  harnessed  to  trigger  a  switch  from  a  protective  
complex  to  one  favoring  release.  Ternary  polyplexes  can  be  formed  by  the  inclusion  of  
enzymes  or  genes  meant  to  help  relax  the  ECM  to  facilitate  extracellular  transport  or  
degrade  the  polymeric  carrier  intracellularly  to  allow  DNA  release.      
Fortunately,  the  developmental  pace  for  imaging  technologies  and  engineering  
models  is  accelerating.  Fluorescence  imaging  techniques  have  advanced  from  the  
colocalization  of  fluorescently  labeled  DNA  and  polymer  to  much  more  sophisticated  
technologies  such  as  quantum  dot  mediated  FRET,  fluorescence  correlation  
spectroscopy,  and  non-­‐‑fluorescence  techniques  like  MRI.  Furthermore,  these  techniques  
are  often  combined  with  three-­‐‑dimensional  models  that  can  recapitulate  native  tissues  
with  high  fidelity.  It  is  at  the  interface  between  materials  science,  imaging,  and  biology  
that  nonviral  gene  delivery  will  make  progress  towards  meaningful  clinical  translation.  
While  the  task  remains  daunting,  successful  nonviral  gene  therapy  is  crucial  to  realizing  
the  potential  of  genetic  medicine.  As  future  therapeutics  will  increasingly  rely  on  nucleic  
acids  such  as  DNA,  antisense  oligonucleotides,  therapeutic  RNA,  and  siRNA,  the  
rewards  for  this  line  of  investigation  will  continue  to  multiply.  
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2.7 QD-FRET Nanosensors 
The  rational  design  of  improved  carriers  depends  on  a  quantitative,  mechanistic  
understanding  of  the  rate-­‐‑limiting  barriers  to  efficient  intracellular  delivery.  Separation  
of  the  nucleic  acid  from  the  carrier  is  one  of  the  barriers,  which  may  be  analyzed  by  
Förster  resonance  energy  transfer  (FRET),  a  mechanism  used  to  detect  interactions  
between  fluorescently  labeled  molecules.  When  applied  to  the  molecular  components  of  
polymer  or  lipid-­‐‑based  nanocomplexes,  FRET  provides  information  on  their  
complexation  status,  uptake,  release,  and  degradation.  Recently,  the  design  of  FRET  
systems  incorporating  quantum  dots  as  energy  donors  has  led  to  improved  signal  
stability  allowing  prolonged  measurements,  as  well  as  increased  sensitivity  enabling  
direct  detection  and  the  potential  for  multiplexing.  The  union  of  quantum  dots  and  
FRET  is  providing  new  insights  into  the  mechanisms  of  nonviral  nucleic  acid  delivery  
through  convergent  characterization  of  delivery  barriers,  and  has  the  potential  to  
accelerate  the  design  of  improved  carriers  to  realize  the  potential  of  nucleic  acid  
therapeutics  and  gene  medicine.  
2.7.1 Role of QD-FRET in Nonviral Gene Delivery 
Delivery  of  gene-­‐‑loaded  nanocomplexes  into  cells  has  emerged  as  an  essential  
tool  in  modern  therapeutics  and  biomedical  research.  Compared  with  viral  vectors,  the  
main  advantages  of  nonviral  gene  carriers  are  diminished  immunogenicity,  ease  of  
scale-­‐‑up,  and  tremendous  potential  for  optimization.  Their  primary  weakness,  however,  
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has  been  poor  transfection  efficiency.  The  putative  barriers  associated  with  the  low  
efficiency  of  nonviral  vectors  are  illustrated  in  Figure  6:  (i)  cellular  binding  and  uptake,  
(ii)  endosomal  escape,  (iii)  cytosolic  transit  to  the  nucleus  and  unpacking,  (iv)  nuclear  
entry,  and  (v)  transcriptional  processing.  
  
  
Figure  6.  Intracellular  Transport  and  Release  	  The  putative  barriers  contributing  to  the  low  transfection  efficiency  typically  achieved  
by  nonviral  delivery  systems  are  illustrated.  Additional  processes  such  as  exocytosis  and  
endolysosomal  degradation  may  also  contribute  to  diminished  transfection.  Unpacking  
may  occur  in  any  of  the  subcellular  compartments,  while  it  is  also  possible  for  intact  
complexes  to  enter  the  nucleus.  
  
Quantitative  intracellular  trafficking  studies  enable  the  identification  of  these  
rate-­‐‑limiting  barriers,  which  can  differ  widely  between  delivery  systems.  Some  carriers,  
especially  those  incorporating  polyethylene  glycol  (PEG)  for  steric  stabilization,  are  
plagued  by  poor  cellular  uptake  [104,  105].  Others  lack  sufficient  buffering  capability  to  
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exploit  the  proton  sponge  effect  for  efficient  endosomal  escape  [106].  Some  types  of  
nanoparticles  reach  the  nucleus  of  target  cells  but  still  fail  to  mediate  robust  transgene  
expression  [107].  With  such  disparate  behavior  among  different  types  of  nanocomplexes,  
the  ability  to  track  the  delivery  of  nucleic  acids  within  cells  is  crucial  to  understanding  a  
carrier’s  unique  strengths  and  limitations.  However,  measuring  only  the  spatiotemporal  
trafficking  activity  of  nanoparticles  neglects  other  critical  aspects  of  the  complex  process.  
To  be  effective,  nucleic  acids  must  be  condensed  and  protected  from  enzymatic  
degradation  en  route  to  their  destination,  where  they  should  be  quickly  released  [108].  
The  dissociation  status  of  the  nanocomplex  and  payload  integrity  at  each  point  are  
equally  as  important  as  their  transport  in  ensuring  that  the  therapeutic  agent  is  
delivered  intact  and  available  for  processing.  The  ability  to  simultaneously  detect  
subcellular  location,  nanocomplex  stability,  and  payload  integrity  with  increased  
precision  would  promote  the  establishment  of  more  robust  structure-­‐‑function  
relationships  and  accelerate  the  rational  design  of  improved  gene  carriers.  
Fluorescence-­‐‑based  methods  have  been  the  techniques  of  choice  to  study  the  
physicochemical  properties  and  intracellular  trafficking  of  nanocomplexes  [109-­‐‑111].  
Interactions  between  a  nucleic  acid  payload  and  its  polymer  or  lipid  carrier  can  be  
probed  using  fluorescently  labeled  molecular  components  and  followed  from  the  
extracellular  domain  to  the  cytoplasm  or  nucleus  under  physiological  conditions  [47,  62,  
109,  112].  Colocalization  of  their  signals  provides  some  indirect  information  about  their  
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interactions  [113].  However,  detection  of  dissociation  and  release  is  limited  by  the  need  
to  resolve  distinct  signals  from  components  that  may  not  have  achieved  sufficient  
separation.  Therefore,  such  detection  methods  do  not  offer  the  requisite  sensitivity  to  
precisely  detect  the  onset  of  dissociation,  or  to  differentiate  between  molecules  that  are  
interacting  or  simply  adjacent.  FRET  has  advantages  over  colocalization  due  to  its  
unique  ability  to  resolve  molecular  interactions  beyond  the  diffraction  limit  of  
conventional  microscopy  [114].  When  FRET  occurs,  a  donor  fluorophore  excites  an  
acceptor  via  a  non-­‐‑radiative  dipole-­‐‑dipole  interaction  if  they  are  sufficiently  close  
(within  ~10nm).  This  so-­‐‑called  “molecular  ruler”  can  be  used  to  determine  distances  
between  labeled  molecules  inside  cells,  including  gene  carriers  and  nucleic  acids.  The  
ability  to  detect  nanometer-­‐‑scale  separations  of  nanocomplex  components  makes  FRET  a  
more  powerful  tool  than  fluorescence  colocalization  for  studying  nanocomplex  stability  
and  dissociation.  
Recently,  some  researchers  have  chosen  to  design  FRET  pairs  that  employ  
luminescent  semiconducting  nanocrystals  called  quantum  dots  (QDs)  as  energy  donors.  
Conventional  fluorophores  suffer  from  chemical  and  photodegradation,  photobleaching,  
and  broad  spectra.  Conversely,  QDs  possess  resistance  to  bleaching  and  chemical  
degradation,  broad  absorption  spectra,  tunable  narrow  emission  spectra,  and  large  
energy  separation  between  excitation  and  emission  [115].  The  increased  stability  of  QDs  
makes  the  imaging  of  FRET  signals  over  extended  periods  of  time  possible.  
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Furthermore,  the  ability  to  tune  emissions  and  excite  multiple  QDs  at  a  single  
wavelength  creates  the  potential  for  multiplexing  [116].  The  first  reports  proposing  the  
use  of  QDs  in  biological  sensing  applications  generated  significant  excitement  [117,  118].  
In  2006,  the  specific  benefits  of  FRET  incorporating  QDs  (QD-­‐‑FRET)  for  the  study  of  
nonviral  gene  delivery  were  published  [58].  Since  then,  several  groups  adapted  and  
refined  the  technique  to  study  many  aspects  of  nonviral  nucleic  acid  delivery.  In  this  
section,  we  focus  on  the  use  of  QD-­‐‑FRET  as  a  tool  to  investigate  the  intracellular  fates  of  
nanocomplexes  used  to  deliver  nucleic  acids.  We  begin  by  detailing  the  rationale  and  
appeal  of  the  technique  before  exploring  specific  examples  of  its  use  and  considerations  
when  adopting  QD-­‐‑FRET  to  study  nonviral  nucleic  acid  delivery.  
2.7.2 Why QD-FRET? 
FRET  is  a  process  by  which  the  energy  of  a  donor  chromophore  is  non-­‐‑
radiatively  transferred  to  a  nearby  acceptor  molecule  via  a  dipole-­‐‑dipole  interaction,  
leading  to  a  decrease  in  the  donor  emission  and  a  concomitant  increase  in  acceptor  
emission  [49,  114].  A  general  expression  of  energy  transfer  efficiency,  E,  defined  in  
Equation  1,  accounts  for  the  fraction  of  excitons  transferred  from  the  donor  to  acceptor,  
where  kT  is  the  rate  of  nonradiative  energy  transfer,  τD  is  the  excited-­‐‑state  radiative  





















The  Förster  radius  R0,  defined  as  where  50%  of  energy  transfer  occurs,  is  a  
function  of  the  refractive  index  of  the  medium  (n,  typically  ranges  from  1.3  to  1.5),  the  
unperturbed  donor  photoluminescence  quantum  yield  (QD),  the  spectral  integral  from  
the  overlap  of  donor  emission  and  acceptor  absorption  (J(λ),  in  units  of  M-­‐‑1cm-­‐‑1nm4)  and  
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For  most  FRET  pairs,  R0  is  typically  a  few  nanometers,  enabling  optical  
measurements  of  changes  in  donor-­‐‑acceptor  separation  with  angstrom  resolution.  
Meanwhile,  the  sixth-­‐‑power  dependence  of  FRET  efficiency  on  the  donor-­‐‑acceptor  
distance  makes  FRET  well  suited  for  probing  conformational  changes  of  molecules  or  
detecting  interactions  between  molecules.      
Equation  2  illustrates  that  optimal  FRET  occurs  when  there  is  appreciable  
spectral  overlap  between  the  emission  spectrum  of  the  donor  and  the  absorption  
spectrum  of  the  acceptor,  while  the  spectral  overlap  of  the  donor  and  acceptor  emissions  
is  minimized.  Therefore,  the  broad  absorption  and  emission  spectra  of  organic  
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fluorophores  used  in  FRET  present  significant  challenges  for  reducing  direct  acceptor  
excitation  (simultaneous  excitation  of  energy  acceptor  and  donor)  and  crosstalk  (overlap  
of  donor  and  acceptor  emission  spectra),  as  depicted  in  Figure  7.  To  cope  with  these  
concerns,  some  researchers  are  turning  to  QDs  as  energy  donors  for  FRET  applications  
in  an  attempt  to  overcome  some  of  the  limitations  associated  with  conventional  organic  
FRET  pairs.  Their  benefits  include  diminished  spectral  crosstalk  and  direct  acceptor  
excitation  due  to  QDs  unique  photophysical  properties:  narrow  size-­‐‑tunable  emissions,  
extremely  high  extinction  coefficients  over  a  broad  absorption  range,  and  enhanced  
photostability  [119].  QDs  have  been  preferentially  adopted  as  energy  donors  rather  than  
acceptors  due  to  their  relatively  long  radiative  lifetime,  broad  excitation  range,  and  high  
extinction  coefficients  [120].  Readers  seeking  a  deeper  discussion  of  the  photophysics  of  





Figure  7.  Quantum  Dot-­‐‑FRET  
Absorption  and  emission  spectra  for  (A)  a  conventional  organic  fluorophore-­‐‑based  FRET  
pair  and  (B)  a  QD-­‐‑FRET  pair  with  a  QD  energy  donor.  Direct  acceptor  excitation  and  
donor-­‐‑acceptor  crosstalk  are  common  problems  with  traditional  organic  fluorophores.  
Substituting  QD  donors  avoids  these  concerns,  while  improving  other  properties  such  as  
a  larger  spectral  overlap  between  donor  emission  and  acceptor  absorption.  
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2.7.3 QD-FRET as a Novel Strategy to Study Nonviral Delivery 
Barriers 
Many  nonviral  systems  depend  on  interactions  such  as  electrostatic  attraction  
and  chain  entanglement  to  condense  and  protect  nucleic  acids  during  delivery.  Such  
interactions  have  been  studied  using  FRET  pairs  of  organic  fluorophores  either  doubly  
labeled  on  DNA  [52]  or  separately  labeled  on  gene  carriers  and  nucleic  acids  [121].  
However,  the  former  depends  on  stable  coil-­‐‑globule  transition  states  of  DNA  and  both  
require  additional  ratiometric  analysis  and  disambiguation.  Furthermore,  the  organic  
fluorophores  used  in  conventional  FRET  are  susceptible  to  photobleaching,  limiting  
their  utility  in  real-­‐‑time  studies  of  intracellular  trafficking  [114].  These  weaknesses  
highlighted  the  need  for  an  alternative.      
The  initial  report  of  QD-­‐‑FRET  for  the  study  of  nonviral  nucleic  acid  delivery  
described  a  sensitive  and  quantitative  indicator  of  the  stability  and  composition  of  
chitosan-­‐‑DNA  nanocomplexes  [58].  The  authors  labeled  biotinylated  plasmid  DNA  with  
streptavidin-­‐‑decorated  QDs,  and  conjugated  the  natural  polysaccharide  chitosan  with  
Cy5  dye.  The  resulting  high  signal-­‐‑to-­‐‑noise  ratio  enabled  digital  detection  of  the  
formation  and  dissociation  of  single  nanocomplexes  using  single  molecule  detection  
(Figure  8).  They  also  used  the  frequencies  of  QD  emission  before  and  after  nanocomplex  
disruption  to  estimate  the  number  of  plasmid  copies  contained  within  each  particle  
(~30),  which  they  validated  with  transmission  electron  microscopy.  Cells  readily  
internalized  the  QD-­‐‑FRET  nanocomplexes,  and  confocal  microscopy  revealed  intact  
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particles  in  both  the  cytoplasmic  and  nuclear  domains.  The  intracellular  dissociation  rate  
of  the  complexes  was  quantified,  and  the  disappearance  of  QD-­‐‑FRET  emission  showed  
that  most  particles  unpacked  within  48  hours.  
  
  
Figure  8.  QD-­‐‑FRET  Detection  of  Intracellular  Release.  
When  labeled  molecular  components  are  condensed  into  a  nanocomplex,  QD-­‐‑FRET  
results  in  acceptor  emission  upon  excitation  of  the  donor.  Once  the  complex  unpacks  in  
the  cell,  QD-­‐‑FRET  is  abolished  and  donor  emission  regained.  
  
Utilizing  the  ability  to  precisely  detect  DNA  release,  the  same  group  developed  a  
quantitative  model  to  describe  and  predict  distributions  of  free  DNA  throughout  several  
subcellular  compartments  over  time  [122].  The  average  unpacking  rate  constants  in  the  
endosomal,  cytoplasmic,  and  nuclear  domains  were  recorded  for  chitosan,  
polyethylenimine  (PEI),  and  poly(phosphoramidate)  (PPA)  nanocomplexes.  The  results  
were  then  correlated  with  transfection  efficiency  to  further  elucidate  the  contributions  of  
nanocomplex  stability  and  intracellular  trafficking  during  gene  transfer.  The  data  
revealed  a  compartmental  dependence  of  unpacking  between  carriers,  with  PEI  
unpacking  at  equal  rates  in  both  endosomal  and  cytosolic  compartments  and  PPA  
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unpacking  preferentially  in  the  cytosol.  The  results  supported  the  conclusion  that  
nanocomplexes  must  either  escape  the  endosome  quickly  (PEI)  or  remain  stable  within  
them  (PPA).  If  significant  unpacking  and  degradation  occurs  within  the  endosome  
(chitosan),  transfection  efficiency  may  suffer.  The  calculated  unpacking  rate  constants  
agreed  with  published  computational  models  based  on  intracellular  copy  number,  
although  release  of  DNA  from  PEI  nanocomplexes  occurred  earlier  than  previously  
reported  in  studies  using  colocalization  and  conventional  FRET  [123-­‐‑125].    
The  improved  stability  of  the  QD-­‐‑FRET  system  allowed  for  direct  measurement  
of  nanocomplex  stability  over  longer  periods  of  time,  and  its  inherent  sensitivity  led  to  
the  derivation  of  more  robust  quantitative  models  and  the  precise  determination  of  the  
unpacking  rate  constants  for  three  carriers.  The  technique  has  attracted  the  attention  of  
delivery  researchers  as  they  seek  high  quality  quantitative  data  in  understanding  the  
mechanisms  of  nucleic  acid  delivery  and  the  design  of  nonviral  systems.  The  field  is  
gaining  momentum  as  researchers  continue  to  refine  the  technique  and  reports  of  











Detection  approach     Significance  of  findings   Reference  
pDNA  
Chitosan  
Unpacking   Confocal  microscopy,  
single  molecule  
detection  
First  report  of  QD-­‐‑FRET  used  to  study  unpacking  





Unpacking   Confocal  microscopy   Kinetics  of  trafficking  and  unpacking  correlated  







Confocal  microscopy   Correlated  transfection  with  faster  uptake  and  
diminished  endosomal  unpacking  in  multiple  cell  




Unpacking   Confocal  microscopy   Higher  M.W.  chitosan  unpacks  faster  at  low  pH  






Confocal  microscopy   Demonstrated  intact  QD-­‐‑DNA  complexes  delivered  




Unpacking   Confocal  microscopy   Showed  that  different  carriers  deliver  DNA  to  




Unpacking   Confocal  microscopy   Validated  increased  extracellular  stability  of  
crosslinked  micelles,  leading  to  increased  




Unpacking   Confocal  microscopy   Showed  that  different  carriers  deliver  DNA  to  










Three  distinct  states  of  DNA  condensation  and  








Adding  Hph-­‐‑1  to  QD-­‐‑PEI  results  in  faster  






Confocal  microscopy   QDs  coated  with  amphipol  delivered  siRNA  










ODN  complexes  formed  with  a  polycation  are  











Complexation   Fluorescence  
microscopy  
Determined  kinetics  of  nanocomplex  self-­‐‑assembly  






Drug  release   Confocal  microscopy   Simultaneous  detection  of  drug  release,  
identification  of  cancer  cells,  and  targeted  cell  





2.7.4 Recent Applications of QD-FRET to Study Nonviral Delivery 
2.7.4.1  QD-­‐‑FRET  for  Delivery  of  Plasmid  DNA  
Plasmid  DNA  is  the  most  commonly  delivered  nucleic  acid,  and  it  follows  that  
QD-­‐‑FRET  has  been  most  often  applied  in  the  study  of  its  delivery.  Ulasov  et  al.  
employed  QD-­‐‑FRET  to  study  transfection  by  PEI-­‐‑DNA  nanocomplexes  in  multiple  cell  
types,  and  used  the  results  to  derive  new  mathematical  models  to  quantify  intracellular  
trafficking  [126].  They  functionalized  the  particles  with  PEG  and  TAT  peptide  to  
modulate  stability  and  cellular  uptake.  PEG  incorporation  conceals  the  surface  charge  of  
nanoparticles  and  results  in  prolonged  residence  in  circulation  following  systemic  
delivery,  and  the  incorporation  of  TAT-­‐‑peptide  enhances  cellular  penetration.  The  
authors  delivered  complexes  with  different  PEI:PEG  and  PEI:DNA  ratios  to  cells  and  
studied  their  trafficking  via  colocalization  with  fluorescently  labeled  plasma  
membranes,  endolysosomal  compartments,  and  nuclei.  Relying  on  QD-­‐‑FRET  to  detect  
particle  integrity,  they  used  experimental  data  to  calculate  the  rates  of  15  different  
aspects  of  the  transfection  process  including  unpacking  and  accumulation  of  DNA  in  the  
cytosolic,  endolysosomal,  and  nuclear  compartments.  They  observed  that  transfection  
efficiency  was  positively  correlated  with  the  rate  of  cellular  uptake  but  negatively  
correlated  with  the  rate  of  unpacking  within  the  endosomes  and  lysosomes,  and  used  
these  correlations  to  explain  differences  in  transfection  and  establish  the  optimal  
component  ratios  in  their  carrier  design  to  maximize  efficiency.  
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For  chitosan-­‐‑based  delivery  systems,  it  is  known  that  transfection  depends  
heavily  on  polymer  molecular  weight,  and  overly  tight  binding  is  typically  considered  a  
critical  barrier  [138].  As  chitosan  possesses  no  stimulus-­‐‑responsive  degradative  
mechanism,  DNA  must  be  released  in  response  to  natural  chemical  changes  in  its  
surroundings.  For  instance,  increasing  ionic  strength  in  the  endosomal  compartment  
may  disrupt  electrostatic  interactions  between  DNA  and  the  polycation.  Another  
possibility  is  that  hyperprotonation  of  the  amine  groups  of  chitosan  may  occur  during  
endosomal  acidification,  leading  to  electrostatic  repulsion,  elongation,  and  
disentanglement  of  polymer  chains  from  DNA.  This  effect  would  be  more  pronounced  
with  higher  weight  chitosan.  Lee  et  al.  observed  this  phenomenon  using  QD-­‐‑FRET,  and  
demonstrated  that  nanoparticles  generated  with  higher  molecular  weight  chitosan  
dissociate  faster  in  acidic  conditions  similar  to  those  found  in  the  lysosome  [127].  The  
result  was  reproduced  in  living  cells,  lending  credence  to  the  proposed  mechanism  by  
which  high  molecular  weight  chitosan  mediates  higher  transfection  levels  than  shorter  
polymer  chains.  
Some  researchers  choose  to  use  intercalating  DNA  dyes  as  QD-­‐‑FRET  
components.  While  the  amount  of  dye  must  be  tuned  to  optimize  the  signal-­‐‑to-­‐‑noise  
ratio,  no  chemical  conjugation  or  separation  steps  are  necessary.  Intercalating  dyes  may  
also  be  a  means  to  include  more  acceptors  per  donor  than  would  otherwise  be  possible,  
increasing  the  overall  FRET  efficiency.  In  one  such  case,  a  lipid-­‐‑based  transfection  
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reagent  was  used  to  deliver  QD  donors  conjugated  to  DNA  labeled  with  the  BOBO-­‐‑3  
intercalating  dye  as  the  acceptor  [128].  Four  hours  after  transfection,  QD-­‐‑FRET  signal  
was  detected  throughout  the  cytoplasm  and  perinuclear  region,  indicating  the  presence  
of  intact  complexes  in  those  regions.  Although  the  QDs  and  DNA  were  stably  
conjugated,  differences  in  QD-­‐‑FRET  signal  were  detected  between  condensed  particles  
and  those  that  were  released.  As  the  signal  dissipated,  the  authors  measured  both  
trafficking  and  unpacking  kinetics.  The  application  of  QD-­‐‑FRET  in  a  lipid-­‐‑based  
delivery  system  and  use  of  DNA  intercalating  acceptors  are  the  most  novel  and  
interesting  features  of  these  studies.  
QD-­‐‑FRET  has  also  been  incorporated  into  more  complex  delivery  systems.  
Harashima’s  group  has  engineered  a  lipid  based  tetra-­‐‑lamellar  multifunctional  
envelope-­‐‑type  nano  device  (T-­‐‑MEND)  containing  a  polycation-­‐‑DNA  core  encapsulated  
by  inner  nuclear  membrane  and  outer  endosome  fusogenic  envelopes  that  facilitate  
nuclear  entry  and  endosomal  escape,  respectively  [129].  T-­‐‑MEND  particles  were  formed  
with  QD-­‐‑labeled  DNA  and  their  synthetic  polymer,  a  biocleavable  polyrotaxane  
modified  with  dimethylaminoethyl-­‐‑modified  α−cyclodextrin  and  a  disulfide-­‐‑linked  PEG  
chain  (DMAE-­‐‑ss-­‐‑PRX),  labeled  with  rhodamine  energy  acceptors.  Using  QD-­‐‑FRET  they  
found  that  modulation  of  the  supra-­‐‑molecular  structure  of  DMAE-­‐‑ss-­‐‑PRX  caused  a  shift  
in  decondensation  to  regions  of  euchromatin  in  the  nucleus.  This  was  the  first  report  of  
directed  unpacking  to  a  specific  nuclear  sub-­‐‑domain  using  a  polymeric  carrier.  Using  
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low  molecular  weight  polymer  resulted  in  equal  delivery  to  regions  of  hetero-­‐‑  and  
euchromatin,  but  unpacking  occurred  preferentially  in  regions  of  heterochromatin.  
Particles  containing  higher  molecular  weight  polymer  delivered  more  DNA  to  the  
nucleus,  with  more  than  70%  deposited  to  euchromatin  regions.  The  authors  
hypothesized  that  the  shorter  polymer  generates  a  weakly  associated  core  that  is  easily  
disrupted  by  the  high  concentration  of  cationic  histones  contained  in  the  
heterochromatin  adjacent  to  the  nuclear  membrane.  More  stable  cores  may  reach  the  
euchromatin  regions  intact,  where  activity  of  the  nuclear  transcriptional  machinery  may  
encourage  their  dissociation.  Deposition  of  free  DNA  into  transcriptionally  active  
euchromatin  regions  increases  transgene  expression  levels.  Using  QD-­‐‑FRET  the  authors  
quantified  three  states  of  complex  dissociation  and  intranuclear  disposition,  elucidating  
a  mechanism  that  accounts  for  the  different  efficiencies  of  two  carriers.  
Characterization  and  optimization  of  custom  delivery  systems  have  proven  to  be  
valuable  applications  for  QD-­‐‑FRET.  Jiang  et  al.  designed  micellar  DNA  nanocomplexes  
with  a  PEG-­‐‑b-­‐‑PPA  polymer  for  targeted  delivery  to  the  liver  [130].  Micelles  made  with  
high  molecular  weight  PPA  blocks  exhibited  instability  in  physiological  salt  solutions  
[131].  Taking  advantage  of  this  rapid  mode  of  unpacking,  they  added  bioreducible  
crosslinkers  to  enhance  stability  prior  to  reaching  the  cytoplasm.  The  crosslinked  
micelles  remained  stable  in  serum  and  ionic  solutions,  but  degraded  in  a  similar  manner  
to  non-­‐‑crosslinked  analogs  in  the  presence  of  salt  following  crosslink  reduction  in  the  
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cytoplasm.  This  dual  sensitivity  provided  stability  in  the  extracellular  and  endocytic  
compartments,  while  enabling  rapid  cytosolic  release  of  DNA.  As  expected,  the  custom  
carrier  mediated  higher  and  more  prolonged  transfection  levels  than  non-­‐‑crosslinked  
analogs.  The  authors  used  QD-­‐‑FRET  to  study  the  intracellular  behavior  of  crosslinked  
and  non-­‐‑crosslinked  carriers  by  measuring  distributions  of  intact  and  unpacked  micelles  
in  the  cytosol,  endolysosomal,  and  nuclear  compartments.  The  dual-­‐‑sensitive  micelles  
unpacked  much  more  slowly,  and  tended  to  release  their  payload  in  the  cytoplasm  and  
nucleus.  They  yielded  higher  transfection  levels,  improved  extracellular  stability,  and  
more  sustained  gene  expression.  In  this  case,  quantitative  QD-­‐‑FRET  studies  elucidated  
the  mechanism  by  which  enhanced  extracellular  micelle  stability  results  in  improved  
performance.  
2.7.4.2  QD-­‐‑FRET  for  Alternative  Nucleic  Acid  Payloads  
In  addition  to  plasmid  DNA,  delivery  of  other  nucleic  acids  is  also  attractive  for  
both  clinical  and  research  applications.  Small  interfering  RNA  (siRNA)  delivered  
intracellularly  triggers  RNA  interference  (RNAi)  and  leads  to  the  specific  knockdown  of  
expression  of  the  target  gene.  While  efficient  uptake,  subcellular  trafficking,  and  
cytoplasmic  release  remain  necessary,  delivery  of  siRNA  does  not  require  nuclear  entry  
or  transcription.  To  study  siRNA  delivery  and  the  effect  of  carrier  functionalization  with  
cell  penetrating  peptides,  Lee  et  al.  designed  a  QD-­‐‑FRET  pair  by  attaching  QDs  to  PEI  
and  Cy5  to  siRNA  [132].  Instead  of  using  image  analysis  to  quantify  nanocomplex  
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disassembly,  the  authors  instead  opted  for  a  high-­‐‑throughput  approach  using  flow  
cytometry.  They  measured  the  kinetics  of  endocytic  and  non-­‐‑endocytic  uptake,  
intracellular  trafficking,  and  dissociation  of  nanocomplexes  with  and  without  the  cell  
penetrating  peptide  (CPP)  Hph-­‐‑1.  Detection  of  QD-­‐‑FRET  intensity  by  flow  cytometry  
showed  that  QD-­‐‑PEI-­‐‑CPP  complexes  were  both  internalized  and  unpacked  faster  than  
those  composed  of  non-­‐‑functionalized  QD-­‐‑PEI.  Both  types  ultimately  unpacked  almost  
completely  within  five  hours.  The  difference  in  early-­‐‑stage  behavior  was  attributed  to  
the  need  for  QD-­‐‑PEI  complexes  to  escape  endosomes  before  unpacking,  and  there  was  
no  difference  in  gene  silencing  after  24  hours.  Interestingly,  QD-­‐‑PEI  complexes  mediated  
more  gene  silencing  than  unconjugated  PEI,  which  the  authors  attributed  to  altered  
physical  properties  that  increased  endocytic  uptake.  In  this  case,  QD-­‐‑FRET  coupled  with  
flow  cytometry  enabled  high-­‐‑throughput  quantification  of  dissociation  kinetics.  
However,  confocal  fluorescence  microscopy  techniques  and  image  analysis  were  needed  
to  determine  the  subcellular  compartment  in  which  dissociation  occurred.  
Another  group  used  QD-­‐‑FRET  to  study  complexes  formed  with  QDs  modified  to  
bind  and  deliver  siRNA  [133].  Qi  et  al.  conjugated  poly(maleic  anhydride-­‐‑alt-­‐‑1-­‐‑decene)  
modified  with  dimethylamino  propylamine  to  custom  synthesized  QDs.  The  resulting  
carriers  were  small  (~  12  nm),  water-­‐‑soluble  particles  with  a  positive  zeta  potential  that  
could  bind,  protect,  and  efficiently  deliver  siRNA  into  cells.  Binding  of  FITC-­‐‑labeled  
siRNA  was  detected  by  the  quenching  of  FITC  signal  by  FRET  following  addition  of  
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sufficient  red-­‐‑emitting  QDs  serving  as  acceptors.  The  nanocomplexes  remained  
colloidally  stable  and  mediated  robust  gene  silencing  in  both  serum-­‐‑free  and  complete  
culture  media.  QD  emission,  along  with  the  absence  of  FITC  signal,  allowed  tracking  of  
the  binding  and  uptake  of  intact  complexes.  Appearance  of  FITC  signal  after  1.5  hours  
indicated  the  onset  of  siRNA  release.  After  5  hours,  FITC-­‐‑labeled  free  siRNA  was  
observed  distributed  throughout  the  cytoplasm.  By  functionalizing  QDs  with  an  
amphipathic  brush,  the  authors  generated  a  novel  QD-­‐‑based  siRNA  delivery  system  
with  integrated  imaging  capabilities.  As  QDs  are  further  developed  as  carriers  
themselves,  QD-­‐‑FRET  promises  to  play  an  even  greater  role  in  the  design  and  use  of  
such  delivery  systems.  
Another  payload  of  interest  is  oligodeoxynucleotides  (ODN).  Antisense  ODN  
delivered  to  the  cytoplasm  of  cells  can  inhibit  expression  of  a  specific  gene  by  binding  its  
complimentary  mRNA  transcript  to  block  ribosomal  access  and  hasten  its  degradation.  
QD-­‐‑FRET  has  been  used  to  study  and  compare  the  uptake  and  intracellular  fate  of  ODN  
delivered  by  either  lipoplex  or  polyplex  [134].  Incorporation  of  QD-­‐‑FRET  pairs  did  not  
affect  the  performance  of  the  ODN  in  either  case.  PEI-­‐‑ODN  nanocomplexes  were  
internalized  more  readily  during  the  first  hour  of  transfection,  likely  due  to  a  more  
positive  zeta  potential  than  the  lipoplexes.  The  intracellular  QD-­‐‑FRET  signals  from  both  
carrier  types  equilibrated  by  the  end  of  the  four-­‐‑hour  transfection  period,  and  some  
unpacking  was  observed  as  early  as  four  hours  post-­‐‑transfection.  Polymer-­‐‑ODN  
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nanocomplexes  demonstrated  a  much  higher  rate  of  dissociation  than  lipoplexes,  and  
unpacking  of  nearly  all  complexes  of  both  types  was  observed  by  48  hours  post-­‐‑
transfection.  Furthermore,  the  presence  of  intracellular  QD-­‐‑FRET  signal  in  cells  
incubated  with  liposomes  indicates  that  the  complexes  are  internalized  via  endocytosis  
rather  than  membrane  fusion,  which  would  result  in  immediate  dissociation  and  
elimination  of  FRET.  In  this  case,  despite  the  differences  in  uptake  and  unpacking  rates,  
ODN-­‐‑mediated  inhibition  of  gene  expression  was  similar  for  both  delivery  systems.  
2.7.4.3  QD-­‐‑FRET  for  Mechanistic  Studies  
In  addition  to  its  utility  in  the  study  of  nanoparticle  trafficking  and  identification  
of  intracellular  barriers  to  delivery,  QD-­‐‑FRET  is  also  applicable  to  the  more  
fundamental,  mechanistic  studies  associated  with  the  design  phase  of  nonviral  carrier  
systems.  Specifically,  QD-­‐‑FRET  has  been  used  in  cell-­‐‑free  systems  to  scrutinize  
nanocomplex  self-­‐‑assembly,  composition,  and  stability.  A  thorough  understanding  of  
these  processes  and  properties  combined  with  precise  quantitative  data  will  accelerate  
the  evolution  of  improved  carriers.  
An  interesting  quenching  phenomenon  discovered  between  QDs  and  the  
pentablock  copolymer,  poly(diethylaminoethylmethacrylate)  (PDEAEM)/Pluronic  F127  
allowed  Zhang  et  al.  to  study  the  effects  of  chloroquine  on  complex  stability  and  DNA  
release  in  a  cell  free  assay  [135].  Chloroquine  is  a  lysosomotropic  agent  known  to  
enhance  transfection  in  many  systems,  and  may  participate  in  the  dissociation  of  DNA  
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from  polymer  carriers.  The  emission  of  cysteine  coated  QDs  was  quenched  via  FRET  by  
both  plasmid  DNA  and  pentablock  copolymer,  but  not  by  pre-­‐‑formed  polymer-­‐‑DNA  
nanocomplexes.  Reductions  in  QD  emission  in  the  presence  of  complexes  thus  indicated  
dissociation  and  the  release  of  freed  components.  Addition  of  chloroquine  resulted  in  
quenching  that  varied  linearly  with  the  concentration  of  chloroquine  added.  This  result  
revealed  the  contribution  of  chloroquine  to  complex  destabilization  and  demonstrated  
the  feasibility  of  using  QD-­‐‑FRET  to  measure  induced  dissociation  in  a  well-­‐‑defined,  cell-­‐‑
free  setting  
In  an  attempt  to  understand  the  poorly  understood  process  of  nanocomplex  self-­‐‑
assembly,  Ho  et  al.  combined  QD-­‐‑FRET  with  microfluidic  technology  to  monitor  
polymer-­‐‑DNA  complexation  with  millisecond  resolution  [136].  By  generating  complexes  
on  a  microfluidic  chip,  they  were  able  to  eliminate  many  of  the  forces  involved  with  
typical  bulk  mixing  to  isolate  the  assembly  process.  Solutions  of  Cy5-­‐‑labeled  chitosan  
and  QD-­‐‑DNA  were  introduced  into  microchannels  under  laminar  flow  conditions,  and  
self-­‐‑assembly  occurred  at  the  channel  interface.  The  band  of  QD-­‐‑FRET-­‐‑mediated  Cy5  
signal  grew  wider  and  brighter  with  distance  as  the  complexes  nucleated,  matured,  and  
diffused  outward,  creating  a  spatial  signal  pattern  that  was  subsequently  transformed  to  
determine  the  kinetic  parameters  of  self-­‐‑assembly.  The  authors  described  two  distinct  
stages  of  the  assembly  process:  a  primary  stage  where  assembly  was  determined  to  be  
diffusion-­‐‑limited,  and  a  secondary  diffusion-­‐‑reaction  limited  stage.  QD-­‐‑FRET  provided  
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a  sensitive  and  quantitative  indication  of  the  onset  and  progression  of  molecular  
interactions  throughout  the  self-­‐‑assembly  process.  Such  a  system  could  be  used  to  screen  
the  chemical  properties  of  carriers  that  affect  DNA  condensation,  nanocomplex  size  and  
structure,  and  ultimately  their  efficiency.  The  same  group  also  used  single  molecule  
detection  to  compare  the  rates  of  QD  emission  before  and  after  nanocomplex  disruption  
to  determine  the  number  of  plasmid  copies  within  each  nanoparticle  [58].  The  single  
particle  analysis  of  the  nanocomplex  facilitates  understanding  of  the  physicochemical  
basis  for  its  biological  performance.  
2.7.4.4  Two-­‐‑Step  QD-­‐‑FRET  
The  narrow  emission  spectra  and  broad  absorption  windows  of  QDs  make  them  
a  natural  choice  for  multiplexed  applications,  allowing  the  simultaneous  detection  of  
two  or  more  processes.  Instead  of  investigating  each  delivery  barrier  independently,  
Chen  et  al.  recently  proposed  an  integrated  approach  to  monitor  DNA  release  and  
degradation  simultaneously  with  two-­‐‑step  QD-­‐‑FRET  [131].  Their  system  is  based  on  
three-­‐‑fluorophores  and  two  parallel  energy  transfers  (Figure  9).  Three  distinct  states  of  
DNA  could  be  distinguished  through  quantitative  ratiometric  analysis  of  FRET  
efficiencies:  (I)  When  double-­‐‑labeled  plasmid  DNA  (QD/nuclear  dye  (ND)-­‐‑DNA)  is  
condensed  in  stable  nanocomplexes,  the  QD  donor  drives  energy  transfer  through  the  
ND  (E12)  which  acts  as  a  relay  to  Cy5  (E23)  conjugated  on  the  polymeric  gene  carrier.  For  
stable  nanocomplexes,  both  the  ND  and  Cy5  are  ‘on’,  or  actively  exhibiting  FRET-­‐‑
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mediated  emission.  (II)  When  the  nanocomplex  begins  to  unpack  and  release  intact  
DNA,  only  the  ND  is  ‘on’  through  E12  while  Cy5  is  ‘off’  due  to  the  loss  of  E23.  (III)  When  
free  DNA  is  degraded,  both  ND  and  Cy5  are  ‘off’  due  to  the  loss  of  both  E12  and  E23.  The  
system  was  developed  with  two  different  carrier  systems:  quickly  dissociating  PEG-­‐‑b-­‐‑
PPA  and  more  stable  chitosan,  and  resolved  mechanistic  differences  between  them.  
Chitosan  protects  DNA  more  effectively,  but  its  slow  release  ultimately  limits  its  efficacy  
relative  to  PEG-­‐‑b-­‐‑PPA.  This  novel  two-­‐‑step  QD-­‐‑FRET  method  allows  for  detailed  
assessment  of  the  onset  of  DNA  release  and  degradation  simultaneously,  and  is  only  
possible  due  to  the  narrow  emission  spectra  of  the  QD  donor.  An  organic  donor  
fluorophore  would  likely  have  resulted  in  significant  levels  of  direct  second  acceptor  
excitation,  which  may  bias  the  analysis.  Given  the  heterogeneity  of  nanocomplexes  and  
intracellular  microenvironments,  the  single-­‐‑particle  resolution  makes  two-­‐‑step  QD-­‐‑






Figure  9.  Two-­‐‑Step  QD-­‐‑FRET  
Two-­‐‑step  QD-­‐‑FRET  enables  the  simultaneous  detection  of  nanocomplex  unpacking  and  
nucleic  acid  degradation  using  a  three-­‐‑fluorophore  system  (1:  QD,  2:  nuclear  dye  (ND),  
and  3:  Cy5)  through  two  parallel  energy  transfer  processes  (E12  and  E23).  Under  
excitation  of  the  QD  donor,  three  distinct  states  of  DNA  could  be  distinguished:  (I)  
When  condensed  within  intact  nanocomplexes,  the  QD  donor  drives  energy  transfer  
through  the  ND  (E12)  which  acts  as  a  relay  to  the  carrier-­‐‑bound  acceptor  (E23),  resulting  
in  emission  from  Cy5.  (II)  When  the  nanocomplex  is  unpacked  only  the  ND  is  ‘on’  
through  E12  while  Cy5  is  ‘off’  due  to  the  loss  of  E23.  Emission  from  the  ND,  through  E12,  
suggests  that  DNA  remains  intact.  (III)  When  free  DNA  is  degraded,  both  ND  and  Cy5  
are  ‘off’  due  to  the  loss  of  both  E12  and  E23,  leaving  only  emission  from  the  QD  donor.  
  
Similarly,  another  group  used  two-­‐‑step  QD-­‐‑FRET  to  monitor  the  delivery  of  the  
chemotherapeutic  drug  doxorubicin  by  a  QD-­‐‑RNA  carrier  [137].  They  conjugated  QDs  
to  RNA  aptamers,  loaded  with  intercalated  doxorubicin  and  targeting  the  prostate  
specific  membrane  antigen.  In  the  intact  complex,  both  QD  donor  and  doxorubicin  
acceptor  fluorescence  were  quenched,  the  QD  being  quenched  by  doxorubicin  and  
doxorubicin  in  turn  by  intercalation  with  the  aptamer.  Drug  release  resulted  in  recovery  
of  both  QD  and  doxorubicin  fluorescence,  which  were  then  used  to  detect  cancer  cells  
that  internalized  the  targeted  nanocomplexes.  The  complexes  used  in  this  study  killed  
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antigen-­‐‑expressing  cancer  cells  with  high  selectivity,  demonstrating  that  QD-­‐‑FRET  has  
potential  in  combined  therapeutic  and  diagnostic  applications.  
2.7.5 Selection of QD-FRET Pairs and Practical Concerns 
To  maximize  the  benefits  of  QD-­‐‑FRET  in  the  study  of  nonviral  nucleic  acid  
delivery,  a  researcher  planning  to  adopt  the  technique  should  give  some  thought  to  the  
relevant  practical  considerations  when  designing  the  system.  Adoption  of  QD-­‐‑FRET  has  
likely  been  slowed  by  the  perceived  complexity  of  the  chemical  modification  process  
and  potential  effect  on  the  bioactivity  of  nucleic  acids  that  arises  from  the  size  and  
surface  properties  of  conjugated  QDs.  One  group  did  report  a  decrease  in  DNA  
bioactivity  after  conjugation,  likely  due  to  a  combination  of  random  incorporation  of  
biotin  sites  into  coding  regions  and  steric  hindrance  of  the  transcriptional  machinery  
[58].  However,  other  groups  have  demonstrated  high  expression  levels  with  QD-­‐‑labeled  
DNA  [139],  and  total  retention  of  nucleic  acid  bioactivity  is  often  not  crucial  in  
mechanistic  studies.  
Determination  of  the  ideal  labeling  frequency  requires  some  optimization.  Less  
than  one  QD  per  plasmid  DNA  molecule  on  average  would  provide  sufficiently  high  
sensitivity,  given  that  each  complex  typically  consists  of  multiple  plasmids.  Such  a  
configuration  would  also  guarantee  minimum  interference  to  complexation  as  well  as  
false  positives  from  excess  free  QDs.  Similar  principles  apply  to  the  labeling  of  gene  
carriers,  although  multiple  organic  fluorophore  acceptors  are  typically  required.  The  
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optimization  involves  the  number  of  fluorophores  per  molecule,  acceptor  to  donor  ratio  
(which  could  also  be  tuned  by  adjusting  the  carrier  to  payload  ratio),  and  balance  
between  reasonable  energy  transfer  efficiency  and  unaltered  expression.  When  reduced  
bioactivity  is  a  problem,  one  alternative  is  to  use  mixtures  of  labeled  and  unlabeled  
reagents.  An  additional  consideration  unique  to  the  use  of  intercalating  dyes  for  
intracellular  studies  is  that  nuclear  staining  may  occur,  reducing  the  detectable  
fluorescence  from  nanocomplexes  or  released  nucleic  acids.  Some  QDs  are  large,  so  the  
physical  properties  of  labeled  and  naïve  particles  should  be  compared  before  moving  
forward.  Cell-­‐‑free  characterization  of  the  QD-­‐‑FRET  signal  and  nanocomplex  formation  
is  strongly  recommended  before  moving  to  intracellular  studies.  QDs  are  poorly  suited  
as  acceptors  in  QD-­‐‑FRET,  due  to  their  broad  excitation  windows  and  long  exciton  
lifetimes.  The  cytotoxicity  of  labeled  complexes  should  also  be  evaluated  to  avoid  
unexpected  complications.      
To  date,  most  published  QD-­‐‑FRET  pairs  have  been  comprised  of  commercially  
available  fluorophores.  The  optical  characteristics  of  the  pairs  described  here  have  been  
summarized  in  Table  2.  Theoretically  speaking,  QD-­‐‑FRET  pairs  are  chosen  for  their  
substantial  spectral  overlap  J(λ).  Practically,  however,  detection  sensitivity  is  also  
determined  by  the  optical  capabilities  available  to  the  user,  including  the  excitation  
source,  filter  combinations,  and  spectral  response  of  the  detector.  While  cellular  imaging  
reveals  the  spatial  distribution  of  complexes  at  given  time  points,  flow  cytometry-­‐‑based  
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detection  enables  the  rapid  screening  of  a  range  of  experimental  conditions.  A  
combination  of  the  two  techniques  would  supply  a  more  complete  picture  of  where  and  
when  nanocomplexes  unpack.  While  a  more  exhaustive  discussion  of  detection  
techniques,  modes  of  analysis,  and  methods  of  determining  QD-­‐‑FRET  are  beyond  the  
our  scope,  we  refer  interested  readers  to  a  comprehensive  review  on  FRET  imaging  [50].  
  
Table  2:	  Optical  Parameters  of  QD-­‐‑FRET  Pairs  Used  to  Study  Nucleic  Acid  Delivery  
Fluorophores	  /QDFRET	  Pair	   Emission	  (nm)	   Extinction	  coefficient	  (M–1cm–1)	   Quantum	  Yield	   Spectral	  Overlap,	  J(l)	  (M–1cm–1nm4)	   Förster	  Radius,	  R0	  (Å)	   Ref	  Cy3	   570	   1.5x105	  (Ex:	  552nm)	   0.15	   	   	   	  Cy5	   670	   2.5x105	  (Ex:	  650nm)	   0.28	   	   	   	  Texas	  Red	   614	   8.5x104	  (Ex:	  596nm)	   N.A.	   	   	   	  Rhodamine	   573	   1.29x105	  (Ex:	  560nm)	   N.A.	   	   	   	  AlexaFluor647	   668	   2.37x105	  (Ex:	  633nm)	   0.33	   	   	   	  BOBO3	   605	   1.48x105	  (Ex:	  570nm)	   0.39	   	   	   	  Adirondack	  Green	  QD	   525	   1.3x105	  (Ex:	  488nm)	   0.4	   	   	   	  Qdot545	   545	   2.9x105	  (Ex:	  488nm)	   0.4	   	   	   	  Qdot605	   603	   11x105	  (Ex:	  488nm)	   0.4	   	   	   	  Qdot625	   621	   27x105	  (Ex:	  488nm)	   0.4	   	   	   	  Qdot525-­‐Cy3	   	   	   	   7.02x1015	   59.19	   [131]	  Qdot525-­‐BOBO3	   	   	   	   4.44x1015	   52.26	   [128,	  131]	  Adirondack	   Green	   QD	   -­‐	  Texas	  Red	   	   	   	   1.17x1015	   43.92	   [127]	  Qdot545-­‐Rhodamine	   	   	   	   8.07x1015	   60.58	   [129]	  Qdot605-­‐Cy5	   	   	   	   1.24x1016	   65.09	   [58,	  122,	  130,	  134,	  136]	  Qdot605-­‐AlexaFluor647	   	   	   	   1.11x1016	   63.89	   [126]	  Qdot625-­‐Cy5	   	   	   	   2.13x1016	   71.24	   [132]	  	  *	  Remarks:	  These	  values	  were	  estimated	  according	  to	  Eq.	   (2)	   for	   the	  FRET	  pairs	  used	   in	   the	  studies	  reviewed	  here.	   Orientation	   factor	   (κ2)	   and	   refraction	   index	   (n)	   were	   assumed	   to	   be	   2/3	   and	   1.4,	   respectively.	   Other	  parameters	   were	   obtained	   from	   the	   manufacturers	   when	   possible,	   or	   adopted	   from:	   (i)	   Invitrogen:	  http://www.invitrogen.com/,	   (ii)	   Fluorophores	   Database:	   http://fluorophores.mgfb.at/,	   and	   (iii)	   Pubspectra:	  http://home.earthlink.net/~pubspectra/	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2.7.6 Future Perspectives for QD-FRET 
Nonviral  delivery  of  nucleic  acids  represents  a  potentially  safe  and  effective  
treatment  option  for  many  diseases.  However,  success  to  date  has  been  hindered  by  
poor  transfection  efficiency.  Elucidation  of  the  rate-­‐‑limiting  barriers  in  nonviral  gene  
transfer  will  help  the  engineering  of  more  efficient  carriers.  QD-­‐‑FRET  has  been  a  
valuable  addition  to  the  arsenal  of  tools  used  to  quantify  the  formation,  composition,  
unpacking,  and  degradation  of  nucleic  acid  nanocomplexes.  The  unique  optical  
properties  of  QDs  result  in  improved  sensitivity,  increased  precision,  and  ultimately  the  
ability  to  derive  more  robust  structure-­‐‑function  relationships.  The  versatility  of  QD-­‐‑
FRET  enables  not  only  studies  of  specific  subcellular  behavior  with  confocal  microscopy,  
but  also  multiplexing  and  high-­‐‑throughput  analysis  using  flow  cytometry.  
Quantum  dots  encounter  some  criticism  for  potentially  interfering  with  
biological  entities  due  to  their  larger  size  compared  to  organic  fluorophores  [140].  The  
challenges  to  QD-­‐‑based  assays  are  retention  of  bioactivity  and  functionality,  although  
QD-­‐‑conjugation  has  been  shown  to  have  minimal  effects  in  many  cases.  Furthermore,  
the  additional  mass  of  larger  QD  may  alter  the  diffusivity  of  biomolecules,  or  disrupt  the  
movement  of  biomolecules.  However,  the  ongoing  improvement  of  QD  synthesis  yields  
fluorophores  with  reduced  size  but  undiminished  brightness,  emission,  and  
photostability.  These  QDs  promise  to  facilitate  future  QD-­‐‑FRET  studies  with  reduced  
concerns  about  interference.    
  75  
The  utility  of  QD-­‐‑FRET  in  understanding  nucleic  acid  delivery  will  continue  to  
expand.  QDs  are  already  used  in  a  number  of  in  vivo  applications  [141],  and  can  be  
tuned  to  operate  in  the  near  infrared  range  required  for  tissue  penetration.  This  would  
open  the  door  for  the  development  of  QD-­‐‑FRET  theranostics  [142],  as  the  field  
transitions  from  the  molecular  to  the  integrative  level.  As  QD  synthesis  is  further  refined  
so  that  multiple  QDs  can  be  excited  at  a  single  wavelength  and  emit  in  distinct  spectral  
ranges,  the  frequency  of  multicolor  applications  and  multiplexing  should  increase.  This  
will  lead  to  even  more  detailed  information,  as  multiple  processes  are  monitored  
simultaneously.  QD-­‐‑FRET  will  continue  to  offer  prolonged,  sensitive,  and  real-­‐‑time  
imaging  of  the  nonviral  nucleic  acid  delivery  process,  and  should  help  the  field  move  
away  from  trial-­‐‑and-­‐‑error  approaches  and  redouble  its  effort  toward  the  rational  design  
of  effective  systems.  
2.8 Traditional Methods of Nanocomplex Assembly 
It  is  understood  that  the  cellular  uptake,  transfection  efficiency,  circulatory  
residence  time,  and  toxicity  of  nanoparticles  all  depend  to  some  degree  on  physical  
attributes  such  as  size,  shape,  and  charge.  However,  little  attention  has  been  paid  to  the  
manufacturing  process  of  polymer-­‐‑nucleic  acid  nanocomplexes,  and  how  it  may  affect  
these  properties.  The  assembly  of  nanocomplexes  by  charge  neutralization  is  a  rapid,  
highly  energetic  thermodynamic  process.  To  quantify  the  kinetics  of  the  complexation  
reaction,  Ho  et  al.  studied  parallel  laminar  streams  of  fluorescently  labeled  chitosan  
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polymer  and  plasmid  DNA  on  a  microfluidic  T-­‐‑junction  chip.  Using  the  FRET  signal  
that  occurred  as  complexes  formed  at  the  stream  interface,  the  reaction  was  determined  
to  occur  within  milliseconds  [136].  This  result  matched  that  of  an  earlier  study  using  
polyamidoamine  dendrimer  carriers  [143].  Currently,  the  vast  majority  of  nanocomplex  
assembly  is  accomplished  by  bulk  mixing  methods.  These  involve  pipetting  a  solution  of  
polycation  into  a  nucleic  acid  solution  and  either  shaking,  inverting,  pipetting  up  and  
down,  or  more  commonly  vortex  mixing.  While  convenient,  bulk  mixing  is  poorly  suited  
to  produce  uniform  particles,  given  the  fast  reaction  kinetics  involved.  Bulk  mixing  
introduces  significant  variability  into  the  preparation  and  often  yields  metastable  
products  of  non-­‐‑equilibrium  composition  [5].  The  final  properties  and  composition  of  
the  product  depend  on  how  the  polyelectrolytes  initially  encounter  one  another,  which  
is  determined  by  the  chaotic  mixing.  Irreproducibility  is  rampant,  as  slight  perturbations  
of  mixing  protocols  are  known  to  produce  particles  of  differing  qualities.  The  resulting  
heterogeneity  is  an  impediment  to  the  progress  of  nonviral  gene  delivery  in  multiple  
ways.    
While  complexation  is  impossible  to  control  in  a  bulk  setting  where  mixing  takes  
much  longer  than  milliseconds,  a  reduction  of  the  reaction  volume  would  reduce  the  
time  required  to  reach  a  fully  mixed  state.  Calculations  using  a  coarse-­‐‑grain  model  and  
the  estimated  diffusivities  of  typical  DNA  and  polymer  reagents  have  been  used  to  
calculate  that  volumes  in  the  picoliter  range  would  be  required  to  give  complete  mixing  
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within  milliseconds  [144],  motivating  our  efforts  to  develop  a  system  to  generate  
picoliter  droplets.  However,  we  are  not  the  only  group  to  have  become  concerned  with  
the  problem  of  nanocomplex  manufacturing.  The  heterogeneity  resulting  from  bulk  
synthesis  universally  hinders  advances  in  nonviral  gene  delivery  with  respect  to  rational  
carrier  design,  mechanistic  understanding,  and  optimization.  As  the  field  has  begun  to  
consider  nanoparticle  assembly  as  an  opportunity  for  innovation,  several  novel  
assembly  techniques  have  emerged.  
2.9 Recent Innovations in Nanocomplex Assembly 
The  need  for  greater  control  in  the  manufacturing  of  delivery  systems  has  been  
recently  identified  as  a  critical  unmet  need  the  drug  delivery  field  [145-­‐‑147].  One  
technique  to  emerge  as  a  result  is  the  top-­‐‑down  nanoimprinting  system  called  Particle  
Replication  in  Non-­‐‑wetting  Templates  (PRINT).  Pioneered  by  DeSimone,  this  approach  
offers  the  ability  to  produce  precisely  controlled  particles  with  defined  shape  and  size  
[146].  These  particles  have  proven  valuable  in  deconvoluting  the  effects  of  distinct  
properties  on  mechanisms  such  as  cellular  internalization  and  biodistribution.  However,  
such  top-­‐‑down  approaches  would  be  difficult  to  adapt  to  suit  the  bottom-­‐‑up  self-­‐‑
assembly  of  polymer-­‐‑nucleic  acid  nanocomplexes.  The  rapid  reaction  kinetics,  aqueous  
conditions,  and  room  temperature  assembly  instead  favor  microfluidic  approaches.  
A  number  of  groups  have  explored  the  use  of  microfluidic  systems  to  synthesize  
DNA  nanocomplexes  with  both  polymer  and  lipid  carrier  systems.  Koh  et  al.  formulated  
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Bcl-­‐‑2  antisense  oligonucleotide  lipoplexes  using  a  hydrodynamic  focusing  system,  and  
demonstrated  a  more  efficient  knockdown  of  Bcl-­‐‑2  expression  than  with  the  bulk-­‐‑mixed  
controls  [148].  The  report  attributed  the  effects  to  the  smaller  size,  diminished  
polydispersity,  and  lower  zeta  potential  of  the  lipoplexes  made  with  microfluidics.  The  
same  group  applied  the  same  hydrodynamic  focusing  system  to  the  production  of  PEI-­‐‑
DNA  particles,  and  again  reported  enhanced  performance  relative  to  bulk-­‐‑mixed  
controls  in  terms  of  cytotoxicity  and  transfection  efficiency  in  NIH  3T3  fibroblasts  and  
mouse  embryonic  stem  cells  [149].  When  applied  to  chitosan-­‐‑DNA  particles,  the  
hydrodynamic  focusing  platform  gave  similar  improvements  with  respect  to  
cytotoxicity,  but  only  modest  gains  in  transfection  efficiency  [136].  Hydrodynamic  
focusing  may  be  suboptimal  for  polymer  nanocomplex  assembly;  in  this  latter  study  the  
authors  observed  two  distinct  stages  of  particle  formation  –  an  initial  period  of  rapid  
electrostatic  binding  in  the  millisecond  range,  followed  by  a  second  stage  of  
nanocomplex  flocculation  caused  by  dispersion  of  the  interface  in  the  third  dimension.  
This  phenomenon  led  to  a  wider  distribution  in  particle  size.  Another  microfluidic  
approach,  developed  by  Hsieh  et  al.,  was  designed  to  produce  lipoplexes  within  
picoliter  droplets  [150].  This  Picoliter  Microfluidic  Reactor  and  Incubator  (PMRI)  yielded  
more  monodispersed  lipoplexes  that  mediated  more  reproducible,  though  not  always  
higher,  levels  of  transfection.  The  microfluidics-­‐‑assisted  confinement  (MAC)  
nanomanufacturing  platform  studied  in  this  dissertation  was  modeled  after  this  system,  
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and  its  adaptation  and  application  to  polymer-­‐‑nucleic  acid  nanocomplexes  could  be  
even  more  effective.  Unlike  cationic  lipids  that  are  typically  of  low  and  uniform  
molecular  weight,  polycations  are  typically  polydispersed,  unless  produced  by  
recombinant  methods,  and  thus  even  more  susceptible  to  the  deleterious  effects  of  non-­‐‑
equilibrium  mixing  conditions.    
Proof-­‐‑of-­‐‑principle  studies  with  the  MAC  system  were  completed  using  two  
commercial  transfection  reagents  and  evaluated  in  HEK293  cells  [144].  Synthesis  of  
particles  with  Turbofect  (poly(2-­‐‑hydroxypropyleneimine))  and  jetPEI  (linear  
polyethylenimine,  20kD)  and  GFP-­‐‑encoding  plasmid  DNA  resulted  in  complexes  that  
were  smaller  and  more  uniform  in  size,  lower  in  zeta  potential,  less  toxic,  and  more  
potent.  While  promising,  these  preliminary  results  do  not  prove  the  broad  applicability  
of  the  technique,  and  do  not  demonstrate  the  benefits  of  MAC  particles  in  more  complex  
systems.  Among  the  issues  that  still  need  to  be  addressed  is  the  ability  of  MAC  to  
improve  particles  loaded  with  different  types  of  nucleic  acids.  Plasmid  DNA  remains  of  
high  interest  in  gene  medicine,  but  messenger  RNA  as  a  payload  obviates  the  
requirement  of  delivery  into  the  nucleus  and  more  readily  produces  transgene  
expression  in  slowly  dividing  or  post-­‐‑mitotic  cells.  Finally,  siRNA  presents  new  options  
of  therapeutic  intervention  via  post-­‐‑transcriptional  gene  silencing.  However,  
substitution  of  the  payload  may  not  be  trivial,  as  there  is  mounting  evidence  that  
polycations  may  interact  differently  with  DNA  than  they  do  with  RNA  [151].  Double  
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stranded  DNA  has  a  longer  persistence  length  than  dsRNA,  rendering  it  a  stiffer  
molecule.  Shorter  nucleic  acids  may  require  more  polycation  to  achieve  condensation,  
due  to  a  reduction  in  the  effects  of  chain  entanglement.  Testing  different  types  of  nucleic  
acids  and  carriers  will  be  necessary  to  demonstrate  broad  potential  of  MAC  to  control  
nanocomplex  self-­‐‑assembly.  Products  should  be  evaluated  in  terms  of  size,  size  
distribution,  zeta  potential,  payload  protection  efficiency,  binding  affinity  between  the  
polycations  and  nucleic  acids,  stability  in  the  presence  of  competitors,  aggregation  
behavior,  amount  of  unreacted  species,  cytotoxicity,  and  transfection  efficiency.  
Evaluation  on  these  bases  will  give  a  strong  justification  to  continue  the  development  of  
MAC  for  applications  in  more  complex  and  translationally  relevant  systems.  
2.10 Alternative Microfluidic Approaches 
Hydrodynamic  focusing  (HF)  approaches  may  offer  complementary  benefits  as  
compared  to  emulsion-­‐‑based  platforms  such  as  MAC.  HF  operates  using  exclusively  
aqueous  reagents,  and  may  be  more  amenable  to  scale-­‐‑up  to  increase  throughput.  
However  conventional  2-­‐‑D  HF,  as  described  previously,  suffers  from  dispersion  of  the  
reagents  and  products  in  the  third  dimension,  resulting  in  diminished  quality.  
Consequently,  Huang  et  al.  have  developed  a  3-­‐‑D  HF  technology  where  the  streams  are  
also  compressed  in  the  third  dimension  [59].  The  device  is  fabricated  using  soft  
lithography,  and  focuses  the  streams  using  a  phenomenon  called  “microfluidic  drifting”.  
The  input  flow  is  first  focused  in  the  vertical  direction  while  passing  through  a  90-­‐‑  
  81  
degree  curve  in  a  microfluidic  channel.  Around  the  curve,  a  pair  of  transverse  secondary  
Dean  vortices  is  induced.  These  vortices  cause  the  sample  stream  to  drift  laterally  to  the  
opposite  side  of  the  channel.  With  proper  flow  control,  the  sample  stream  is  compressed  
into  a  thin  horizontal  plane  in  the  middle  of  the  microchannel.  Further  focusing  of  the  
sample  stream  in  the  horizontal  direction  is  achieved  by  injecting  two  orthogonal  
focusing  sheath  flows  from  both  directions  to  form  a  3-­‐‑D  focused  sample  stream  at  the  
center  of  the  microfluidic  channel.  This  method  has  shown  promise  as  an  alternative  
microfluidic  nanomanufacturing  platform  with  potential  benefits  primarily  in  scale-­‐‑up  
and  throughput,  but  it  must  be  confirmed  that  the  shear  forces  experienced  by  the  
polymer  and  nucleic  acids  do  not  compromise  their  activity  and  that  polyplex  quality  is  
improved.    
2.11 Clinical Needs in Neurodegenerative Disease 
One  of  the  most  pressing  unmet  clinical  needs,  given  the  United  States’  aging  
population,  is  the  rise  in  prevalence  of  intransigent  neurodegenerative  diseases.  The  cost  
to  society,  whether  measured  in  dollars,  disability,  or  deaths,  is  tremendous.  Whether  
environmental,  genetic,  or  idiopathic  in  origin,  the  root  causes  of  neurodegenerative  
disease  tend  to  be  multifactorial.  As  such,  they  are  difficult  to  prevent  and  treat,  even  
with  timely  diagnoses.  The  Alzheimer’s  Association  estimates  that  the  costs  of  caring  for  
people  with  Alzheimer’s  disease  and  other  forms  of  dementia  will  increase  from  $203  
billion  this  year  to  $1.2  trillion  in  2050,  while  one  in  three  seniors  currently  dies  with  
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Alzheimer’s  or  another  form  of  dementia.  The  average  post-­‐‑diagnosis  life  expectancy  is  
seven  years  [152].  The  only  drugs  available  for  Alzheimer’s  patients  are  cholinesterase  
inhibitors  and  NMDA  receptor  antagonists,  which  only  provide  temporary  effects  in  a  
subset  of  cases  [153].  Parkinson’s  disease  also  exacts  a  heavy  cost  on  society,  affecting  
half  a  million  Americans  annually  with  a  cost  of  $11  billion  [154].  The  treatment  options  
for  Parkinson’s  disease  include  L-­‐‑DOPA,  anticholinergics,  MAO-­‐‑B  inhibitors,  and  deep  
brain electrical  stimulation.  Again,  these  options  provide  temporary  relief  of  some  
symptoms,  but  inevitably  lose  effectiveness.  While  pharmaceutical  intervention  may  
slow  the  loss  of  neurons,  the  diseases  continue  to  progress.  Only  cell  replacement  
therapy  has  the  potential  to  reverse  the  disease  course  once  a  patient’s  own  cells  are  lost.  
2.12 Current Approaches to Treatment 
Patients  with  Alzheimer’s  or  Parkinson’s  disease  may  see  temporary  
improvements  with  pharmacologic  intervention  or  deep  brain  stimulation,  but  the  
clinical  benefits  inevitably  decline  with  the  progressive  loss  of  neuronal  function.  These  
diseases  are  characterized  by  the  loss  of  neurons  in  the  neocortex  and  hippocampus  
caused  by  an  accumulation  of  amyloid  plaques  in  the  case  of  Alzheimer’s,  and  by  the  
loss  of  dopaminergic  neurons  in  the  substantia  nigra  in  the  case  of  Parkinson’s.  Cell  
replacement  therapy  has  been  proposed  as  a  long-­‐‑term  solution  [155,  156].  However,  
finding  an  appropriate  cell  source  has  been  a  challenge  while  safety  and  ethical  concerns  
preclude  the  use  of  embryonic  stem  cells.  Early  clinical  trials  involving  transplantation  
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of  fetal  dopaminergic  neurons  into  the  striatum  of  patients  have  shown  survival  and  
engraftment  of  the  cells  but  inconsistent  clinical  outcome  [156-­‐‑161].  Advances  in  human  
embryonic  stem  cell  (ESC)  engineering  offer  a  viable  source  of  neurons  since  ESCs  can  
undergo  neurogenesis  in  vitro  with  the  appropriate  biochemical  cues  [162,  163].  
However,  the  same  ethical  issue  of  fetus  usage  and  concerns  of  teratoma  formation  
hinder  progress  [164,  165].  The  translation  of  therapies  derived  from  induced  
pluripotent  stem  cells  (iPSC)  have  also  been  slowed  by  concerns  of  teratogenic  potential.  
It  would  be  ideal  to  identify  a  source  of  cells,  preferably  autologous,  that  do  not  possess  
a  differentiative  or  proliferative  phenotype.  If  such  cells  could  be  generated  in  sufficient  
quantities,  they  could  be  grafted  to  achieve  therapeutic  effects,  either  by  replacing  the  
function  of  lost  cells  directly  or  supporting  existing  neurons  by  producing  soluble  
factors  (e.g.  neurotrophins).  Diffuse  diseases  such  as  Alzheimer’s  pose  a  targeting  
challenge,  as  compared  to  Parkinson’s.  However,  ESC-­‐‑derived  cholinergic  neurons  
implanted  into  Alzheimer’s  rodent  models  have  given  partial  restoration  of  function  
[166,  167].  Parkinson’s  disease  may  represent  a  simpler  scenario  for  cell  replacement,  as  
the  disease  is  localized  to  a  more  defined  region  of  the  brain.  As  mentioned  above,  
allogeneic  grafting  of  dopaminergic  neurons  has  shown  some  positive  results.  Induced  
pluripotent  stem  cells  have  also  effected  a  restoration  of  motor  function  in  animals  
following  differentiation  to  dopaminergic  neurons  and  implantation  [168].  These  studies  
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show  that  the  potential  of  cell  replacement  therapy  exists,  if  a  safe,  abundant,  and  
effective  source  of  cells  can  be  identified.    
2.13 Direct Conversion of Fibroblasts to Neurons 
Recently,  the  reprogramming  of  adult  somatic  cells  from  one  type  to  another  was  
reported.  In  2010,  researchers  found  that  expression  of  three  genes  encoding  
transcription  factors  (Ascl1,  Brn2,  Myt1l:  BAM  factors)  delivered  by  lentivirus  was  
sufficient  to  convert  fibroblasts  to  functional  neurons  without  going  through  complete  
de-­‐‑differentiation  to  a  pluripotent  state.  Neuronal  transdifferentiation  was  first  
demonstrated  by  Wernig  et  al.,  where  delivery  of  the  BAM  factors  to  mouse  and  human  
fibroblasts  converted  them  into  functional  neurons  with  up  to  20%  efficiency,  referred  to  
as  induced  neuronal  (iN)  cells  [6,  169].  The  iN’s  were  electrophysiologically  active  and  
formed  functional  synapses  when  cultured  with  primary  neurons.  This  was  the  first  
report  of  the  direct  conversion  of  somatic  cells  from  one  type  to  another  derived  from  a  
different  germ  layer.  Such  transdifferentiation  brings  the  prospect  of  an  ethical,  
practical,  and  safe  neuronal  cell  therapy  one  step  closer  to  reality.  Subsequently,  
transcription  factors  have  been  identified  to  generate  induced  dopaminergic  neurons  
that  have  been  implanted  to  achieve  a  degree  of  phenotypic  correction  in  animals  [170-­‐‑
173].  Additional  factor  combinations  are  able  to  generate  motor  neurons  [171].  These  iNs  
are  postmitotic  and  do  not  pass  through  a  proliferative  progenitor  state  [6,  174,  175],  
attributes  making  them  an  attractive  cell  source  for  cell-­‐‑based  therapy  of  CNS  disorders  
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such  as  epilepsy,  stroke,  Huntington  disease,  and  Parkinson’s  disease.  However,  the  
unpredictable,  potentially  genotoxic,  integration  of  viral  DNA  sequences  into  the  
genome  of  the  converted  cells  renders  them  unsuitable  for  transplantation.    
An  important  result  of  the  published  neuronal  transdifferentiation  studies  is  that  
the  iN  cell  state  is  maintained  even  when  exogenous  transgene  expression  is  
discontinued  [169].  Endogenous  BAM  factor  gene  expression  continues  to  increase  after  
the  dox-­‐‑inducible  exogenous  expression  is  shut  down  by  doxycycline  withdrawal.  This  
suggests  that  analogous  reprogramming  is  possible  even  with  the  transient  nature  of  
nonviral  gene  delivery.  Prior  to  our  report,  all  instances  of  neuronal  transdifferentiation  
were  achieved  with  viral  delivery  methods.  In  Chapter  five,  we  show  the  generation  of  
mouse  and  human  fibroblasts  expressing  pan-­‐‑neuronal  markers  by  nonviral  delivery  of  
the  BAM  factors.  The  nonviral  transdifferentiation  efficiency  was  initially  low,  but  we  
also  show  that  there  exists  room  for  improvement  through  optimization  of  the  delivery  
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Nonviral  nucleic  acid  delivery  is  feasible  and  attractive.  However,  some  
polymeric  gene  carriers  can  be  too  stable  for  efficient  intracellular  dissociation  from  their  
nucleic  acid  payloads.  A  challenging  nonviral  gene  delivery  barrier  is  the  efficient  
release  of  intact  DNA  into  the  cytoplasm  or  nucleus  of  a  target  cell.  The  natural  
polysaccharide  chitosan  has  been  used  for  oral  gene  delivery  in  mice,  achieving  
phenotypic  correction  in  multiple  disease  models  [75,  176].  However,  quantitative  
intracellular  trafficking  studies  have  shown  that  the  chitosan  system  used  in  those  
studies  is  limited  by  overly  stable  binding  of  nucleic  acids.  We  made  efforts  to  improve  
the  transfection  capabilities  of  chitosan  by  adjusting  physical  properties  such  as  
molecular  weight,  degree  of  deacetylation,  and  the  addition  of  ternary  components.  
Additionally,  we  investigated  another  class  of  stimulus-­‐‑responsive  synthetic  polymers  
as  an  alternative  carrier  system  with  improved  dissociation  characteristics.  Unlike  
natural  polymers,  bioreducible  linear  poly(amido  amine)s  (SS-­‐‑PAAs)  can  be  designed  
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from  the  bottom  up  to  meet  the  manifold  requirements  of  nonviral  gene  delivery,  and  
they  can  be  engineered  to  possess  the  competing  functionalities  of  DNA  protection  and  
efficient  release.  We  studied  SS-­‐‑PAAs  functionalized  with  either  4-­‐‑amino-­‐‑1-­‐‑butanol  
(ABOL)  or  a  combination  of  histamine  and  3-­‐‑(dimethylamino)-­‐‑1-­‐‑propylamine  
(HIS/DMPA).  Coupling  these  functionalities  that  control  buffer  capacity  for  endosomal  
escape  and  charge  density  for  DNA  binding  with  the  bioreducibility  of  the  backbone  
results  in  a  gene  carrier  with  advantageous  properties.  Cytotoxicity  (IC50  =  160-­‐‑190  
µg/mL)  is  an  order  of  magnitude  lower  than  25  kDa  branched  PEI,  and  transfection  in  
cell  monolayers  is  30-­‐‑fold  higher  than  Lipofectamine  2000  and  100-­‐‑fold  higher  than  390  
kDa,  83.5%  deacetylated  chitosan.  The  high  transfection  and  low  toxicity  of  SS-­‐‑PAAs  
allows  for  the  delivery  of  multiple  doses  to  sustain  robust  transgene  expression  for  
prolonged  periods  of  time,  a  requirement  of  many  current  applications.    
3.1 Introduction 
Chitosan  is  a  naturally-­‐‑sourced  polysaccharide  derived  from  the  partial  
deacetylation  of  chitin,  primarily  from  crustacean  and  insect  shells.  It  consists  of  
repeating  units  of  glucosamine  and  N-­‐‑acetyl-­‐‑glucosamine,  the  proportions  of  which  
determine  the  degree  of  deacetylation  of  the  polymer.  Positively  charged  chitosan  will  
bind  to  cell  membranes,  decrease  the  trans-­‐‑epithelial  electrical  resistance  (TEER)  of  cell  
monolayers,  and  increase  paracellular  permeability  [177-­‐‑181].  The  per  os  mechanism  of  
action  includes  interactions  with  the  tight  junction  proteins  occludin  and  ZO-­‐‑1,  re-­‐‑
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distribution  of  F-­‐‑actin,  and  slight  de-­‐‑stabilization  of  the  plasma  membrane  [182-­‐‑184].  It  is  
generally  considered  non-­‐‑toxic  and  biodegradable,  with  an  oral  LD50  in  mice  of  over  16  
g/kg  [185].  The  safety  of  chitosan,  its  ability  to  prolong  residence  time  in  the  
gastrointestinal  tract  through  mucoadhesion  [186],  and  its  ability  to  enhance  absorption  
by  increasing  cellular  permeability  have  all  been  major  factors  contributing  to  its  
widespread  evaluation  as  a  component  of  oral  dosage  forms.  It  has  also  been  
investigated  as  a  gene  carrier  in  recent  years  [14,  75,  187-­‐‑196].  The  bioavailability  of  
delivered  DNA  can  be  improved  via  protection  from  serum  nucleases  by  the  polymer  
matrix,  and  there  is  little  release  of  bound  DNA  until  the  nanoparticle  is  sequestered  
into  the  endolysosomal  pathway.  The  nanoparticles  can  also  be  lyophilized  without  loss  
of  bioactivity,  so  that  chitosan  polyplexes  can  be  handled  more  like  conventional  
pharmaceutical  formulations  in  terms  of  production,  reproducibility,  and  storage.    
However,  recent  quantitative  studies  on  the  intracellular  trafficking  and  
unpacking  kinetics  of  chitosan  nanoparticles  for  gene  delivery  have  revealed  that  a  rate-­‐‑
limiting  barrier  is  the  efficient  release  of  DNA  into  the  cell  [57].  Chen  et  al.  labeled  both  
chitosan  and  PEI  and  their  nucleic  acid  payloads  with  QD-­‐‑FRET  components  to  detect  
discrete  changes  in  intracellular  polyplex  stability.  The  uptake  and  unpacking  of  
polyplexes  was  captured  over  time  with  confocal  microscopy,  and  the  data  used  to  
construct  a  three  compartment  first-­‐‑order  kinetic  model  of  intracellular  nucleic  acid  
release.  The  photostability  of  the  QD-­‐‑FRET  system  enabled  monitoring  the  distributions  
  89  
of  intact  and  unpacked  particles  for  up  to  72  hours.  At  two  hours  post-­‐‑transfection,  over  
80%  of  PEI  nanoparticles  had  unpacked,  whereas  only  about  half  of  chitosan  particles  
had  released  their  payload.  PEI  also  resulted  in  an  earlier  shift  toward  nuclear  plasmid  
translocation,  perhaps  encouraged  by  faster  release  of  free  plasmid  in  the  cytoplasmic  
compartment.  The  unpacking  time  constant  for  chitosan  was  more  than  twice  as  large  as  
that  of  PEI,  adversely  affecting  its  transfection  capabilities.  We  first  attempted  to  address  
this  inefficiency  through  substitution  of  the  390  kDa,  83.5%  deacetylated  chitosan  with  
shorter  polymer  chains  bearing  different  degrees  of  deacetylation.  The  rationale  was  that  
shorter  chains  and/or  a  reduction  in  charge  density  may  result  in  a  slight  relaxation  of  
binding  and  accelerated  intracellular  release,  while  maintaining  adequate  levels  of  
protection.  In  a  parallel  attempt  to  modulate  the  binding  stability  of  chitosan  polyplexes,  
we  added  the  ternary  component  poly(γ-­‐‑glutamic  acid)  (PGA)  as  a  biodegradable  
anionic  modulator  of  binding.  It  has  been  reported  that  addition  of  such  ternary  anionic  
components  can  increase  transfection  efficiency,  but  using  nucleic  acids  themselves  can  
be  undesirable  due  to  premature  enzymatic  degradation  [197].  PGA  is  a  water  soluble,  
non-­‐‑toxic,  naturally-­‐‑occurring  peptide  that  has  been  tested  in  the  oral  nanoparticulate  
delivery  of  insulin  and  other  drugs  [176].  Despite  the  reported  ability  of  PGA  to  improve  
transfection  with  low  molecular  weight  chitosan  [198],  neither  modulation  of  chitosan  
physical  properties  nor  systematic  incorporation  of  PGA  was  sufficient  to  effect  
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adequate  enhancement  of  transfection.  As  a  result,  we  shifted  our  focus  to  a  class  of  
synthetic,  bioresponsive  polymeric  gene  carriers. 
Bioreducible  poly(amido  amine)s  (SS-­‐‑PAAs)  are  a  class  of  synthetic  
peptidomimetic  cationic  polymers  that  has  been  tested  for  gene  delivery  [199].  The  
rationale  of  including  SS-­‐‑PAAs  as  gene  carriers  in  this  study  comes  from  the  desire  to  
overcome  the  barrier  of  releasing  nucleic  acids  from  nanoparticles,  and  from  in  vitro  
studies  showing  that  they  are  as  efficient  as  PEI  but  much  less  toxic  [22].  The  disulfide  
links  in  the  polymer  backbone  allow  for  rapid  degradation  once  a  SS-­‐‑PAA  polyplex  
reaches  the  reducing  environment  of  the  cytoplasm,  facilitating  efficient  unpacking  and  
release  of  the  payload.  The  ease  of  chemical  functionalization  of  these  polymers  during  
their  synthesis  allows  for  the  incorporation  of  side  chains  that  can  yield  a  variety  of  
characteristics.  We  studied  SS-­‐‑PAAs  functionalized  with  either  4-­‐‑amino-­‐‑1-­‐‑butanol  
(ABOL)  or  a  mix  of  histamine  and  3-­‐‑(dimethylamino)-­‐‑1-­‐‑propylamine  (HIS/DMPA).  
Coupling  these  functionalities  that  control  buffer  capacity  for  endosomal  escape  and  
charge  density  for  DNA  binding  with  the  bioreducibility  of  the  backbone  results  in  a  
gene  carrier  with  desirable  properties.  We  show  that  SS-­‐‑PAAs  can  form  polyplexes  of  
appropriate  size  and  charge,  dissociate  readily  upon  challenge  with  typical  intracellular  
concentrations  of  reducing  agents,  and  transfect  cells  efficiently.  We  demonstrate  their  
ability  to  achieve  modest  levels  of  transfection  in  vivo,  and  show  that  their  favorable  
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cytotoxicity  profiles  allow  for  repeated  doses  to  be  delivered  in  order  to  sustain  high  
transgene  expression  levels.    
3.2 Methods 
3.2.1 Polymer Synthesis 
High  molecular  weight  chitosans  of  390,000  Daltons  and  83.5%  deacetylation,  
209,000  Daltons  and  86.9%  deacetylation,  and  350,000  Daltons  and  77.3%  deacetylation  
were  gifts  from  Vanson  Chemicals  (Redmond,  WA).  Chitosans  were  dissolved  at  1%  in  
1%  acetic  acid  overnight,  then  filtered  through  filter  paper  under  vacuum  and  
precipitated  with  NaOH.  They  were  then  collected  by  centrifugation  at  6k  RPM  for  20  
minutes,  washed  four  times  with  purified  water,  and  lyophilized  for  storage.  PGA  
(20,000  Daltons)  was  purchased  from  Vedan  (Taichung,  Taiwan).  Poly(CBA-­‐‑HIS/DMPA)  
was  a  gift  from  Prof.  Johan  Engbersen  (Univ.  of  Twente,  Netherlands).  Poly(CBA-­‐‑ABOL)  
was  synthesized  by  Michael-­‐‑type  polyaddition  of  3.67  g  N,N-­‐‑cystaminebisacrylamide  
(CBA)  (Polysciences,  Warrington,  PA)  and  1.26  g  4-­‐‑amino-­‐‑1-­‐‑butanol  (ABOL)  (Sigma-­‐‑
Aldrich,  Saint  Louis,  MO)  as  described  by  Lin  et  al  [22].  The  reaction  product  was  
purified  by  dialysis  (3.5  kDa  cutoff)  in  acidified  deionized  water  (pH  4)  and  then  
lyophilized.  The  polymer  was  collected  in  its  HCl-­‐‑salt  form  (1.63  g,  33%  yield).  Polymer  
products  were  validated  by  Matrix  Assisted  Laser  Desorption/Ionization  (MALDI)  mass  
spectrometry  and  1H  NMR  prior  to  use.  
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3.2.2 Cell Culture and Transfections 
For  all  cell  culture  experiments,  20,000  cells  cm-­‐‑2  cells  were  seeded  24  hours  prior  
to  transfection  in  TCPS  plates  (BD,  Franklin  Lakes,  NJ)  and  cultured  at  37  °C  and  5%  
CO2  in  the  appropriate  complete  growth  media  recommended  by  the  supplier.  The  cell  
types  studied  were  human  embryonic  kidney  HEK293  (ATCC,  Manassas,  VA),  human  
hepatocellular  carcinoma  HepG2  (ATCC),  human  colon  carcinoma  (Caco-­‐‑2)  (ATCC),  
and  normal  human  dermal  fibroblasts  (NHDF)  (Millipore).  For  transwell  studies,  Caco-­‐‑2  
cells  were  expanded  to  approximately  80%  confluence,  harvested  by  trypsinization,  then  
washed  and  resuspended  in  culture  medium.  3x105  cells  were  then  seeded  onto  the  
upper  chamber  of  a  transwell  (6.5mm  diameter,  3.0  micron  pore-­‐‑size  membrane)  
(Costar,  Cambridge,  MA).  All  transport  experiments  were  performed  using  polyester  
(PE)  transwell  membranes.  The  cells  were  cultured  for  14  days  before  validation  of  
monolayer  integrity  by  TEER  analysis  and  subsequent  use.  All  transfections  were  
carried  out  at  37°C  and  5%  CO2  in  serum-­‐‑  and  antibiotic-­‐‑free  OptiMEM  (Invitrogen)  
unless  otherwise  specified,  which  was  replaced  with  the  appropriate  complete  growth  
medium  4  hours  after  the  onset  of  transfection.  Transfection  efficiency  and  transgene  
expression  were  assayed  at  24  hours  post-­‐‑transfection  unless  otherwise  indicated.  
Luminescence  measurements  to  quantify  luciferase  expression  were  performed  using  
the  SteadyGlo  kit  (Promega,  Madison,  WI)  according  to  the  manufacturer’s  protocol.  For  
flow  cytometric  analysis,  cells  were  trypsinized,  resuspended  in  PBS,  and  analyzed  on  a  
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FACScan  flow  cytometer  (Becton-­‐‑  Dickinson,  Mountain  View,  CA)  with  gating  such  that  
the  negative  untransfected  controls  were  one  percent  positive.  At  least  10,000  cells  were  
analyzed  per  experimental  condition.  
3.2.3 Nanocomplex Preparation 
Plasmids  pDNA  (pmaxGFP,  Lonza,  Switzerland),  pLuc  (VR1255  Luciferase,  
Vical,  San  Diego,  CA)  and  pT7-­‐‑EGFP-­‐‑N1  (gift  from  David  Boczkowski,  Duke  University)  
were  propagated  in  Escherichia  coli  DH5α  (Invitrogen,  Carlsbad,  CA)  and  purified  with  
EndoFree  Plasmid  Mega  and  Maxi  kits  (Qiagen,  Germantown,  MD).  Following  
linearization,  in  vitro  transcription  was  performed  on  T7-­‐‑EGFP-­‐‑N1  with  the  
mMESASGE  mMACHINE  T7  kit  (Invitrogen)  to  generate  mRNA  encoding  GFP.  
Chitosan  nanoparticles  were  formed  by  adding  10  µμg  of  pDNA  or  mRNA  to  100  µμL  of  
50  mM  sodium  sulfate  and  subsequently  mixing  with  100  µμL  of  0.02%  chitosan  solution  
under  high-­‐‑speed  vortex  mixing.  When  PGA  was  added  to  the  formulation,  1%  PGA  
dissolved  in  deionized  water  was  used.  The  reactions  were  performed  at  55°C.  SS-­‐‑PAA  
polyplexes  were  prepared  by  adding  a  complexation  buffer  solution  (20  mM  HEPES,  5  
wt  %  glucose,  pH  7.4)  of  polymer  (844  µμg  mL-­‐‑1  for  DNA,  1125  µμg  mL-­‐‑1  for  RNA)  to  a  
complexation  buffer  solution  of  nucleic  acid  (75  µμg  mL-­‐‑1)  followed  immediately  by  20  
seconds  of  vortex  mixing.  Reaction  sizes  ranged  from  5  to  15  µμg  of  nucleic  acid.  
Lipofectamine  2000  (Invitrogen)  lipoplexes  were  prepared  as  per  the  manufacturer’s  
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recommendations.  The  sizes  and  zeta-­‐‑potentials  of  the  nanoparticles  were  measured  
using  a  Zetasizer-­‐‑3000  (Malvern  Instruments,  Southborough,MA).  
3.2.4 Transepithelial Electrical Resistance Measurements 
The  transepithelial  electrical  resistance  (TEER)  across  the  intestinal  epithelium  is  
a  measure  of  paracellular  ion  movement  and  indicator  of  monolayer  integrity.  A  drop  in  
TEER  is  interpreted  as  an  increase  in  tight  junction  permeability.  The  TEER  of  each  
cellular  insert  was  determined  by  means  of  a  voltohmmeter  –  EVOM  manufactured  by  
World  Precision  Instruments  (Sarasota,  FL).  All  TEER  studies  were  conducted  after  a  15-­‐‑
minute  equilibration  period  at  room  temperature.  Measurements  were  performed  in  
triplicate  and  the  mean  value  used  for  any  subsequent  calculations.  
3.2.5 Transmission Electron Microscopy 
Nanoparticles  used  for  transmission  electron  microscopy  (TEM)  transport  
studies  were  synthesized  using  pGeneGrip  Gold  10  nm  colloidal  gold-­‐‑conjugated  
plasmid  DNA  (Genlantis,  San  Diego,  CA).  9x106  Caco-­‐‑2  cells  were  seeded  in  35mm  
tissue  culture  dishes  and  cultured  for  16  days  prior  to  transfection.  Prior  to  transfection,  
the  culture  medium  was  changed  to  OptiMEM.  A  6  µμg  DNA  dose  of  nanoparticles  was  
added  for  4  hours  at  37°C,  then  fixed  in  a  4%  formaldehyde,  2%  glutaraldehyde  solution  
overnight  at  4°C.  The  cells  were  post-­‐‑fixed  in  1%  osmium  tetroxide  and  stained  en  bloc  
with  0.5%  uranyl  acetate,  then  dehydrated  with  a  graded  series  of  ethanol.  Samples  were  
embedded  in  Polybed  812  resin,  thin-­‐‑sectioned,  and  picked  up  on  150  mesh  copper  
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grids.  After  further  staining  with  1%  uranyl  acetate  and  0.4%  lead  citrate,  grids  were  
examined  on  a  FEI  Tecnai  G2  Twin  instrument  under  80kV.      
3.2.6 Animal Studies 
Wistar  rats  (male,  200–250  g)  were  laparotomized  under  general  anesthesia  and  
the  liver  was  isolated  from  the  surrounding  tissue.  A  33  G  needle  was  inserted  into  the  
common  bile  duct  and  a  tie  was  used  to  secure  the  needle.  Nanoparticles  and  naked  
DNA  were  administered  at  a  dose  of  20  µμg  of  plasmid  in  4  mL  of  5%  glucose  medium  
into  the  common  bile  duct  over  20  min  (0.2  ml/min)  using  a  syringe  pump.  A  tie  was  
then  placed  around  the  bile  duct  between  the  liver  and  the  point  of  infusion  to  prevent  
back  flow,  and  the  needle  was  withdrawn.  After  30  min,  all  ties  were  removed.  If  the  
needle  hole  in  the  bile  duct  required  stitches  to  prevent  leakage,  10-­‐‑O  nylon  suture  
(Ethicon,  Somerville,  NJ,  USA)  was  used.  Luciferase  expression  was  monitored  non-­‐‑
invasively  at  4,  24,  and  72  h  post-­‐‑infusion  with  an  IVIS  Imaging  System.  
3.3 Results 
3.3.1 Chitosan Transfections 
Chitosan  (Figure  10)  of  high  molecular  weight  (390  kDa,  C390)  and  83.5%  
deacetylation  has  been  used  successfully  in  a  variety  of  gene  delivery  applications  
despite  its  inherent  disadvantages  with  respect  to  overly  tight  binding  of  DNA.  We  first  
examined  the  potential  of  high  molecular  weight  chitosan  to  deliver  mRNA  more  
efficiently.  Messenger  RNA  is  a  shorter  molecule  than  plasmid  DNA,  diminishing  the  
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contribution  of  chain  entanglement  to  the  complexation.  Furthermore,  its  single  
stranded  nature  corresponds  with  a  reduction  in  charge  density  that  may  also  contribute  
to  a  relaxation  of  binding  stability.  To  test  whether  these  properties  would  translate  to  
an  increase  in  expression,  we  delivered  chitosan-­‐‑GFP  pDNA  and  mRNA  polyplexes  to  
HepG2  cells  and  compared  their  expression  after  48  hours  with  RT-­‐‑PCR  (Figure  11).  Gel  
electrophoresis  of  the  amplified  RT-­‐‑PCR  product  revealed  that  although  mRNA  delivery  
did  yield  a  modest  improvement  in  intracellular  transcript  levels  at  this  time  point,  
substitution  of  plasmid  payloads  with  mRNA  is  insufficient  to  boost  delivery  to  levels  
achievable  with  PEI  and  Lipofectamine  2000.  Still,  the  result  suggested  that  slight  
destabilization  of  high  molecular  weight  chitosan  polyplexes  may  promote  increased  
transfection,  so  we  next  explored  a  variety  of  alternative  methods  to  modulate  the  
complexation  of  chitosan  with  nucleic  acids.  
  
  
Figure  10.  Chemical  Structure  of  Chitosan  
Chitosan  is  a  naturally-­‐‑sourced  polysaccharide  derived  from  the  partial  deacetylation  of  
chitin,  primarily  from  crustacean  and  insect  shells.  It  consists  of  repeating  units  of  
glucosamine  and  N-­‐‑acetyl-­‐‑glucosamine,  the  proportions  of  which  determine  the  degree  




Figure  11.  Delivery  of  Messenger  RNA  with  Chitosan  Polyplexes.  
GFP  transcript  levels  in  HepG2  cells  quantified  by  RT-­‐‑PCR  following  delivery  of  mRNA  
with  chitosan  is  slightly  higher  than  levels  mediated  by  pDNA.  
  
3.3.2 Optimization of Chitosan Polyplex Formulation 
Operating  under  the  assumption  that  excessive  binding  stability  of  C390  hinders  
its  ability  to  efficiently  release  nucleic  acids  within  target  cells,  we  next  tested  two  
additional  high  molecular  weight  chitosan  formulations.  C209  (209  kDa,  86.9%  
deacetylation)  and  C350  (350  kDa,  77.3%  deacetylation)  were  evaluated  for  their  ability  
to  form  nanocomplexes,  protect  nucleic  acids,  and  transfect  cells.  To  determine  the  
appropriate  formulation  for  each  polymer,  physical  polyplex  properties  were  analyzed  
over  a  range  of  N/P  ratios.  We  determined  that  C209  formed  the  best  particles  at  an  N/P  
ratio  of  5  (diameter  ~  120  nm,  zeta  potential  ~  14  mV),  while  C350  was  unable  to  stably  




Figure  12.  Size  and  Zeta  Potential  of  C209  Polyplexes  
Physical  characterization  of  C209  polyplexes  to  determine  the  N/P  ratio  required  to  
produce  nanoparticles  with  the  desired  properties  
  
We  confirmed  the  complexation  and  protection  of  DNA  using  a  gel  retardation  
assay  and  DNase  protection  assay,  respectively  (Figure  13).  In  the  gel  retardation  
studies,  the  migration  of  free  anionic  nucleic  acid  is  prevented  upon  complexation,  
condensation,  and  charge  neutralization  by  cationic  polymer.  At  N/P  ratios  greater  than  
two,  C209  completely  prevented  the  migration  of  DNA.  When  the  particles  were  
incubated  with  DNase  I  prior  to  electrophoretic  analysis,  no  smear  was  evident  to  
indicate  degradation  of  DNA.  The  DNA  protection  assay  suggests  that  C209  is  able  to  
protect  a  payload  from  enzymatic  degradation,  even  at  low  concentrations.  Considering  
the  corresponding  polyplex  size,  zeta  potential,  and  DNA  protection  ability,  we  selected  




Figure  13.  Characterization  of  C209  Polyplex  Binding  and  Stability  
Gel  retardation  and  DNA  protection  assays  show  that  an  N/P  ratio  of  5  is  sufficient  for  
C209  to  complex  and  protect  nucleic  acid  payloads.  
  
3.3.3 Quantification of Transfection Efficiency 
Using  this  optimized  C209  formulation,  we  tested  the  transfection  capabilities  of  
the  polyplexes  in  HepG2  and  HEK293  cells.  Flow  cytometric  analysis  of  HepG2  cells  
transfected  with  GFP  pDNA  and  mRNA  matched  well  with  previous  RT-­‐‑PCR  results.  
Delivery  of  mRNA  with  C390  resulted  in  approximately  twice  as  many  GFP+  cells  than  
with  pDNA  (Figure  14).  In  both  cases,  C209  mediated  lower  transfection  efficiency  than  
C390.  In  the  case  of  HEK293  cells,  mRNA  transfections  were  lower  than  pDNA,  and  
C209  again  performed  poorly  compared  to  C390  (Figure  15).  The  poor  performance  of  
mRNA  particles  in  this  cell  line  may  be  attributed  to  the  higher  metabolic  activity  and  
faster  intracellular  RNA  turnover  rate  as  compared  to  hepatocytes.  To  validate  these  
results,  we  also  measured  gross  transgene  expression  levels  with  a  luciferase  assay  
(Figure  16).  Again,  C209  underperformed  relative  to  C390  in  the  delivery  of  the  
luciferase  reporter  plasmid  to  HEK293  cells.  To  confirm  that  cells  readily  internalize  
both  C209  and  C390  polyplexes,  we  delivered  both  types  to  mature  monolayers  of  Caco-­‐‑
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2  cells  to  mimic  delivery  to  the  intestinal  epithelium.  The  samples  were  treated  with  
equal  doses  of  polyplexes  loaded  with  colloidal  gold-­‐‑functionalized  plasmid  DNA,  and  
fixed  following  a  four-­‐‑hour  transfection  period.  When  visualized  with  transmission  
electron  microscopy,  nanocomplexes  of  both  types  were  observed  at  similar  
concentrations  within  the  intracellular  compartment  (Figure  17).  With  transfection  
efficiencies  only  slightly  higher  than  background  levels  despite  similarly  high  levels  of  
cellular  uptake,  it  was  clear  that  simple  carrier  substitution  among  the  available  high  
molecular  weight  chitosans  would  be  insufficient  to  increase  transfection  efficiencies  to  
acceptable  levels.  Next,  we  elected  instead  to  systematically  modulate  the  binding  
stability  of  C390  polyplexes  using  the  ternary  anionic  component  PGA.    
  
  
Figure  14.  Flow  Cytometric  Quantification  of  GFP+  HepG2  Cells  Following  




Figure  15.  Flow  Cytometric  Quantification  of  GFP+  HEK293  Cells  Following  








Figure  17.  Transmission  Electron  Microscopy  of  Chitosan  Polyplex  Uptake  
TEM  images  show  cellular  internalization  of  C209  (left)  and  C390  (right)  polyplexes  
loaded  with  pDNA  functionalized  with  colloidal  gold  for  detection.  
  
3.3.4 Systematic Modulation of Binding with PGA 
PGA  is  a  polyanionic,  non-­‐‑toxic  peptide  that  has  been  used  in  oral  drug  delivery  
applications  (Figure  18).  It  was  chosen  because  it  has  been  shown  to  compete  with  DNA  
for  binding  of  chitosan,  resulting  in  weakened  chitosan-­‐‑DNA  interactions.  The  
carboxylic  (C)  moieties  on  PGA  compete  with  the  phosphate  (P)  groups  on  nucleic  acids  
for  the  amines  (N)  of  chitosan.  We  added  increasing  amounts  of  PGA  into  the  synthesis  
of  C390  polyplexes  to  screen  for  increased  transfection  capabilities.  The  N/P/C  ratio  was  
varied  from  3.2/1/0  to  3.2/1/4.2.  Above  the  ratio  3.2/1/1.6,  visible  precipitation  appeared  
in  the  tube  during  synthesis.  This  presumed  flocculation  caused  by  the  slight  excess  of  
polyanion  and  more  neutral  polyplex  zeta  potentials  ceased  above  ratio  3.2/1/4.2,  at  
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which  point  the  polyplexes  possessed  negative  zeta  potentials.  C390-­‐‑PGA  polyplexes  
were  loaded  with  pLuc  and  delivered  to  HEK293  cells.  Luminescence  detection  at  48  
hours  after  transfection  was  performed  to  quantify  luciferase  gene  expression  (Figure  
19).  Transfection  was  essentially  absent  at  N/P/C  conditions  resulting  in  flocculation  and  
precipitation.  No  amount  of  PGA  addition  resulted  in  an  appreciable  increase  in  
luciferase  transgene  expression  levels  in  HEK293  cells.  Contrary  to  the  success  seen  by  
others  with  the  inclusion  of  PGA  with  low  molecular  weight  chitosan  to  generate  more  
efficient  ternary  polyplexes,  the  addition  of  PGA  to  high  molecular  weight  chitosan  
polyplexes  yields  deleterious  effects  on  their  transfection  capabilities.  We  concluded  
from  these  results  that  destabilization  of  C390-­‐‑DNA  polyplexes  with  PGA  is  insufficient  
to  improve  transfection  efficiency  beyond  levels  that  are  achievable  with  binary  C390  
formulations.  
  




Figure  19.  Quantification  of  Luciferase  Transfections  by  C390  Polyplexes  with  
Systematic  Addition  of  PGA  
Above  the  ratio  3.2/1/1.6,  visible  precipitation  appeared  in  the  tube  during  synthesis.  
This  presumed  flocculation  caused  by  the  slight  excess  of  polyanion  and  more  neutral  
polyplex  zeta  potentials  ceased  above  ratio  3.2/1/4.2,  at  which  point  the  polyplexes  
possessed  negative  zeta  potentials.  No  amount  of  PGA  addition  resulted  in  an  
appreciable  increase  in  luciferase  transgene  expression  levels  in  HEK293  cells.  
  
3.3.5 Selection and Characterization of SS-PAA Polyplexes 
When  adjustment  of  polymer  properties  and  systematic  addition  of  ternary  
destabilizing  components  proved  inadequate  to  improve  chitosan-­‐‑mediated  gene  
transfer  by  increasing  the  efficiency  of  nucleic  acid  release,  we  opted  to  test  a  new  class  
of  carriers  with  an  incorporated  bioresponsive  release  mechanism  built  in.  We  tested  the  
linear  bioreducible  poly(amido  amine)s  (SS-­‐‑PAAs)  poly(CBA-­‐‑ABOL)  and  poly(CBA-­‐‑
HIS70/DMPA30)  (Figure  20).  The  side  chain  derived  from  1-­‐‑amino-­‐‑4-­‐‑butanol  (ABOL)  is  
slightly  hydrophobic  and  increases  interactions  with  cell  and  endocytic  membranes.  
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Histamine  (HIS)  provides  increased  buffer  capacity  at  low  pH  by  virtue  of  its  low  
basicity  amino  groups  (pKa  ~  6.5)  that  are  unprotonated  at  physiological  pH,  while  
dimethyl  aminopropylamine  (DMPA)  adds  high  basicity  amino  groups  (pKa  ~  8.0)  that  





Figure  20.  Chemical  Structures  of  Poly(CBA-­‐‑HIS/DMPA)  and  Poly(CBA-­‐‑ABOL)    
  
SS-­‐‑PAAs  showed  good  transfection  capabilities  and  favorable  toxicity  profiles  in  
preliminary  screening,  and  are  likely  unhindered  by  inefficient  release  due  to  their  
engineered  degradation  mechanism.  A  salient  feature  of  SS-­‐‑PAAs  is  the  disulfide  bond  
present  in  their  backbone,  lending  stability  to  the  particles  in  the  extracellular  
environment  where  glutathione  concentrations  are  2-­‐‑20  µμM,  but  facilitating  rapid  
degradation  and  release  in  the  reducing  environment  of  the  cytoplasm  where  
glutathione  species  are  present  at  0.5-­‐‑10  mM.  Poly(CBA-­‐‑ABOL)  was  synthesized  by  
Michael  addition  of  N,N-­‐‑cystamine  bisacrylamide  with  4-­‐‑amino-­‐‑1-­‐‑butanol,  purified,  and  
characterized  by  1H  NMR  and  Matrix  Assisted  Laser  Desorption/Ionization  (MALDI)  
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mass  spectrometry  (Figure  21).  The  polymer  to  DNA  mass  ratio  selected  for  use  was  
determined  by  a  systematic  gel  retardation  study  to  determine  the  ratio  necessary  to  
fully  condense  DNA  (Figure  22).  In  the  same  experiment,  reductive  release  was  verified  
by  adding  2.5  mM  dithiothreitol  (DTT)  to  the  particles.  The  mass  ratios  48:1  and  60:1  
were  chosen  for  p(CBA-­‐‑ABOL)  DNA  and  RNA  particles,  respectively.  The  ratios  24:1  
and  36:1  were  chosen  for  p(CBA-­‐‑HIS70/DMPA30).  The  presence  of  DMPA  side  chains  
increases  the  polymer  charge  density,  thereby  reducing  the  polymer  mass  required  to  
achieve  the  same  degree  of  complexation  of  SS-­‐‑PAAs  bearing  neutral  moieties.  
  
  
Figure  21.  Matrix  Assisted  Laser  Desorption/Ionization  (MALDI)  Mass  Spectrometry  
of  Poly(CBA-­‐‑ABOL)  





Figure  22.  Gel  Retardation  and  Reductive  Release  Assays  for  SS-­‐‑PAA  Polyplexes  
  
3.3.6 Cytotoxicity and Transfection Efficiency of SS-PAA Polyplexes 
In  order  to  confirm  the  favorable  cytotoxicity  profile  of  the  SS-­‐‑PAA  carriers,  we  
conducted  a  dose  escalation  study  to  determine  the  IC50  of  each  polymer  (Figure  23).  
Using  the  WST-­‐‑1  colorimetric  metabolic  assay,  we  compared  the  concentrations  at  which  
fifty  percent  of  cells  were  inhibited  (IC50)  for  each  SS-­‐‑PAA  as  well  as  25  kDa  PEI.  We  
chose  the  Caco-­‐‑2  and  HepG2  cell  types  for  their  importance  in  the  oral  route  of  
administration.  In  each  case,  the  SS-­‐‑PAAs  were  significantly  less  toxic  than  PEI,  with  
IC50  values  at  least  an  order  of  magnitude  higher.  In  comparison,  reported  IC50  values  for  
Lipofectamine  are  approximately  6-­‐‑10  µμg/mL.  We  next  assessed  the  transfection  
capabilities  of  the  SS-­‐‑PAA  carriers  in  the  same  cell  types.  We  delivered  doses  of  GFP  
pDNA  to  cells  in  24-­‐‑well  plates,  then  quantified  transgene  expression  after  24  hours  with  
fluorescence  microscopy  and  flow  cytometry  (Figure  24).  Poly(CBA-­‐‑ABOL)  gave  25  to  85  
percent  higher  transfection  levels  than  PEI  with  significantly  less  obvious  cytotoxicity.  
To  assess  its  potential  for  oral  gene  delivery,  we  applied  p(CBA-­‐‑ABOL)  and  chitosan  
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particles  to  the  transwell  cell  culture  system  to  simulate  the  transepithelial  transport  
required  by  the  oral  route  of  administration.  Administration  of  the  particles  did  not  
damage  the  integrity  of  the  epithelial  monolayer,  as  indicated  by  the  maintenance  of  
pre-­‐‑transfection  TEER  values  following  dosing  (Figure  25).  GFP  expression  was  evident  
by  fluorescence  microscopy  in  both  cell  layers  with  p(CBA-­‐‑ABOL)  particles,  however  
the  increase  in  transfection  in  the  basal  HepG2  layer,  relative  to  transfection  with  C390  




Figure  23.  Cytotoxicity  of  SS-­‐‑PAAs  and  PEI  in  Caco-­‐‑2  and  HepG2  Cells  





Figure  24.  SS-­‐‑PAA  Transfection  Efficiency  in  Caco-­‐‑2  and  HepG2  Cell  Monolayers  
  
  
Figure  25.  Transwell  Transfections  with  p(CBA-­‐‑ABOL)  Polyplexes  
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As  it  did  not  appear  that  p(CBA-­‐‑ABOL)  polyplexes  were  ideally  suited  for  the  
transepithelial  transport  and  subsequent  transfection  of  distal  target  cells  required  by  
oral  administration,  we  tested  them  instead  in  an  intrabiliary  retrograde  infusion  model  
to  determine  if  they  could  mediate  gene  transfer  in  the  liver  directly  without  having  to  
cross  a  cellular  barrier  first.  The  liver  is  an  important  delivery  target  as  it  is  the  site  of  
many  diseases  and  proteins  produced  in  the  liver  have  easy  access  to  circulatory  system  
for  systemic  introduction.  Under  anesthesia,  the  livers  of  Wistar  rats  were  isolated  from  
the  surrounding  tissue,  then  a  needle  was  inserted  into  the  common  bile  duct  and  a  tie  
was  used  to  secure  the  needle.  Nanoparticles  and  naked  DNA  were  administered  at  a  
dose  of  20  µμg  of  minicircle  luciferase  plasmid  in  4  mL  of  5%  glucose  into  the  common  
bile  duct  over  20  min  (0.2  ml/min)  using  a  syringe  pump.  A  tie  was  then  placed  around  
the  bile  duct  between  the  liver  and  the  point  of  infusion  to  prevent  back  flow,  and  the  
needle  was  withdrawn.  After  30  min,  all  ties  were  removed.  In  these  studies,  a  minicircle  
luciferase  construct  was  utilized.  Bacterial  sequences  integral  to  plasmid  replication  and  
amplification  during  the  manufacturing  process  contain  CpG  motifs.  These  bacterial  
motifs  cause  gene  silencing  in  mammalian  cells  [200],  which  can  be  overcome  using  a  
plasmid  that  only  contains  the  elements  essential  to  mammalian  expression  [201,  202].  
During  the  plasmid  amplification  process,  recombination  is  induced  just  prior  to  
plasmid  purification,  producing  a  mammalian  expression  cassette  minicircle  and  the  
bacterial  amplification  cassette,  which  is  then  degraded.  In  addition  to  diminished  gene  
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silencing,  the  smaller  plasmid  also  enables  delivery  of  a  higher  effective  transgene  dose.  
Following  dosing  of  the  rats,  luciferase  expression  was  monitored  non-­‐‑invasively  at  4,  
24,  and  72  hours  post-­‐‑infusion  with  an  IVIS  Imaging  System.  Imaging  revealed  that  the  
animals  given  polyplexes  showed  significantly  less  transgene  expression  than  the  naked  
plasmid  control  at  each  time  point  (Figures  26  and  27).  Expression  was  restricted  to  the  
liver  and  remained  detectable  up  to  the  72-­‐‑hour  time  point.    
  
  
Figure  26.  In  Vivo  Luciferase  Imaging  of  Rats  Following  Retrograde  Bile  Duct  
Delivery  of  p(CBA-­‐‑ABOL)  Polyplexes  or  Naked  Plasmid  DNA  
Animals  given  polyplexes  showed  significantly  less  transgene  expression  than  the  naked  
plasmid  control  at  each  time  point.  Expression  was  restricted  to  the  liver  and  remained  




Figure  27.  Quantification  of  In  Vivo  Luciferase  Imaging  Results  
  
Having  determined  that  SS-­‐‑PAA  polyplexes  may  not  be  best  suited  for  in  vivo  
gene  delivery,  we  pivoted  our  efforts  to  exploit  their  potent  in  vitro  transfection  
capabilities  and  favorable  cytotoxicity  toward  the  goal  of  cellular  reprogramming.  Many  
cellular  reprogramming  applications  demand  that  genetic  reprogramming  factors  be  
expressed  at  sustained  high  levels  for  periods  of  days  to  weeks.  To  confirm  that  p(CBA-­‐‑
ABOL)  is  capable  of  achieving  this,  we  systematically  determined  the  maximum  
tolerated  dose  and  potential  to  deliver  subsequent  doses  in  adult  NHDF  cells  in  a  6-­‐‑well  
plate  format.  Quantification  of  GFP  transfection  efficiency  with  flow  cytometry  showed  
that  sustained,  robust  expression  is  achievable.  The  majority  that  became  GFP+  following  
a  single  dose  remained  positive  at  the  twelve-­‐‑day  time  point.  Cells  that  received  a  
second  dose  on  day  ten  recovered,  and  in  some  cases  exceeded,  the  fraction  of  GFP+  cells  
generated  by  the  first  dose  (Figure  28).  This  result  demonstrates  the  feasibility  of  serial  





Figure  28.  Serial  Transfections  with  p(CBA-­‐‑ABOL)  Polyplexes  
A  single  dose  of  pDNA  p(CBA-­‐‑ABOL)  polyplexes  gives  prolonged  transgene  expression  
in  NHDF  cells,  while  a  second  dose  at  day  ten  boosts  expression  to  levels  similar  to  
those  observed  following  the  initial  dose.  
  
3.4 Discussion 
An  ideal  gene  carrier  would  provide  total  protection  of  nucleic  acid  cargo  from  
degradation  prior  to  releasing  it  efficiently  near  or  within  the  nucleus  of  target  cells.  
While  independent  optimization  of  polymer  properties,  such  as  molecular  weight  and  
charge  density,  has  proven  largely  inadequate  in  addressing  this  challenge,  applying  
polymeric  carriers  that  respond  to  biological  cues  to  switch  from  a  tight,  protective  
complex  to  a  relaxed  interaction  favoring  release  has  shown  promise.  We  first  attempted  
to  improve  upon  the  modestly  successful  high  molecular  weight  chitosan  carrier  system  
that  has  been  used  previously.  However,  efforts  to  solve  the  known  issue  of  overly  
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stable  binding  through  payload  substitution,  adjustment  of  molecular  weight  and  
charge  density,  and  the  addition  of  the  ternary  anionic  component  PGA  all  proved  
inadequate  to  significantly  improve  transfection  levels.  Despite  attempts  to  optimize  
chitosan  polyplex  formulation,  no  appreciable  enhancement  was  detected  in  any  cell  
type  or  co-­‐‑culture  tested  by  fluorescence  microscopy,  luminescence  quantification,  flow  
cytometry,  transmission  electron  microscopy,  or  quantitative  RT-­‐‑PCR.    
We  subsequently  pivoted  our  efforts  to  an  alternative  carrier  system  -­‐‑  a  
bioreducible  linear  poly(amido  amine)  able  to  give  sustained,  robust  transgene  
expression  through  serial  dosing.  Poly(CBA-­‐‑ABOL)  possesses  an  inherent  degradative  
response  mechanism  to  changes  encountered  in  the  redox  environment  while  
transitioning  from  the  extracellular  space  to  the  cytoplasmic  domain.  It  is  designed  to  
unpack  efficiently  within  cells,  and  to  break  down  to  minimize  associated  sequelae.  
Following  selection  and  synthesis  of  this  promising  carrier,  we  showed  that  it  forms  
polyplexes  of  appropriate  size  and  charge,  dissociates  readily  upon  challenge  with  
intracellular  concentrations  of  reducing  agents,  and  transfects  cells  efficiently.  We  also  
demonstrated  its  ability  to  achieve  modest  levels  of  transfection  in  vivo,  and  show  that  
its  favorable  cytotoxicity  profiles  allows  for  repeated  dosing  in  order  to  sustain  high  
transgene  expression  levels.  The  following  two  chapters  describe  efforts  to  optimize  this  
carrier’s  formulation  and  application,  to  generate  uniform,  potent,  and  reproducible  
polyplexes  that  satisfy  the  contrary  requirements  of  protection  and  efficient  release.  
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4. Microfluidic Preparation of Polymer-Nucleic Acid 
Nanocomplexes Improves Nonviral Gene Transfer 
  
Some  of  the  material  in  Chapter  4  is  included  in:    
1)  Microfluidic  preparation  of  polymer-­‐‑nucleic  acid  nanocomplexes  improves  
nonviral  gene  transfer.  Grigsby  CL,  Ho  YP,  Lin  C,  Engbersen  JFJ,  Leong  KW.  2013.  Sci  
Rep.  3:3155  
2)  Tuning  physical  properties  of  nanocomplexes  through  microfluidics-­‐‑assisted  
confinement.  Ho  YP,  Grigsby  CL,  Zhao  F,  Leong  KW.  2011.  Nano  Lett.  11(5):2178-­‐‑82  
  
As  the  designs  of  polymer  systems  used  to  deliver  nucleic  acids  continue  to  
evolve,  it  is  becoming  increasingly  apparent  that  the  basic  bulk  manufacturing  
techniques  of  the  past  will  be  insufficient  to  produce  polymer-­‐‑nucleic  acid  
nanocomplexes  that  possess  the  uniformity,  stability,  and  potency  required  for  their  
successful  clinical  translation  and  widespread  commercialization.  Traditional  bulk-­‐‑
prepared  products  are  often  physicochemically  heterogeneous  and  may  vary  
significantly  from  one  batch  to  the  next.  Here  we  show  that  preparation  of  bioreducible  
nanocomplexes  with  an  emulsion-­‐‑based  droplet  microfluidic  system  produces  
significantly  improved  nanoparticles  that  are  up  to  fifty  percent  smaller,  more  uniform,  
and  are  less  prone  to  aggregation.  The  intracellular  integrity  of  nanocomplexes  prepared  
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with  this  microfluidic  method  is  significantly  prolonged,  as  detected  using  a  high-­‐‑
throughput  flow  cytometric  QD-­‐‑FRET  nanosensor  system.  These  physical  attributes  
conspire  to  consistently  enhance  the  delivery  of  both  plasmid  DNA  and  messenger  RNA  
payloads  in  stem  cells,  primary  cells,  and  human  cell  lines.  Innovation  in  processing  is  
necessary  to  move  the  field  toward  the  broader  clinical  implementation  of  safe  and  
effective  nonviral  nucleic  acid  therapeutics,  and  preparation  with  droplet  microfluidics  
nanomanufacturing  represents  a  step  forward  in  addressing  the  critical  barrier  of  robust  
and  reproducible  nanocomplex  production.    
4.1 Introduction 
Recent  clinical  trials  hint  at  the  therapeutic  potential  of  gene  therapy,  but  this  
potential  remains  stymied  by  the  dearth  of  safe  and  efficient  delivery  systems  [203-­‐‑206].  
While  tremendous  creativity  and  innovation  in  carrier  design  have  produced  very  
sophisticated  polymeric  gene  delivery  systems,  nonviral  methods  remain  prohibitively  
inefficient  for  most  applications  [207-­‐‑210].  The  circulatory  residence  time,  cellular  
uptake,  transfection  efficiency,  and  toxicity  of  nanoparticles  all  depend  to  some  extent  
on  physicochemical  attributes  such  as  size,  stability,  shape,  and  charge  [108,  211].  
However,  the  physical  aspects  of  polyplex  production,  and  their  role  in  determining  
these  properties,  have  been  largely  overlooked.  
The  assembly  of  nanocomplexes  by  charge  neutralization  is  a  process  that  occurs  
in  milliseconds  [136,  143].  While  preparation  in  bulk  formats  by  pipetting,  shaking,  or  
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oscillatory  mixing  is  convenient,  these  methods  are  poorly  suited  to  reproducibly  
generate  uniform  particles  given  the  kinetically  determined  nature  of  the  formation  
process  [5].  Irreproducibility  is  typical;  slight  perturbations  of  bulk  mixing  protocols  
often  yield  particles  of  varied  properties.  The  poor  quality  of  these  polyplexes  
exacerbates  the  challenge  of  establishing  precise  structure-­‐‑function  relationships  and  
precludes  mechanistic  understandings  of  the  gene  transfer  process,  as  subpopulations  of  
particles  may  be  responsible  for  observed  phenomena.  The  inability  to  manufacture  
nonviral  delivery  systems  in  a  reproducible  and  scalable  manner  also  hinders  their  
clinical  translation.  As  the  field  has  begun  to  consider  the  physical  control  of  
nanoparticle  assembly  as  an  opportunity  for  innovation,  several  novel  techniques  have  
emerged  [146,  147,  212].  Top-­‐‑down  nanoimprinting  systems  produce  nanoparticles  with  
defined  shape  and  size  that  have  proven  valuable  in  deconvoluting  the  mechanistic  
effects  of  such  characteristics.  However,  the  rapid  reaction  kinetics,  aqueous  conditions,  
and  temperature  sensitivity  of  polyplex  assembly  favor  microfluidic  approaches,  which  
have  included  both  monophasic  laminar  flow  systems  and  emulsion-­‐‑based  designs  [136,  
144,  148-­‐‑150,  213].  The  former  suffer  from  flocculation  at  high  concentrations,  while  the  
latter  have  been  used  successfully  in  production  of  both  lipoplexes  and  polyplexes.  
Here,  we  have  used  an  emulsion-­‐‑based  microfluidic  system  to  confine  the  synthesis  of  
polyplexes  to  picoliter  sized  water-­‐‑in-­‐‑oil  droplets.  This  system  for  microfluidics  assisted  
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confinement  (MAC)  enables  the  mixing  of  polyelectrolyte  components  to  proceed  more  
rapidly  so  that  polyplexes  are  formed  under  equilibrium  conditions.  
For  such  a  system  to  be  broadly  useful,  it  must  perform  well  with  different  
payloads  and  across  multiple  cell  types.  Plasmid  DNA  is  the  predominant  payload  in  
gene  delivery,  but  messenger  RNA  eliminates  the  requirement  of  nuclear  delivery  and  
more  easily  produces  transgene  expression  in  some  slowly  dividing  or  post-­‐‑mitotic  cells.  
However,  substitution  of  the  payload  may  not  be  trivial,  as  there  is  mounting  evidence  
that  polycations  interact  differently  with  DNA  than  they  do  with  RNA  [151].  Double  
stranded  DNA  is  a  stiffer  molecule  with  a  longer  persistence  length  than  single-­‐‑stranded  
messenger  RNA,  and  shorter  nucleic  acids  may  diminish  the  effects  of  molecular  chain  
entanglement.  In  line  with  our  aim  to  establish  the  broad  potential  of  MAC  to  control  
polyplex  self-­‐‑assembly,  in  this  study  we  utilized  a  promising  bioreducible  linear  
poly(amido  amine)  gene  carrier  and  hypothesized  that  DNA  polyplexes  prepared  with  
MAC  would  be  more  homogeneous  and  more  potent.  Next,  we  tested  whether  the  
benefits  of  MAC  preparation  would  also  apply  to  complexes  loaded  with  RNA  
payloads,  and  we  probed  particle  potency  in  multiple  translationally  relevant  and  
difficult-­‐‑to-­‐‑transfect  target  cell  types.  We  evaluated  the  products  in  terms  of  size,  
polydispersity,  zeta  potential,  binding  stability,  aggregation  behavior,  amount  of  
unreacted  polyion  species,  and  transfection  efficiency.  Through  the  use  of  a  QD-­‐‑FRET  
based  assay,  we  furthermore  quantified  the  cellular  uptake  and  intracellular  unpacking  
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of  MAC  polyplexes  in  an  attempt  to  correlate  their  performance  with  their  ability  to  
overcome  these  two  specific  rate-­‐‑limiting  barriers  to  delivery.  This  study  helps  bridge  a  
void  in  the  structure-­‐‑function  understanding  of  gene  delivery  by  demonstrating  how  
physical  polyplex  attributes  dictated  by  their  preparation  can  influence  intracellular  
behavior  and  transfection  efficiency.  Together,  the  results  of  these  studies  demonstrate  
that  nonviral  gene  delivery  can  be  improved  not  only  by  chemical  design  and  
optimization,  but  also  through  innovation  in  processing  and  preparation  techniques.  
4.2 Methods 
4.2.1 Polymer Synthesis and Labeling  
Poly(CBA-­‐‑ABOL)  was  synthesized  by  Michael-­‐‑type  polyaddition  of  3.67  g  N,N-­‐‑
cystaminebisacrylamide  (CBA)  (Polysciences,  Warrington,  PA)  and  1.26  g  4-­‐‑amino-­‐‑1-­‐‑
butanol  (ABOL)  (Sigma-­‐‑Aldrich,  Saint  Louis,  MO)  as  described  by  Lin  et  al.  [22].  The  
reaction  product  was  purified  by  dialysis  (3.5  kDa  cutoff)  in  acidic  deionized  water  (pH  
4)  and  then  lyophilized.  The  polymer  was  collected  in  its  HCl-­‐‑salt  form  (1.63  g,  33%  
yield).  Due  to  the  absence  of  primary  amines  on  poly(CBA-­‐‑ABOL)  for  conjugation  of  
fluorescent  labels,  we  also  synthesized  the  copolymer  poly(CBA-­‐‑ABOL90/BDA10)  by  
substituting  10%  N-­‐‑Boc-­‐‑1,4-­‐‑butanediamine  (BDA)  for  4-­‐‑amino-­‐‑1-­‐‑butanol  in  the  
polymerization.  Deprotection  of  the  Boc-­‐‑protected  amino  groups  in  the  copolymers  was  
performed  in  a  mixture  of  methanol/trifluoroacetic  acid  (10  mL,  1/1,  v/v)  overnight  prior  
to  dialysis.  The  primary  amines  on  the  BDA  side  chains  of  the  copolymer  were  then  
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functionalized  with  Cy5-­‐‑NHS  (Amersham  Biosciences,  Piscataway,  NJ)  fluorescent  dye  
and  purified  again  by  dialysis.  Labeled  polymer  was  used  at  a  1:4  ratio  with  unlabeled  
p(CBA-­‐‑ABOL)  to  maximize  the  efficiency  of  the  QD-­‐‑FRET  sensor.  The  incorporation  of  
fluorescent  labels  did  not  affect  the  size,  zeta  potential,  or  transfection  efficiency  of  
polyplexes.  Polymer  structures  were  validated  by  Matrix  Assisted  Laser  Desorption  
Ionization  (MALDI)  mass  spectrometry  and  1H  NMR.  
4.2.2 Nucleic Acid Production and Labeling 
Plasmids  pDNA  (pmaxGFP,  Lonza,  Switzerland),  pLuc  (VR1255  Luciferase,  
Vical,  San  Diego,  CA)  and  pT7-­‐‑EGFP-­‐‑N1  (gift  from  David  Boczkowski,  Duke  University)  
were  propagated  in  Escherichia  coli  DH5α  (Invitrogen,  Carlsbad,  CA)  and  purified  with  
EndoFree  Plasmid  Mega  and  Maxi  kits  (Qiagen,  Germantown,  MD).  Following  
linearization,  in  vitro  transcription  was  performed  on  T7-­‐‑EGFP-­‐‑N1  with  the  
mMESASGE  mMACHINE  T7  kit  (Invitrogen)  to  generate  mRNA  encoding  GFP.  To  
enable  attachment  of  fluorescent  labels,  pDNA  was  biotinylated  as  described  by  the  
manufacturer  (Label  IT  Biotin,  Mirus  Bio,  Madison,  WI)  but  scaled  to  have  
approximately  one  to  two  biotin  labels  per  molecule,  then  purified  from  unreacted  
reagents  by  ethanol  precipitation.  Biotinylated  samples  were  reacted  with  streptavidin-­‐‑
functionalized  quantum  dots  (QDs,  Qdot  605  ITK,  Invitrogen)  as  described  previously  
[58].  Nucleic  acid  was  added  in  excess  to  QDs  to  ensure  no  unreacted  QDs  remained.  
The  QDs  were  matched  with  the  Cy5  used  to  label  the  polymer  to  comprise  a  quantum  
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dot  Förster  resonance  energy  transfer  (QD-­‐‑FRET)  pair  that  was  used  to  assess  the  
intracellular  binding  status  of  polyplexes.  
 4.2.3 Fabrication and Operation of Microfluidic Devices 
Cross-­‐‑flow  droplet  generators  were  fabricated  using  conventional  soft  
lithography  [214,  215].  PDMS  prepolymer  was  cast  and  cured  on  an  SU-­‐‑8  3025  
(MicroChem,  Newton,  MA)  master  (Transparency  mask,  CAD/Art  Services,  Bandon,  
OR),  which  produced  a  channel  height  of  approximately  35  µμm.  PDMS  prepolymer  
(Sylgard  184  Silicone  Elastomer  Kit,  Dow  Corning,  Midland,  MI)  was  prepared  in  a  10:1  
(base:curing  agent)  ratio  and  cured  at  65°C  for  one  hour.  The  cured  PDMS  was  then  
excised,  punched  with  through-­‐‑holes  to  accept  fluidic  connections,  and  bonded  to  glass  
cover  slips  using  a  thin  layer  of  spin-­‐‑coated  PDMS  to  create  channels  surrounded  by  
PDMS  on  all  sides.  The  fully  assembled  chips  were  then  left  in  an  oven  at  95°C  overnight  
to  ensure  complete  bonding.    
Prior  to  use,  the  microfluidic  channels  were  flushed  with  the  oil  phase  solution  
for  30  minutes  to  ensure  wetting.  To  generate  polyplexes,  two  syringe  pumps  (PHD2000,  
Harvard  Apparatus,  Holliston,  MA)  were  used  to  infuse  the  oil/surfactant  mix  and  
aqueous  reagents  independently  through  syringe  tubing  adapters  (Hamilton,  Reno,  
NV).  The  oil  phase  consisted  of  FC-­‐‑40  fluorocarbon  oil  (3M,  St.  Paul,  MN)  and  2%  
PEGylated  fluorosurfactant  (EA  Surfactant  RainDance  Technologies,  Lexington,  MA  or  
PicoSurf  1,  Dolomite  Microfluidics,  Royston,  UK).  Flow  rates  were  set  at  7.5  µμL  min-­‐‑1  for  
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the  oil  phase  input  and  2.5  µμL  min-­‐‑1  for  each  of  the  three  aqueous  inputs.  Water-­‐‑in-­‐‑oil  
droplets  (~  100  pL)  were  generated  at  the  channel  junction,  where  the  polymer  and  
nucleic  acid  solutions,  separated  by  a  buffer  channel,  were  introduced  to  the  continuous  
oil  phase.  Polyplexes  self-­‐‑assembled  while  confined  to  the  droplets,  while  mixing  of  
their  components  was  enhanced  by  the  inclusion  of  a  serpentine  channel  segment  [216].  
MAC  polyplexes  were  collected  by  breaking  the  droplets  (Droplet  Destabilizer,  
RainDance  Technologies)  and  used  directly  from  the  aqueous  supernatant  for  
subsequent  characterization  or  cellular  investigation  without  any  further  purification.  
Bulk  preparation  was  performed  following  published  protocols  [22].  Briefly,  polyplexes  
were  prepared  by  adding  a  complexation  buffer  solution  (20mM  HEPES,  5  wt  %  glucose,  
pH  7.4)  of  polymer  (844  µμg  mL-­‐‑1  for  DNA,  1125  µμg  mL-­‐‑1  for  RNA)  to  a  complexation  
buffer  solution  of  nucleic  acid  (75  µμg  mL-­‐‑1)  followed  immediately  by  20  seconds  of  
vortex  mixing.  Reaction  sizes  ranged  from  5  to  15  µμg  of  nucleic  acid.  The  presence  of  the  
reagents  used  for  MAC  droplet  generation  did  not  significantly  affect  the  activity  of  bulk  
products.  Identical  reagent  solutions  and  concentrations  were  introduced  into  the  
droplet  generator  to  produce  MAC  polyplexes.    
4.2.4 Nanocomplex Characterization 
Polyplex  sizes  and  zeta  potentials  were  measured  with  a  Zetasizer  NanoZS-­‐‑90  
(Malvern  Instruments,  Southborough,  MA).  Polyplexes  were  assayed  at  a  nucleic  acid  
concentration  of  15  µμg  mL-­‐‑1  for  size  measurements.  Measurements  of  five  independent  
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samples  were  performed  at  25°C  using  a  90°  scattering  angle.  To  assess  aggregation  
kinetics,  measurements  were  repeated  at  five-­‐‑minute  intervals  over  a  four-­‐‑hour  period.  
Size  is  reported  as  the  Z-­‐‑average  diameter,  or  intensity  weighted  mean  hydrodynamic  
diameter.  Zeta-­‐‑potential  measurements  were  performed  on  five  independent  samples  at  
a  final  DNA  concentration  of  3  µμg  mL-­‐‑1  using  capillary  flow  cells  (Malvern  Instruments)  
in  complexation  buffer  at  pH  7.4  and  at  25  ºC.  
4.2.5 Cell Culture and Transfection 
For  all  cell  culture  experiments,  20,000  cells  cm-­‐‑2  cells  were  seeded  24  hours  prior  
to  transfection  in  12-­‐‑well  or  24-­‐‑well  TCPS  plates  (BD,  Franklin  Lakes,  NJ)  and  cultured  at  
37°C  and  5%  CO2  in  the  appropriate  complete  growth  media  recommended  by  the  
supplier.  The  cell  types  studied  were  human  embryonic  kidney  HEK293  (ATCC,  
Manassas,  VA),  human  hepatocellular  carcinoma  HepG2  (ATCC),  primary  mouse  
embryonic  fibroblasts  (PMEF)  (Millipore,  Manassas,  VA),  and  human  mesenchymal  
stem  cells  (hMSC)  (ATCC).  All  transfections  were  carried  out  at  37°C  and  5%  CO2  in  
serum-­‐‑  and  antibiotic-­‐‑free  OptiMEM  (Invitrogen),  which  was  replaced  with  the  
appropriate  complete  growth  medium  4  hours  after  the  onset  of  transfection.  Each  
transfection  was  performed  in  duplicate  and  quantified  results  represent  three  
independent  experiments.  Transfection  efficiency  and  transgene  expression  were  
assayed  at  24  hours  post-­‐‑transfection.  Luminescence  measurements  to  quantify  
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luciferase  expression  were  performed  using  the  SteadyGlo  kit  (Promega,  Madison,  WI)  
according  to  the  manufacturer’s  protocol.    
4.2.6 Flow Cytometry 
Flow  cytometric  analysis  was  performed  using  a  FACSCanto  II  (BD  Biosciences,  
Franklin  Lakes,  NJ)  with  at  least  10,000  cells  analyzed  per  sample.  To  quantify  
transfection  efficiency  24  hours  after  transfection,  cells  were  washed  briefly  with  PBS  
without  Ca2+  and  Mg2+  (Mediatech,  Washington,  DC),  and  released  from  TCPS  surfaces  
with  0.25%  Trypsin-­‐‑EDTA  (Invitrogen).  The  trypsin  was  inactivated  with  serum-­‐‑
containing  media  and  the  cells  were  centrifuged  at  4°C,  resuspended  in  ice-­‐‑cold  PBS,  
centrifuged  again,  and  resuspended  in  PBS  containing  1%  paraformaldehyde  (PFA)  
(EMS,  Hatfield,  PA).  The  FSC/SSC  was  gated  with  untreated  cells  to  exclude  the  dead  
cells  or  cell  debris.  Cells  transfected  with  non-­‐‑fluorescent  pLuc  plasmid  served  as  
negative  controls  for  each  equivalent  pDNA  or  mRNA  dose,  with  gating  such  that  1%  of  
these  cells  were  considered  GFP+.    
Cellular  uptake  of  polyplexes  was  evaluated  in  separate  experiments  using  
unlabeled  poly(CBA-­‐‑ABOL)  polymer  and  QD-­‐‑labeled  pDNA.  After  predetermined  post-­‐‑
transfection  incubation  periods  at  37°C,  cells  were  washed  briefly  with  PBS  without  Ca2+  
and  Mg2+  and  released  from  TCPS  surfaces  with  0.25%  Trypsin-­‐‑EDTA.  The  trypsin  was  
inactivated  with  serum-­‐‑containing  media  and  the  cells  were  centrifuged  at  4°C,  
resuspended  in  ice-­‐‑cold  PBS,  centrifuged  again,  and  resuspended  in  PBS  containing  4%  
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PFA  and  2%  glutaraldehyde  for  15  minutes.  The  cells  were  washed  with  PBS,  washed  
again  with  PBS  containing  heparin  in  PBS  (20  units  mL-­‐‑1)  to  remove  membrane  bound  
complexes,  and  then  resuspended  in  PBS  for  analysis  [217].  Timepoints  represent  the  
elapsed  time  from  the  start  of  transfection  until  the  onset  of  trypsinization.  The  405  nm  
laser  served  as  the  excitation  source  and  the  fluorescence  emission  was  captured  using  
the  P10  channel  (dichroric:  502LP,  emission  filter:  622/36  nm).  To  measure  rates  of  
intracellular  unpacking,  cells  were  transfected  using  1:4  Cy5-­‐‑labeled  to  unlabeled  
polymer  complexed  with  QD-­‐‑labeled  pDNA.  Samples  were  prepared  using  the  same  
procedure  described  for  the  cellular  uptake  studies,  however  time  zero  was  defined  
instead  as  the  change  from  transfection  medium  back  to  growth  medium  for  unpacking  
analyses.  We  examined  the  decay  of  the  QD-­‐‑FRET  emission  signal  over  time.  Detection  
was  accomplished  by  excitation  with  the  405  nm  laser  and  650LP  emission  filter.  The  
fluorescence  signals  were  compensated  and  gated  with  negative  and  single-­‐‑color  
controls.  FlowJo  (v.  9.1,  Tree  Star,  Ashland)  and  FACSDiva  (BD)  software  were  used  to  
analyze  the  results.  
4.2.7 Fluorescence Microscopy 
Epifluorescent  images  were  captured  with  an  inverted  fluorescence  microscope  
(TE2000U,  Nikon  Instruments,  Melville,  NY)  equipped  with  a  100-­‐‑W  mercury  arc  lamp  
(X-­‐‑Cite  120  Fluor  system,  EXFO,  Ontario,  Canada)  and  a  cooled  CCD  (CoolSnap  HQ,  
Roper  Scientific,  Tucson,  AZ).  Monochrome  emission  from  GFP  was  collected  and  
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filtered  through  appropriate  filters  and  dichroics.  Image  processing  and  analysis  was  
performed  with  ImageJ  (v1.43,  http://rsb.info.nih.gov/ij).    
4.2.8 Nanocomplex Stability and Free Polymer Measurements 
Titrated  volumes  of  PicoGreen  or  RiboGreen  (Quant-­‐‑iT,  Invitrogren)  reagent  
were  added  to  polyplex  solutions  in  a  96-­‐‑well  plate  and  incubated  for  15  minutes  before  
measuring  the  signal  using  a  plate  reader  (BMG  Labtech  GmbH,  Germany).  To  plot  
polyplex  stability,  the  background  fluorescence  was  subtracted  and  the  measured  
fluorescence  intensity  was  normalized  to  the  signal  in  control  samples  containing  no  
polymer.  To  quantify  the  amount  of  unreacted  polymer  remaining  in  solution  following  
polyplex  preparation,  10  µμg  of  polyplexes  were  prepared  using  4:1  p(CBA-­‐‑ABOL)  to  
Cy5-­‐‑labeled  p(CBA-­‐‑ABOL90/BDA10)  and  centrifuged  at  14,000  x  g  for  30  minutes  to  
remove  the  particulate  fraction.  The  supernatant  was  then  collected,  lyophilized  then  
resuspended  in  100  µμL  of  complexation  buffer.  The  suspensions  were  added  to  a  96-­‐‑well  
plate  and  the  Cy5  signal  was  quantified.  Following  subtraction  of  the  background  signal,  
the  percentage  of  free  polymer  remaining  was  determined  by  a  standard  curve  
constructed  with  titrated  polymer  solutions.  
4.2.9 Statistical Analysis 
Results  are  reported  as  the  mean  ±  S.E.M.  as  described  for  three  or  more  
independently  performed  experiments.  Asterisks  denote  p-­‐‑values  <  0.05.  Statistical  
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significance  was  determined  using  an  unpaired  t-­‐‑test  (Prism  5.0,  GraphPad  Software,  La  
Jolla,  CA).  Two-­‐‑tailed  p-­‐‑values  are  reported  unless  otherwise  stated.    
4.3 Results 
4.3.1 Polyplex Preparation and Physical Characterization 
We  prepared  polyplexes  loaded  with  either  plasmid  DNA  or  messenger  RNA  
using  the  bioreducible  linear  poly(amido  amine)  poly(CBA-­‐‑ABOL)  in  bulk  and  MAC  
formats  (Figure  29).  We  selected  this  gene  carrier  for  its  high  efficiency,  low  toxicity,  and  
ability  to  deliver  multiple  types  of  nucleic  acids  [218,  219].  Following  a  systematic  
optimization  of  binding  characteristics,  DNA  and  RNA  polyplexes  were  synthesized  
exclusively  at  polymer:nucleic  acid  mass  ratios  of  45:1  and  60:1,  respectively.  In  both  
cases,  preparation  with  MAC  resulted  in  the  production  of  smaller  and  more  
monodispersed  polyplexes.  The  Z-­‐‑average  diameters  of  MAC  polyplexes  were  40-­‐‑50%  
smaller  than  those  of  bulk  controls  immediately  following  synthesis  (Figure  30).  The  
width  of  the  size  distribution  was  also  significantly  reduced,  as  evidenced  by  similar  
reductions  in  the  polydispersity  index  (PDI).  To  quantify  the  propensity  of  the  products  
to  aggregate,  we  additionally  measured  changes  in  polyplex  size  at  five-­‐‑minute  intervals  
over  the  course  of  a  typical  four-­‐‑hour  transfection  period  (Figure  30).  Bulk  polyplexes  
began  to  aggregate  immediately,  and  continued  to  grow  in  size  throughout  the  period  
studied.  In  contrast,  MAC  polyplexes  exhibited  a  much  higher  degree  of  colloidal  
stability  and  remained  approximately  unchanged  in  size  throughout  the  measurement  
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period.  The  surface  charge  density  of  the  polyplexes,  represented  by  the  zeta-­‐‑potential,  
was  also  considered  (Figure  30).  MAC  polyplexes  exhibited  lower  zeta-­‐‑potentials,  
suggesting  more  complete  charge  neutralization  or  the  presence  of  a  diminished  
polymer  corona,  either  of  which  may  contribute  to  improved  colloidal  stability  by  
reducing  charge  imbalances  and  intraparticle  heterogeneity  [220].  The  physical  profiles  
of  nanoparticles  are  important,  as  the  putative  rate-­‐‑limiting  barriers  associated  with  the  
low  efficiency  of  nonviral  vectors  include  cellular  binding  and  uptake,  endosomal  
escape,  cytosolic  transport  and  unpacking,  nuclear  entry,  and  transcriptional  processing.  
Physical  particle  properties  determine  the  degree  to  which  particles  are  able  to  overcome  
each  of  these  barriers.  Knowing  that  MAC  preparation  yields  smaller,  more  
monodispersed,  and  less  positively  charged  DNA  and  RNA  polyplexes,  we  next  
examined  complex  binding  stability  and  the  final  disposition  of  the  polymer  component  




Figure  29. Design  of  Microfluidic  Chip  and  Gene  Carriers  
A)  A  microfluidic  cross-­‐‑flow  droplet  generator  chip  is  used  to  produce  emulsified  
aqueous  droplets  containing  the  polymeric  gene  carrier  and  nucleic  acids.  While  
confined  to  these  ~100  pL  droplets,  the  polyions  self-­‐‑assemble  into  nanocomplexes.  
Following  collection  and  disruption  of  the  droplets,  the  polyplexes  are  collected  and  
used  directly.  Channel  dimensions  are  50  µμm  (width)  x  35  µμm  (height)  B)  Chemical  


























Figure  30. Size  and  Charge  Characterization  of  Nanocomplexes    
A)  Size  frequency  distributions  by  intensity  of  polyplexes  measured  by  dynamic  light  
scattering  immediately  following  preparation,  with  Z-­‐‑average  diameters  indicated  with  
black  lines.  Z-­‐‑average  diameter  ±  SEM  and  polydispersity  indices  are  reported  below  for  
bulk  and  MAC  preparations  of  both  pDNA  and  mRNA  polyplexes  (n=5  each).  B)  
Aggregation  propensity  shown  as  the  Z-­‐‑average  diameter  over  time  (n=5  each,  
measured  at  5  minute  intervals)  C)  Zeta  potential  for  each  type  of  polyplex,  shown  as  
mean  ±  SEM  and  analyzed  with  student’s  t-­‐‑test  (*  p  <  0.05)  (n=5  each)  
  
4.3.2 Analysis of Complexation and Binding 
A  common  shortcoming  of  bulk  preparation  is  the  failure  to  exhaust  the  
molecular  reactants  due  to  the  rapid  complexation  under  chaotic  and  heterogeneous  
conditions.  This  is  problematic  because  excess  unreacted  polymer  has  been  shown  to  
contribute  to  polyplex  aggregation  and  cytotoxicity  during  transfection  [221].  To  
quantify  the  amount  of  unreacted  polymer  left  in  solution,  we  prepared  10  µμg  nucleic  
acid  doses  of  polyplexes  with  p(CBA-­‐‑ABOL)  and  Cy5-­‐‑labeled  p(CBA-­‐‑ABOL90/BDA10)  
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in  a  4:1  ratio.  Following  preparation,  we  removed  the  polyplexes  by  centrifugation.  The  
supernatant  was  lyophilized,  reconstituted  in  100  µμL  complexation  buffer,  and  
transferred  to  a  96-­‐‑well  plate  for  quantification  of  the  remaining  excess  polymer.  MAC  
preparation  significantly  reduced  the  fraction  of  polymer  left  unreacted  (Figure  31).  To  
further  probe  the  composition  of  MAC  polyplexes,  we  then  measured  the  binding  
stability  between  polymer  and  payload  using  a  fluorescence-­‐‑based  binding  assay.  
PicoGreen  and  RiboGreen  are  cationic  dyes  that  fluoresce  upon  intercalation  with  DNA  
or  RNA,  respectively.  When  added  in  increasing  concentrations  to  intact  polyplexes,  
they  compete  with  the  gene  carrier  to  bind  nucleic  acids.  As  complexes  are  disrupted  by  
the  competition  and  the  shielding  of  the  nucleic  acids  by  the  polymer  is  diminished,  the  
fluorescent  signal  of  the  dye  intensifies  accordingly  with  little  background  signal  from  
unbound  reagent.  Consequently,  the  increase  in  fluorescence  indicates  the  level  of  
decomplexation  between  nucleic  acid  and  polymer.  As  seen  in  Figure  31,  the  MAC  
polyplexes  remained  comparatively  more  intact  as  increasing  concentrations  of  
competitor  were  introduced.  At  the  maximum  competitor  concentrations,  bulk  controls  
were  significantly  disrupted  while  MAC  polyplexes  remained  resistant.  Such  increased  
binding  stability  and  resistance  to  competitive  disruption  may  lead  to  better  protection  
from  premature  degradation  and  a  more  sustained  intracellular  release  of  payload.  
However,  this  relationship  depends  on  the  gene  carrier  involved;  some  polymers  bind  
nucleic  acids  too  tightly  to  efficiently  deliver  them  to  the  nucleus  [57].  While  this  is  less  
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likely  to  occur  with  bioreducible  and  biodegradable  carriers  such  as  the  one  used  here,  
further  analysis  was  necessary  to  demonstrate  that  increased  complexation  and  tighter  
binding  leads  to  improved  activity.    
  
  
Figure  31: Unreacted  Polymer  and  Binding  Stability  of  Nanocomplexes  
The  amount  of  unreacted  Cy5-­‐‑labeled  polymer  remaining  in  the  product  from  each  
method  was  quantified  after  removal  of  pDNA  polyplexes  by  centrifugation.  Binding  
stabilities  of  pDNA  and  mRNA  polyplexes  were  measured  using  PicoGreen  and  
RiboGreen  competition  assays,  respectively.  Fluorescence  was  corrected  for  background  
signal  and  normalized  such  that  polymer-­‐‑free  controls  =  1.0  arbitrary  units  (AU).  Data  is  
shown  as  mean  ±  SEM  (n=3  each)  
  
4.3.3 Cell Viability, Transfection Efficiency and Cellular Uptake 
The  most  critical  aspect  of  polyplex  performance  is  transfection  efficiency.  We  
tested  both  DNA  and  RNA  polyplexes  in  four  cell  types  that  spanned  the  most  common  
target  classes  for  gene  delivery  applications.  Primary  mouse  embryonic  fibroblast  
(PMEF)  cells  were  selected  for  their  prevalence  in  the  cellular  reprogramming  and  
induced  pluripotent  stem  cell  fields.  Human  mesenchymal  stem  cells  (hMSC)  were  
included  to  represent  primary  human  adult  stem  cells.  HepG2  human  hepatocellular  
carcinoma  cells  were  tested  due  to  their  characteristic  low  transfectability  and  the  
importance  of  hepatocytes  as  a  destination  for  gene  delivery  systems  designed  to  target  
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the  liver.  Lastly,  HEK293  human  embryonic  kidney  cells  were  chosen  to  compare  with  
the  large  body  of  prior  work.  At  24  hours  following  delivery  to  the  four  different  cell  
types,  the  transfection  efficiency  polyplexes  loaded  with  pDNA  or  mRNA  encoding  GFP  
was  assessed  with  fluorescence  microscopy  and  quantified  by  flow  cytometry.  In  each  
case,  transfection  with  MAC  polyplexes  resulted  in  a  larger  fraction  of  cells  expressing  
the  GFP  reporter  protein  (Figure  32).  The  gains  ranged  from  6  to  31  percent  more  cells  
transfected,  and  were  particularly  significant  in  difficult-­‐‑to-­‐‑transfect  cell  types  such  as  
HepG2  and  hMSC.  Several  different  doses  of  polyplexes  were  delivered  to  HEK293  cells  
to  verify  that  this  result  was  not  dose-­‐‑dependent,  and  the  improvement  persisted  across  
the  range  of  doses  (Figure  32).  In  some  applications,  the  total  level  of  transgene  
produced  may  be  more  important  than  the  number  of  individual  cells  transfected.  To  
measure  gross  transgene  expression,  doses  of  pDNA  encoding  luciferase  were  delivered  
to  each  of  the  four  cell  types.  In  each  case,  transfection  with  MAC  polyplexes  resulted  in  






Figure  32.  Transfection  Efficiency  in  Multiple  Cell  Types  
Fluorescence  micrographs  of  four  cell  types  transfected  with  bulk  or  MAC  polyplexes  
loaded  with  either  pDNA  or  mRNA  encoding  GFP  are  shown  (scale  bar  =  50  µμm),  and  
the  transfection  efficiency  quantified  with  flow  cytometry  (p  <  0.05  in  each  case).  
Transfection  efficiency  in  HEK293  cells  across  a  range  of  doses  confirms  that  the  
increased  transfection  by  MAC  polyplexes  is  not  dose-­‐‑dependent.  Total  transgene  
expression  following  transfection  with  pLuc  DNA  complexes  is  also  improved.  
  
To  elucidate  the  mechanistic  relationship  between  the  physical  attributes  of  MAC  
polyplexes  and  their  improved  performance,  we  focused  on  two  of  the  primary  rate-­‐‑
limiting  barriers  of  nonviral  gene  delivery:  cellular  uptake  and  intracellular  unpacking.  
Although  the  optimal  dimensions  of  particles  for  cellular  uptake  remain  a  topic  of  
debate,  endocytosis  is  believed  to  be  a  size-­‐‑dependent  process  [222].  It  follows  that  the  
most  straightforward  means  for  MAC  to  improve  transfection  would  be  through  an  
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increase  in  cellular  uptake  due  to  the  smaller  size  of  MAC  polyplexes.  We  measured  
cellular  uptake  in  a  high-­‐‑throughput  manner  using  flow  cytometric  detection  of  
internalized  QD-­‐‑labeled  pDNA.  Bulk  and  MAC  polyplexes  were  delivered  to  HEK293  
cells,  which  were  fixed  to  arrest  endocytosis  at  defined  timepoints  and  washed  with  
heparin  to  remove  any  remaining  membrane-­‐‑associated  complexes.  Flow  cytometry  was  
used  to  detect  the  percentage  of  cells  containing  the  labeled  plasmid  at  each  point,  as  
well  as  the  mean  fluorescence  signal  that  correlates  with  the  total  mass  of  internalized  
plasmid.  We  observed  no  difference  in  uptake  between  bulk  and  MAC  prepared  
polyplexes  over  the  time  course  of  a  typical  transfection  period  by  either  metric  (Figure  
33).  While  the  size  of  MAC  polyplexes  is  reduced,  the  difference  may  not  be  sufficient  to  
alter  the  rates  or  modes  of  endocytosis.  If  increased  uptake  is  not  responsible  for  the  
functional  benefits  of  MAC  polyplexes,  the  improvements  likely  arise  from  a  subsequent  
process.    
4.3.4 Intracellular Behavior of Nanocomplexes 
Next,  we  used  QD-­‐‑FRET  detection  to  examine  the  intracellular  decondensation  
rates  of  MAC  polyplexes.  FRET  provides  the  unique  ability  to  resolve  molecular  
interactions  beyond  the  diffraction  limit  of  conventional  microscopy.  When  FRET  
occurs,  a  donor  fluorophore  excites  an  acceptor  via  a  nonradiative  dipole–dipole  
interaction  if  they  are  sufficiently  close  (within  ~10  nm).  This  so-­‐‑called  ‘molecular  ruler’  
can  be  used  to  determine  distances  between  labeled  molecules  inside  cells,  including  
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gene  carriers  and  nucleic  acids  [223].  Fluorescence  colocalization  methods  do  not  offer  
the  requisite  sensitivity  to  precisely  detect  the  onset  of  particle  dissociation,  to  
differentiate  between  molecules  that  are  interacting  or  simply  adjacent,  or  allow  for  
high-­‐‑throughput  analysis.  Furthermore,  conventional  fluorophores  suffer  from  chemical  
and  photodegradation,  photobleaching  and  broad  spectra.  Conversely,  semiconductor  
QDs  possess  broad  absorption  spectra,  tunable  narrow  emission  spectra,  resistance  to  
bleaching  and  chemical  degradation,  and  large  energy  separation  between  excitation  
and  emission  eliminating  the  need  for  ratiometric  disambiguation.  In  our  case,  excited  
QD  donors  transfer  energy  to  Cy5  acceptors  as  long  as  polyplexes  containing  both  
constituents  remain  intact.  When  the  complexes  dissociate,  the  energy  donors  and  
acceptors  become  separated  and  the  FRET-­‐‑mediated  Cy5  emission  is  lost,  giving  a  
precise  digital  indication  of  polyplex  dissociation  (Figure  33).  It  has  been  previously  
shown  that  QD-­‐‑FRET  labeling  does  not  significantly  alter  the  physical  properties  or  
bioactivity  of  polyplexes  [57].  We  again  chose  flow  cytometric  detection  to  acquire  
precise  temporal  data  on  the  intracellular  unpacking  rates.  It  was  assumed  that  at  the  
first  time  point,  most  of  the  polyplexes  would  still  be  intact,  with  FRET-­‐‑mediated  
emission  signal  deteriorating  over  time  as  polyplexes  unpacked.  The  values  at  the  first  
point  were  thus  chosen  to  represent  maximum  complexation.  Over  24  hours  following  
transfection,  MAC  polyplexes  remained  intact  much  longer  than  the  more  quickly  
unpacked  bulk  samples  (Figure  33).  For  example,  by  the  six-­‐‑hour  time  point,  the  QD-­‐‑
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FRET  signal  for  bulk  polyplexes  had  decayed  to  less  than  half  of  its  maximum.  
Meanwhile,  the  MAC  signal  still  exceeded  75  percent  of  its  initial  value.  This  prolonged  
intracellular  stability  may  provide  better  payload  protection  prior  to  endosomal  escape,  
as  well  as  a  more  sustained  release  of  the  nucleic  acid  that  may  increase  the  chances  of  
nucleic  acids  penetrating  the  nucleus  during  cell  division.  This  flow  cytometric  
population-­‐‑level  rate  quantification  shows  that  the  increased  extracellular  stability  of  
MAC  polyplexes  translates  to  the  intracellular  domain.  This  study  therefore  identifies  a  
mechanistic  relationship  whereby  controlling  the  physical  assembly  of  nanocomplexes  







Figure  33.  Cellular  Internalization  and  Intracellular  Unpacking  
The  labeling  scheme  used  to  detect  uptake  and  unpacking  using  QD-­‐‑FRET  is  shown.  
Biotinylated  pDNA  was  labeled  with  QD  energy  donors,  while  the  polymer  was  
functionalized  with  the  Cy5  QD-­‐‑FRET  acceptor.  QD-­‐‑FRET  emission  is  detected  while  
polyplexes  are  intact.  Following  unpacking,  QD-­‐‑FRET  signal  is  lost  and  separate  donor  
and  acceptor  emissions  are  recovered.  Cellular  internalization  was  quantified  by  
measuring  the  fluorescence  signal  of  QD-­‐‑labeled  pDNA  in  cells  at  different  time  points  
using  flow  cytometry.  No  significant  difference  was  observed  in  the  rates  of  uptake  by  
cell  number  or  normalized  geometric  mean  fluorescence.  Intracellular  unpacking  was  
quantified  by  measuring  the  QD-­‐‑FRET  signal  in  cells  at  different  time  points  using  flow  
cytometry.  Bulk  controls  unpacked  more  rapidly  than  MAC  polyplexes  (p  <  0.05  for  all  
timepoints  after  300  min).  
  
4.4 Discussion 
The  development  of  safe  and  effective  gene  carriers  is  critical  to  the  eventual  
success  of  nonviral  gene  therapy,  and  optimizing  the  assembly  processes  used  to  
prepare  polymer-­‐‑nucleic  acid  nanocomplexes  is  one  strategy  to  move  toward  this  goal.  
We  have  reported  the  benefits  of  a  microfluidic  approach  to  better  control  the  
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preparation  of  polyplexes  and  to  produce  more  uniform  and  more  potent  delivery  
systems.  While  polymer-­‐‑DNA  nanocomplexes  have  been  synthesized  by  microfluidics,  
to  our  knowledge  this  is  the  first  example  of  the  production  of  polymer-­‐‑RNA  
nanocomplexes  with  a  droplet-­‐‑based  microfluidic  nanomanufacturing  approach,  as  well  
as  the  first  time  that  QD-­‐‑FRET  has  been  used  in  combination  with  flow  cytometry  to  
quantify  the  intracellular  unpacking  of  polymer-­‐‑DNA  nanocomplexes.  We  have  
demonstrated  that  MAC  polyplexes  exhibit  significant  and  consistent  decreases  in  size,  
zeta  potential,  and  polydispersity  relative  to  complexes  synthesized  by  traditional  bulk  
mixing.  Both  DNA-­‐‑  and  RNA-­‐‑loaded  nanocomplexes  exhibit  increased  colloidal  and  
binding  stability,  as  quantified  by  fluorescence-­‐‑based  competitive  binding  assays.  
Transfection  was  significantly  improved  in  a  broad  range  of  cell  types,  in  terms  of  both  
the  number  of  cells  transfected  and  gross  transgene  expression.  We  ascribed  this  
improvement  in  part  to  a  more  gradual  release  of  nucleic  acids  offered  by  MAC  
nanocomplexes,  evidenced  by  the  slower  decline  of  intracellular  QD-­‐‑FRET  emission.  
MAC  preparation  not  only  improves  the  biological  performance  of  polyplexes,  but  may  
also  help  establish  clearer  structure-­‐‑function  relationships  to  guide  future  carrier  design  




5. Nonviral Direct Conversion of Fibroblasts to 
Functional Neuronal Cells 
  
Some  of  the  material  in  Chapter  5  is  included  in:    
Nonviral  direct  conversion  of  mouse  embryonic  fibroblasts  to  neuronal  cells.  
Adler  AF*,  Grigsby  CL*,  Kulangara  K,  Wang  H,  Yasuda  R,  Leong  KW.  2012.  Mol  Ther  
Nuc  Acids.  1:e32  
  
In  the  first  example  of  direct  cellular  reprogramming,  where  differentiated  cells  
are  transdifferentiated  into  another  cell  type  without  going  through  an  intermediate  
proliferative  stem  cell-­‐‑like  stage,  the  conversion  of  fibroblasts  into  functional  induced  
neuronal  cells  (iNs)  was  achieved.  Subsequent  reports  of  direct  conversion  into  clinically  
relevant  neuronal  subtypes  have  further  validated  the  potential  of  autologous  cell  
therapies  for  the  treatment  of  neurodegenerative  disorders.  So  far,  all  published  
neuronal  reprogramming  protocols  rely  on  lentiviral  gene  delivery,  which  diminishes  
their  utility  and  potentially  precludes  clinical  translation.  Instead,  we  delivered  plasmids  
encoding  neuronal  transcription  factors  (Brn2,  Ascl1,  Myt1l)  non-­‐‑virally  to  fibroblasts  
with  p(CBA-­‐‑ABOL)  polyplexes.  The  low  toxicity  and  high  transfection  efficiency  of  this  
system  enabled  us  to  adopt  a  serial  dosing  protocol  capable  of  sustaining  high  transgene  
expression  levels  throughout  the  reprogramming  process.  Consecutive  0.25  –  1.0  µμg  cm-­‐‑2  
doses  of  reprogramming  factors  delivered  at  48-­‐‑hour  intervals  to  mouse  and  human  
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fibroblasts  produced  Tuj1+  (neuron-­‐‑specific  class  III  beta-­‐‑tubulin)  cells,  a  subset  of  which  
expressed  MAP2  (microtubule-­‐‑associated  protein  2),  tau,  and  synaptophysin.  A  
synapsin-­‐‑RFP  reporter  helped  identify  more-­‐‑mature,  electrophysiologically  active  cells,  
with  nearly  all  patch-­‐‑clamped  RFP+  cells  firing  action  potentials.  Some  non-­‐‑virally-­‐‑
induced  neuronal  cells  (NiNs)  were  recorded  firing  multiple  and  spontaneous  action  
potentials.  Once  the  feasibility  of  the  nonviral  protocol  was  established,  we  proceeded  to  
apply  p(CBA-­‐‑ABOL)  polyplexes  prepared  by  microfluidic  nanomanufacturing  to  
maximize  the  conversion  efficiency.  Finally,  we  screened  an  array  of  substrate  
topographies  for  positive  influence  on  nonviral  neuronal  reprogramming,  and  identified  
a  subset  of  features  that  promote  conversion  more  readily  than  unpatterned  culture  
surfaces.  This  chapter  demonstrates  the  feasibility  of  nonviral  direct  neuronal  cellular  
reprogramming,  as  well  as  its  optimization  through  the  application  of  microfluidic  
polyplex  nanomanufacturing  and  incorporation  of  substrate  topography.  This  nonviral  
cellular  reprogramming  method,  along  with  its  specific  refinements  developed  here,  
may  also  be  amenable  to  other  direct  transdifferentiation  processes.  
5.1 Introduction 
Neurodegenerative  diseases  include  such  recalcitrant  disorders  as  Alzheimer’s  
disease  (AD),  Parkinson’s  disease  (PD),  Huntington’s  disease,  and  amyotrophic  lateral  
sclerosis  (ALS).  Despite  decades  of  research,  these  conditions  remain  incurable  and  very  
difficult  to  manage  [224,  225];  AD  remains  the  sixth  leading  cause  of  death  in  the  United  
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States.  They  are  characterized  by  extensive  cell  death  -­‐‑  loss  of  neurons  in  the  neocortex  
and  hippocampus  in  the  case  of  Alzheimer’s,  and  loss  of  dopaminergic  (DA)  neurons  in  
the  substantia  nigra  in  the  case  of  Parkinson’s.  In  AD  and  PD,  cell  replacement  therapy  
has  been  proposed  as  a  more  promising  long-­‐‑term  alternative  to  pharmacologic  
intervention  and  deep  brain  electrical  stimulation,  which  lose  efficacy  as  the  diseases  
progress  [155].  However,  identification  of  an  appropriate  therapeutic  cell  source  has  
proven  challenging.  Although  allogeneic  transplantation  of  DA  neurons  from  fetal  
ventral  mesencephalic  tissue  into  the  striatum  of  PD  patients  has  shown  some  clinical  
benefits  [157-­‐‑160],  the  effects  are  modest  and  results  are  mixed  across  several  trials  [156,  
161].  Ethical  concerns  about  the  derivation  of  cells  from  fetal  tissues,  and  low  yields  of  
DA  neurons  present  additional  challenges.  Embryonic  stem  cells  (ESCs)  can  be  
differentiated  into  functional  neuronal  cells  in  sufficient  quantities  [164],  but  safety  and  
ethical  issues  remain.  Induced  pluripotent  stem  cells  (iPSCs)  [226]  sidestep  the  ethical  
issues  of  ESCs,  differentiate  into  DA  neurons,  and  produce  phenotypic  recovery  in  an  
animal  model  of  PD  [168],  but  the  risk  of  teratogenesis  remains  largely  unmitigated.  
In  2010,  Wernig  et  al.  succeeded  in  using  three  neuronal  transcription  factors  
(TFs)  -­‐‑  Brn2,  Ascl1,  and  Myt1l  (BAM  factors)  -­‐‑  to  convert  mouse  fibroblasts  directly  into  
functional  neuronal  cells  [6],  referred  to  as  induced  neuronal  cells  (iNs).  Human  cells  
were  converted  subsequently  with  the  addition  of  NeuroD1  [227].  These  iNs  generate  
action  potentials  and  form  synapses  when  co-­‐‑cultured  with  primary  cortical  neurons  or  
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glia.  Since  the  first  reports,  additional  transcription  factors  that  generate  induced  
functional  human  dopaminergic  neuronal  cells  (iDAs)  [171,  172,  228-­‐‑230],  and  
cholinergic  motor  neuronal  cells  (iMNs)  [231]  have  been  identified.  The  direct  
conversion  of  fibroblasts  from  patients  with  familial  Alzheimer’s  disease  [232],  
hepatocytes  [233],  astrocytes  [230],  as  well  as  from  cells  infected  with  lentiviral  miRNA  
and  transcription  factor  cocktails  [234,  235],  into  functional  neuronal  cells  has  also  been  
published.  Lineage-­‐‑tracing  experiments  confirm  that  iNs  are  not  generated  from,  and  do  
not  transition  through,  an  intermediate  proliferative  state  [231,  233].    
So  far,  neuronal  transdifferentiation  has  only  been  accomplished  via  lentiviral  
gene  delivery  of  the  reprogramming  factors.  Virally-­‐‑generated  iNs  are  important  tools  
for  neuronal  disease  recapitulation,  drug  development,  and  studying  the  biology  of  
transdifferentiation.  However,  potential  genotoxic  sequence  integration  into  the  host  
genome  impedes  the  clinical  translation  of  lentiviral  iNs  [236],  and  creates  a  demand  for  
alternative  methods  to  generate  them.  A  critical  finding  of  viral  neuronal  
reprogramming  studies  is  that  the  epigenetic  program  of  the  source  cells  is  silenced  in  
favor  of  a  stable  iN  state  [233],  which  persists  even  after  exogenous  gene  expression  is  
discontinued.  Endogenous  neuronal  TFs  become  activated  and  continue  to  be  expressed  
even  after  a  relatively  brief  pulse  of  doxycycline-­‐‑inducible  ectopic  transgene  expression  
is  terminated  by  dox  withdrawal  [171,  228].  This  fact,  along  with  the  prior  success  of  
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nonviral  iPSC  generation  [237-­‐‑241],  suggested  that  neuronal  reprogramming  could  be  
accomplished  with  a  nonviral  gene  delivery  strategy.  
The  conversion  efficiency  is  a  critical  parameter  given  the  need  to  generate  a  
sufficient  quantity  of  cells  for  potential  transplantation,  as  neurons  are  non-­‐‑proliferative  
and  cannot  be  expanded  once  induced.  In  order  to  convert  the  greatest  number  of  
fibroblasts  to  induced  neurons,  the  reprogramming  factors  should  be  co-­‐‑expressed  at  
high  levels  in  as  many  source  cells  as  possible  for  long  enough  to  induce  terminal  
transdifferentiation.  It  follows  that  application  of  polyplexes  that  induce  higher  levels  of  
transgene  expression,  along  with  greater  transfection  efficiency,  would  have  the  capacity  
to  improve  the  conversion  rate.  As  the  microfluidic  nanomanufactured  p(CBA-­‐‑ABOL)  
polyplexes  described  in  the  previous  chapters  possess  these  qualities,  we  tested  their  
potential  to  improve  nonviral  neuronal  transdifferentiation.  Furthermore,  the  
incorporation  of  micro-­‐‑  and  nanotopographical  cues  into  the  cell  culture  substrate  has  
been  suggested  as  another  means  to  enhance  nonviral  transfection  efficiency,  while  
certain  substrate  topographies  have  also  been  reported  to  induce  hMSCs  to  express  
neuronal  markers  in  the  absence  of  neural  inductive  factors,  as  well  as  promote  neuronal  
differentiation  of  mNPCs  and  hESCs  [242-­‐‑245].  So,  we  also  made  efforts  to  study  the  
effects  of  substrate  topography  on  nonviral  neuronal  transdifferentiation.  We  performed  
reprogramming  on  arrays  of  micro-­‐‑  nano-­‐‑  and  hierarchical  topographies  to  screen  for  
influence  on  the  efficiencies  of  both  transfection  and  reprogramming.  While  substrate  
  145  
topography  did  not  exert  significant  influence  on  transfection  levels  with  the  p(CBA-­‐‑
ABOL)  system,  a  subset  of  patterns  studied  did  significantly  increase  the  efficiency  of  
neuronal  reprogramming.  The  convergent  optimization  of  reprogramming  factor  
delivery  and  physical  environmental  cues  in  the  form  of  substrate  topography  is  a  step  
toward  establishing  a  viable  platform  for  future  cell  replacement  therapy  for  the  
treatment  of  neurodegenerative  diseases.  
5.2 Methods 
5.2.1 Molecular Cloning and Plasmid Purification 
The  reporter  vectors  pmax-­‐‑GFP  (3486  bp,  Amaxa,  Cologne,  Germany)  and  
VR1255C  (6413  bp,  Vical,  San  Diego,  CA),  which  respectively  express  GFP  and  luciferase  
under  control  of  the  CMV  promoter,  were  used  for  measurement  of  transfection  
efficiency.  Pmax-­‐‑Brn2  (4154  bp),  pmax-­‐‑Ascl1  (3497  bp),  and  pmax-­‐‑Myt1l  (6359  bp),  
which  express  the  mouse  transcription  factors  Brn2,  Ascl1,  and  Myt1l,  respectively,  
under  control  of  the  CMV  promoter,  were  generated  by  first  excising  the  GFP  coding  
sequence  from  pmax-­‐‑GFP  with  SacI  digestion,  blunting  by  DNA  polymerase  I  Klenow  
fragment,  NheI-­‐‑HF  digestion  (NEB,  Ipswich,  MA),  and  gel  extraction  (QIAquick  Gel  
Extraction  Kit,  QIAGEN,  Hilden,  Germany).  Then,  Brn2,  Ascl1,  and  Myt1l  inserts  were  
prepared  by  digestion  of  the  lentiviral  vectors  Tet-­‐‑O-­‐‑FUW-­‐‑Brn2  (Addgene  27151),  Tet-­‐‑O-­‐‑
FUW-­‐‑Ascl1  (Addgene  27150),  and  Tet-­‐‑O-­‐‑FUW-­‐‑Myt1l  (Addgene  27152)  with  EcoRV  and  
NheI-­‐‑HF  (NEB)  and  gel  extraction,  and  were  subsequently  ligated  into  the  empty  pmax  
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vector  with  T4  DNA  ligase  (NEB).  When  used  together,  these  three  plasmids  are  
abbreviated  as  pmax-­‐‑BAM.  pUNO1-­‐‑mAscl1  (3892  bp,  InvivoGen,  San  Diego,  CA)  and  
pUNO1-­‐‑mMyt1lb  (6744  bp,  InvivoGen),  expressing  mouse  Ascl1  and  Myt1l  under  
control  of  the  EF1α/HTLV  promoter,  were  used  in  conjunction  with  pmax-­‐‑Brn2,  and  
when  used  together  are  abbreviated  as  pUNO-­‐‑AM/pmax-­‐‑B.  pUNO-­‐‑Brn2  was  generated  
by  first  replicating  the  Brn2  cassette  from  pmax-­‐‑Brn2  via  PCR  (left  primer:  
CAAATGACCGGTCACCATGGCGACCGC,  right  primer:  CTCCCCCTGAACCTGAAAC).  Primers  
were  designed  to  introduce  an  AgeI  restriction  enzyme  site  at  the  5’  end  of  the  amplicon.  
To  improve  cloning  efficiency,  the  PCR  product  was  subcloned  into  a  TOPO-­‐‑ligase  
conjugated  vector  and  expanded  in  E.  coli  following  transformation,  colony  PCR,  and  
gel  extraction.  After  purification  (Plasmid  Mini-­‐‑Prep,  Qiagen),  the  intermediate  plasmid  
and  pUNO-­‐‑Ascl1  were  digested  with  HpaI  and  AgeI  enzymes,  then  separated  by  
agarose  gel  electrophoresis,  extracted,  and  purified  by  ethanol  precipitation.  The  Brn2  
insert  was  ligated  into  the  pUNO-­‐‑Ascl1  backbone,  transformed  into  E.  coli,  selected  by  
colony  PCR,  expanded  and  purified  (Plasmid  Mini-­‐‑Prep,  Qiagen),  and  validated  by  
sequencing,  immunocytochemistry,  and  Western  blot.  Plasmids  used  for  transfections  
were  propagated  in  Escherichia  coli  DH5α  (Invitrogen,  Carlsbad,  CA)  and  purified  with  
EndoFree  Plasmid  Mega  and  Maxi  kits  (QIAGEN).  Plasmid  DNA  concentrations  were  
quantified  by  measurement  of  absorbance  at  260  nm  with  a  NanoDrop  ND-­‐‑1000  
Spectrophotometer  (Thermo  Scientific,  Waltham,  MA).  
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5.2.2 Production and Purification of Lentiviral Synapsin Reporter 
Stbl3  bacteria  (Invitrogen)  were  transformed  with  pLV-­‐‑hSyn-­‐‑RFP  [246]  (Addgene  
22909)  according  to  the  manufacturer’s  protocol.  Plasmid  DNA  was  propagated  and  
purified  using  the  EndoFree  Maxiprep  kit  (QIAGEN).  For  the  lentiviral  production,  
HEK293T  cells  were  seeded  in  75  cm2  dishes,  cultured  in  DMEM  (Invitrogen)  containing  
10%  Premium  Select  FBS  (Altanta  Biologicals,  Lawrenceville,  GA)  and  1%  penicillin-­‐‑
streptomycin  (Invitrogen),  and  were  transfected  by  the  calcium  phosphate  technique  
with  the  following  plasmids:  16.9  µμg  of  pMD2.G  (Addgene  plasmid  12259)  31.3  µg  of  
psPAX2  (Addgene  plasmid  12260)  and  48.2  µμg  of  pLV-­‐‑hSyn-­‐‑RFP.  The  medium  was  
changed  after  14  hours.  Seventy-­‐‑two  hours  after  transfection,  the  medium  was  collected  
in  50  mL  tubes,  centrifuged,  and  filtered  through  a  0.45  µm  filter  to  remove  cell  and  
membrane  debris.  The  supernatant  was  then  concentrated  to  100x  in  Amicon  Ultra  
centrifugal  filter  tubes,  (Millipore,  Billerica,  MA)  and  the  concentrated  virus  was  stored  
at  -­‐‑80oC.  PMEFs  in  2  cm2  wells  were  infected  with  1  µμL  of  100x  viral  concentrate  in  
PMEF  medium  5  days  before  patch  clamping.  
5.2.3 Poly(CBA-ABOL) Synthesis and Bulk Polyplex Formation 
   Poly(CBA-­‐‑ABOL)  was  synthesized  by  Michael  polyaddition  of  3.67  g  N,N-­‐‑
cystaminebisacrylamide  (CBA)  (Polysciences,  Warrington,  PA)  and  1.26  g  4-­‐‑amino-­‐‑1-­‐‑
butanol  (ABOL)  (Sigma-­‐‑Aldrich,  Saint  Louis,  MO)  as  described  by  Lin  et  al  [22].  The  
reaction  product  was  purified  by  dialysis  (3.5  kDa  cutoff)  in  acidic  deionized  water  (pH  
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4)  and  then  lyophilized.  The  polymer  was  collected  in  its  HCl-­‐‑salt  form  (1.63  g,  33%  
yield),  and  its  structure  validated  by  1H  NMR  (in  D2O)  on  a  Varian  Mercury  300  MHz  
NMR  Spectrometer.  p(CBA-­‐‑ABOL)/DNA  nanocomplexes  (polyplexes)  were  synthesized  
at  a  polymer:DNA  mass  ratio  of  45:1,  which  was  selected  based  on  a  preliminary  
optimization  of  GFP  expression  in  PMEFs.  Polyplexes  were  prepared  by  adding  a  
HEPES  buffer  solution  (20  mM  HEPES,  5  wt  %  glucose,  pH  7.4)  of  p(CBA-­‐‑ABOL)  (900  
µμg/mL)  to  a  HEPES  buffer  solution  (20  mM  HEPES,  5  wt  %  glucose,  pH  7.4)  of  plasmid  
DNA  (75  µμg/mL),  followed  immediately  by  vortexing  for  20  seconds.  Reaction  sizes  
ranged  from  5  to  15  µμg  of  plasmid  DNA.    
5.2.4 Fabrication and Operation of Microfluidic Devices 
Cross-­‐‑flow  droplet  generators  were  fabricated  using  conventional  soft  
lithography  [214,  215].  PDMS  prepolymer  was  cast  and  cured  on  an  SU-­‐‑8  3025  
(MicroChem,  Newton,  MA)  master  (Transparency  mask,  CAD/Art  Services,  Bandon,  
OR),  which  produced  a  channel  height  of  approximately  35  µμm.  PDMS  prepolymer  
(Sylgard  184  Silicone  Elastomer  Kit,  Dow  Corning,  Midland,  MI)  was  prepared  in  a  10:1  
(base:curing  agent)  ratio  and  cured  at  65°C  for  one  hour.  The  cured  PDMS  was  then  
excised,  punched  with  through-­‐‑holes  to  accept  fluidic  connections,  and  bonded  to  glass  
cover  slips  using  a  thin  layer  of  spin-­‐‑coated  PDMS  to  create  channels  surrounded  by  
PDMS  on  all  sides.  The  fully  assembled  chips  were  then  left  in  an  oven  at  95°C  overnight  
to  assure  complete  bonding.    
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Prior  to  use,  the  microfluidic  channels  were  flushed  with  the  oil  phase  solution  
for  30  minutes  to  ensure  wetting.  To  generate  polyplexes,  two  syringe  pumps  (PHD2000,  
Harvard  Apparatus,  Holliston,  MA)  were  used  to  infuse  the  oil/surfactant  mix  and  
aqueous  reagents  independently  through  syringe  tubing  adapters  (Hamilton,  Reno,  
NV).  The  oil  phase  consisted  of  FC-­‐‑40  fluorocarbon  oil  (3M,  St.  Paul,  MN)  and  2%  
PEGylated  fluorosurfactant  (EA  Surfactant  RainDance  Technologies,  Lexington,  MA  or  
PicoSurf  1,  Dolomite  Microfluidics,  Royston,  UK).  Flow  rates  were  set  at  7.5  µμL  min-­‐‑1  for  
the  oil  phase  input  and  2.5  µμL  min-­‐‑1  for  each  of  the  three  aqueous  inputs.  Water-­‐‑in-­‐‑oil  
droplets  (~  100  pL)  were  generated  at  the  channel  junction,  where  the  polymer  and  
nucleic  acid  solutions,  separated  by  a  buffer  channel,  were  introduced  to  the  continuous  
oil  phase.  Polyplexes  self-­‐‑assembled  while  confined  to  the  droplets,  while  mixing  of  
their  components  was  enhanced  by  the  inclusion  of  a  serpentine  channel  segment  [216].  
MAC  polyplexes  were  collected  by  breaking  the  droplets  (Droplet  Destabilizer,  
RainDance  Technologies)  and  used  directly  from  the  aqueous  supernatant  for  
subsequent  characterization  or  cellular  investigation  without  any  further  purification.    
5.2.5 Preparation of Multi-Architecture (MARC) Chip Arrays 
Multi-­‐‑architecture  (MARC)  chips  were  a  gift  from  Prof.  Evelyn  Yim  (National  
University  of  Singapore).  Prior  to  seeding  cells,  chips  were  sterilized  for  one  hour  with  
75%  ethanol  and  ultraviolet  irradiation.  Chips  were  dried  for  30  minutes  in  a  70°C  oven,  
then  air-­‐‑plasma  treated  for  two  minutes  (Harrick  Expanded  Plasma  Cleaner).  They  were  
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then  placed  in  a  6-­‐‑well  plate  and  coated  with  100  µμL  of  fibronectin  (Sigma)  in  sterile  
water  (50  µμg/mL)  in  a  37°C  incubator  for  one  hour.  Chips  were  next  washed  with  PBS,  
and  50,000  cells  seeded  in  a  bubble  on  top,  taking  care  to  cover  the  array  while  
preventing  the  cell  solution  from  reaching  the  edges  of  the  chip.  After  30  minutes  to  
allow  for  cell  attachment,  the  culture  well  was  filled  with  additional  culture  medium  to  
cover  the  chip.  
5.2.6 Cell Culture and Transfection 
40,000  cells  (80,000  cells)  passage  six  (eight)  PMEF-­‐‑HLs  (Millipore,  Billerica,  MA)  
or  40,000  passage  two  PMEFs  (ATCC)  were  seeded  per  well  in  24-­‐‑well  TCPS  plates  (BD,  
Franklin  Lakes,  NJ)  at  37°C  and  5%  CO2  in  complete  PMEF  medium:  Dulbecco’s  
Modified  Eagle’s  Medium  with  4.5  g/L  glucose  (GIBCO  11960-­‐‑044)  (Invitrogen),  10%  
Premium  Select  FBS  (Atlanta  Biologicals),  25  µμg  mL-­‐‑1  gentamicin  (Invitrogen),  and  1x  
GlutaMAX,  non-­‐‑essential  amino  acids,  sodium  pyruvate,  and  β-­‐‑mercaptoethanol  
(Invitrogen).  In  the  case  of  electrophysiology  and  some  immunofluorochemistry  
experiments,  12  mm  BD  BioCoat  poly-­‐‑D-­‐‑lysine/laminin-­‐‑coated  glass  coverslips  were  
placed  in  the  bottom  of  TCPS  wells  prior  to  cell  seeding.  Twenty-­‐‑four  hours  after  
seeding,  PMEFs  were  transfected  with  either:  reporter  plasmids  for  flow  cytometry,  or  
pmax-­‐‑BAM,  pUNO-­‐‑AM/pmax-­‐‑B,  or  pUNO-­‐‑BAM  plasmid  cocktails  for  induced  
neuronal  transdifferentiation.  BAM  factor  plasmids  were  delivered  at  an  equimolar  ratio  
in  all  cases.  A  2:1  ratio  of  Lipofectamine  2000  (Invitrogen)  volume  (µμL)  to  DNA  mass  
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(µμg)  was  used  for  flow  cytometry  experiments,  in  accordance  with  the  manufacturer’s  
protocol.  All  transfections  were  carried  out  in  serum-­‐‑  and  antibiotic-­‐‑free  OptiMEM  
(Invitrogen).  OptiMEM  was  replaced  with  complete  PMEF  medium  four  hours  after  the  
onset  of  transfection.  Forty-­‐‑eight  hours  after  the  final  transfection  was  completed,  PMEF  
medium  was  replaced  with  N3  neural  induction  medium  containing:  DMEM/F-­‐‑12  
(Invitrogen),  25  µμg  mL-­‐‑1  bovine  insulin  (Gemini  Bio-­‐‑Products,  West  Sacramento,  CA),  50  
µμg  mL-­‐‑1  human  apo-­‐‑transferrin,  30  nM  sodium  selenite,  20  nM  progesterone,  100  µμM  
putrescine  (Sigma-­‐‑Aldrich),  10  ng  mL-­‐‑1  human  bFGF2  (Stemgent,  Cambridge,  MA),  and  
25  µμg  mL-­‐‑1  gentamicin  (Invitrogen).  
5.2.7 Viability Assay 
The  quantification  of  PMEF  viability  following  transfection  was  duplexed  with  
flow  cytomety  experiments.  Twenty-­‐‑four  hours  after  the  onset  of  the  final  transfection  
with  pmax-­‐‑GFP,  cells  were  incubated  for  four  hours  with  fresh  PMEF  medium  
containing  alamarBlue  (Invitrogen)  in  accordance  with  the  manufacturer’s  protocol.  
Metabolic  reduction  of  alamarBlue  was  monitored  at  570  nm/590  nm  excitation/emission  
using  a  BMG  Labtech  FLUOStar  Optima  plate  reader  (Ortenberg,  Germany).  
AlamarBlue-­‐‑containing  medium  was  then  removed,  and  the  cells  were  prepared  for  
flow  cytometry.  
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5.2.8 Flow Cytometry 
Twenty-­‐‑four  hours  after  completion  of  the  final  transfection  with  pmax-­‐‑GFP,  
PMEFs  were  washed  briefly  with  PBS  without  Ca2+  and  Mg2+  (Mediatech,  Washington,  
DC),  and  released  from  TCPS  surfaces  with  0.25%  Trypsin-­‐‑EDTA  (Invitrogen).  The  
trypsin  was  inactivated  with  serum-­‐‑containing  medium  and  the  cells  were  centrifuged  
at  4°C,  resuspended  in  ice-­‐‑cold  PBS,  centrifuged  again,  and  resuspended  in  PBS  
containing  1%  PFA  (EMS,  Hatfield,  PA).  Cells  were  then  filtered  through  40  µμm  nylon  
cell  strainers  (BD)  and  analyzed  with  a  BD  FACSCanto  II  flow  cytometer.  PMEFs  
transfected  with  the  non-­‐‑fluorescent  VR1255C  plasmid  served  as  negative  controls  for  
each  equivalent  pmax-­‐‑GFP  dose,  with  gating  such  that  1%  of  these  cells  were  considered  
GFP+.  The  recorded  median  fluorescent  intensities  of  GFP+  cells  (MFIGFP)  were  linearized  
according  to  an  assumption  of  ideal  logarithmic  amplifier  behavior,  and  normalized  by  
the  median  fluorescent  intensity  of  negative  control  cells  (MFINC)  to  calculate  the  
reported  %  MFI  change:  100%*(MFIGFP  -­‐‑  MFINC)/MFINC.  
5.2.9 Real-time RT-PCR 
Comparative  CT  real-­‐‑time  RT-­‐‑PCR  was  performed  in  20  µμL  reactions  using  the  
QuantiTect  SYBR  Green  RT-­‐‑PCR  Kit  (QIAGEN)  with  10  ng  of  starting  mRNA  isolated  
with  RNeasy  and  QIAshredder  kits  (QIAGEN)  from  cells  transfected  with  pmax-­‐‑BAM  
factors.  Messenger  RNA  concentrations  were  quantified  with  a  NanoDrop  ND-­‐‑1000  
Spectrophotometer  (Thermo  Scientific).  PCR  proceeded  for  40  cycles  in  an  ABI  7300  
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Real-­‐‑Time  PCR  System  (Carlsbad,  CA).  Target  mRNA  levels  were  normalized  to  
endogenous  GAPDH  references,  and  presented  as  a  fold-­‐‑change  increase  relative  to  
expression  levels  from  untransfected  PMEF  mRNA  collected  48  hours  after  seeding.  
Correct  RT-­‐‑PCR  target  amplicon  lengths  for  exogenous  pmax-­‐‑BAM  factors  were  verified  
with  gel  electrophoresis  in  a  separate  experiment.  The  primers  (IDT,  Coralville,  Iowa)  
used  were:  Ascl1  forward  (GCTGCAAACGCCGGCTCAAC);  Ascl1  reverse  
(GCGGATGTACTCGACCGCCG);  Ascl1  Endo  forward  (TGGCGGGTTCTCCGGTCTCGT);  Ascl1  
Endo  reverse  (TCCCCATTTGACGTCGTTGGCGA);  Brn2  forward  
(CCATCGTACATGCCGAGCCGC);  Brn2  reverse  (GCGCGGTGATCCACTGGTGAG);  Myt1l  
forward  (CGGGTGTGATGGAACCGGCC);  Myt1l  reverse  (GCCCTGTGCAGCCTGGAGTG);  
GAPDH  forward  (ACGGCCGCATCTTCTTGTGCA);  GAPDH  reverse  
(TTCTCGGCCTTGACTGTGCCG).  
5.2.10 Immunofluorochemistry and Image Analysis 
Transfected  cells  were  washed  briefly  with  PBS  containing  Ca2+  and  Mg2+  
(Mediatech),  and  fixed  with  4%  PFA  (EMS)  at  RT  for  20  minutes.  Cells  were  then  
incubated  for  two  hours  at  room  temperature  (RT)  in  blocking  buffer  containing  0.2%  
Triton  X-­‐‑100,  3%  w/v  BSA,  10%  goat  serum  (Sigma-­‐‑Aldrich),  and  combinations  of  the  
following  primary  antibodies  with  rabbit  anti-­‐‑Tuj1  (Covance,  1:500):  mouse  anti-­‐‑MAP2  
(Sigma-­‐‑Aldrich,  1:500),  mouse  anti-­‐‑synaptophysin  (BD,  1:100),  or  mouse  anti-­‐‑Tau  (BD,  
1:50).  The  cells  were  then  washed  three  times  with  PBS,  and  incubated  for  one  hour  at  
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RT  in  blocking  buffer  containing  Alexa  Fluor  488  goat  anti-­‐‑mouse  IgG  and  Alexa  Fluor  
594  goat  anti-­‐‑rabbit  IgG  (Invitrogen),  washed  three  times  with  PBS,  and  imaged  with  a  
Nikon  Eclipse  TE2000-­‐‑U  inverted  fluorescence  microscope  (Tokyo,  Japan)  with  a  
ProScanII  motorized  stage  (Prior  Scientific,  Rockland,  MA).  
To  quantify  the  relationship  between  Tuj1+  cell  generation  and  the  number  of  
serial  BAM  factor  transfections,  PMEFs  were  transfected  in  TCPS  wells,  stained  for  Tuj1,  
and  scanned  to  produce  large  mosaic  images  of  each  complete  culture  area.  These  
mosaics  were  processed  with  a  FIJI  (Fiji  Is  Just  ImageJ,  http://fiji.sc)  macro  to:  
automatically  and  uniformly  threshold  each  image  according  to  local  contrast,  exclude  
small  debris,  and  to  count  the  number  of  Tuj1+  cells  in  each  well.  These  counts  were  then  
divided  by  the  number  of  PMEFs  seeded  in  each  well  to  calculate  the  efficiency  of  Tuj1+  
cell  generation.  
5.2.11 Electrophysiology 
Non-­‐‑virally-­‐‑induced  neuronal  cells  cultured  on  poly-­‐‑D-­‐‑lysine/laminin-­‐‑coated  
glass  coverslips  (BD)  were  identified  for  patch  clamp  analysis  by  synapsin  promoter-­‐‑
driven  RFP  expression  [246]  after  12-­‐‑17  days  of  culture  in  N3  medium.  One  dose  of  
p(CBA-­‐‑ABOL)/BAM  factors  produced  synapsin-­‐‑RFP+  cells  that  were  too  sparse  to  find  
readily  with  the  patch  clamping  apparatus,  and  five  doses  kept  unconverted  PMEFs  in  
serum-­‐‑containing  medium  for  an  additional  4  days  compared  to  three  doses,  allowing  a  
layer  of  cells  to  develop  on  the  back  of  the  coverslips,  which  made  it  more  difficult  to  
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affix  samples  securely  to  our  patching  setup.  So,  we  elected  to  patch  cells  that  received  
three  doses.  Micropipettes  had  resistances  between  3-­‐‑7  MΩ,  and  were  filled  with  
internal  solution  containing:  130  mM  KMeSO3,  10  mM  HEPES,  10  mM  sodium  
phosphocreatine,  4  mM  MgCl2,  4  mM  Na2ATP,  0.4  mM  Na2GTP,  3  mM  sodium  L-­‐‑
ascorbic  acid,  with  pH  7.24  and  an  osmolarity  of  290  mM.  The  cells  were  perfused  with  
artificial  cerebral  spinal  fluid  (ACSF)  saturated  with  5%  O2  and  95%  CO2  and  containing:  
130  mM  NaCl,  2.5  mM  KCl,  2  mM  NaHCO3,  1.25  mM  NaH2PO4,  25  mM  glucose,  2  mM  
CaCl2,  and  2  mM  MgCl2.  Giga-­‐‑ohm  membrane  seals  were  formed  under  voltage-­‐‑clamp  
conditions.  Action  potentials  were  then  recorded  using  an  Axon  Multiclamp  700B  
Microelectrode  Amplifier  (Molecular  Devices,  Sunnyvale,  CA)  by  stepwise  whole-­‐‑cell  
current  clamp  injections,  and  analyzed  with  custom  in-­‐‑house  MATLAB  programs.  
5.3 Results 
5.3.1 Transfection and Toxicity of p(CBA-ABOL) Polyplexes 
Of  the  four  primary  mouse  embryonic  fibroblast  (PMEF)  cell  sources  screened  
(PMEF-­‐‑HL,  PMEF-­‐‑NL,  and  PMEF-­‐‑CFL  (Millipore),  and  PMEF  (ATCC)),  we  found  
PMEF-­‐‑HLs  and  ATCC  PMEFs  to  be  the  most-­‐‑efficiently  transfected  with  p(CBA-­‐‑ABOL)  
polyplexes  and  used  them  in  all  subsequent  experiments.  Fluorescence  microscopy  
revealed  that  a  1.0  µμg  dose  of  pmax-­‐‑GFP  in  p(CBA-­‐‑ABOL)  polyplexes  produced  high  
transfection  efficiencies  without  noticeable  toxicity  (Figure  34).  2.0  µμg  doses  also  gave  
high  transfection  efficiencies,  with  some  visibly  rounded  and  dead  cells,  and  4.0  µμg  was  
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grossly  toxic.  A  dose  of  1.0  µμg  pmax-­‐‑GFP  delivered  with  p(CBA-­‐‑ABOL)  transfected  cells  
more  efficiently  than  the  same  dose  delivered  with  Lipofectamine  2000.  One  and  two  
doses  of  1.0  µμg  pmax-­‐‑GFP  in  p(CBA-­‐‑ABOL)  polyplexes  were  almost  entirely  nontoxic  
compared  to  untransfected  controls,  and  a  second  transfection  48  hours  later  did  not  
compound  toxicity  up  to  2.0  µμg  (Figure  34).  Lipofectamine  2000  was  significantly  more  
toxic  than  p(CBA-­‐‑ABOL)  when  used  to  deliver  the  same  DNA  dose,  and  its  toxicity  
compounded  with  a  second  serial  dose.  
Flow  cytometric  quantification  of  GFP  expression  confirmed  high  transfection  
efficiencies  for  1.0  and  2.0  µμg  pmax-­‐‑GFP  doses  in  p(CBA-­‐‑ABOL)  polyplexes,  
significantly  higher  than  with  Lipofectamine  2000  lipoplexes  (Figure  34).  Further,  a  
second  dose  maintained  a  high  percentage  of  cells  expressing  GFP  for  an  additional  two  
days;  without  re-­‐‑transfection,  the  percentage  of  GFP+  cells  fell  relatively  by  15  and  28%  
for  1.0  and  2.0  µμg  pmax-­‐‑GFP  in  p(CBA-­‐‑ABOL)  polyplexes,  respectively.  Though  1.0  and  
2.0  µμg  doses  of  pmax-­‐‑GFP  in  p(CBA-­‐‑ABOL)  polyplexes  elicited  similar  percentages  of  
GFP+  cells,  the  median  fluorescence  intensity  (MFI)  change  of  GFP+  cells  over  non-­‐‑
fluorescent  negative  controls  revealed  that  cells  transfected  with  a  2.0  µμg  DNA  dose  had  




Figure  34.  Optimization  of  p(CBA-­‐‑ABOL)  Transfection  in  PMEF  Cells  
(a)  Fluorescence  micrographs  of  PMEF-­‐‑HLs  transfected  with  increasing  doses  of  DNA  in  
p(CBA-­‐‑ABOL)/pmax-­‐‑GFP  polyplexes  (500  µμm  scale  bars),  with  1.0  µμg  of  pmax-­‐‑GFP  
delivered  with  Lipofectamine  2000  (LF2k)  included  for  comparison.  Images  were  taken  
24  hours  after  transfection.  (b)  AlamarBlue  toxicity  assay  multiplexed  with  (c)  flow  
cytometric  measurement  of  GFP  transfection  efficiency  and  (d)  %  median  fluorescence  
intensity  increase  of  GFP+  cells  compared  to  non-­‐‑fluorescent  control  transfections  for  one  
and  two  doses  of  p(CBA-­‐‑ABOL)/pmax-­‐‑GFP  polyplexes,  assayed  24h  after  transfection.  
1.0  µμg  of  pmax-­‐‑GFP  delivered  with  Lipofectamine  2000  (LF2k)  is  again  included  for  
comparison.  Error  bars  represent  mean  +  SEM  of  three  separate  experiments  performed  
in  triplicate.  Two-­‐‑way  ANOVA  were  performed  with  P  <  0.05  considered  significant.  
The  main  effect  of  DNA  mass  was  significant  in  (b-­‐‑d),  and  the  main  effect  of  DNA  dose  #  
was  significant  in  (b).  Letters  (x,y,z)  not  shared  between  columns  denote  significant  
comparisons  between  DNA  masses  by  Tukey  post-­‐‑hoc  tests  (P  <  0.05)  of  one-­‐‑way  
ANOVA  across  DNA  masses,  with  data  from  one  and  two  doses  pooled  in  (c)  and  (d),  
due  to  absence  of  a  main  effect  of  dose  #  by  two-­‐‑way  ANOVA.  All  comparisons  of  
viability  (b)  across  DNA  mass  within  a  given  dose  #  were  significant,  other  than  those  
between  0.5  and  1.0  µμg  pmax-­‐‑GFP  in  p(CBA-­‐‑ABOL)  polyplexes  (marked  ns  –  not  
significant).  
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5.3.2 Delivery and Expression of Reprogramming Factor Genes 
An  equimolar  ratio  of  1.0  µμg  pmax-­‐‑BAM  neuronal  reprogramming  factors  in  
p(CBA-­‐‑ABOL)  polyplexes  was  delivered  to  PMEF-­‐‑HLs  according  to  the  scheme  in  
(Figure  35).  Twenty-­‐‑four  hours  after  the  initial  transfection,  each  of  the  exogenous  BAM  
factor  transcripts  was  expressed  at  levels  that  were  orders  of  magnitude  higher  than  
non-­‐‑transfected  PMEFs  (Figure  35).  Ectopic  expression  of  pmax-­‐‑BAM  factors  diminished  
by  approximately  two  orders  of  magnitude  by  day  10  of  culture  in  N3  medium  as  the  
plasmids  were  silenced,  diluted,  or  degraded,  for  both  one  and  three  doses.  Endogenous  
Ascl1  was  activated  in  some  cells  by  day  10  in  N3  medium,  as  measured  with  primers  
targeted  against  an  untranslated  region  (UTR)  of  the  endogenous  transcript  not  present  
in  the  exogenous  transcript.  Tuj1  and  MAP2  transcripts  were  quantified  but  not  







Figure  35.  Reprogramming  Factor  Expression  and  Dosing  Strategy  
Real-­‐‑time  comparative  CT  RT-­‐‑PCR  of  ectopic  neuronal  reprogramming  factors  (Ascl1,  
Brn2,  Myt1l)  and  endogenous  Ascl1  (Ascl1  Endo)  mRNA  expression.  PMEFs  were  
transfected  with  one  or  three  doses  of  1.0  µμg  pmax-­‐‑BAM  factors  complexed  with  p(CBA-­‐‑
ABOL),  and  total  mRNA  was  collected  24h  after  transfection  (day  2)  or  after  10  days  of  
culture  in  N3.  Error  bars  represent  the  range  of  transcript  produced  by  the  standard  
deviation  about  a  mean  CT  value  (n  =  3).  NiN  generation  scheme:  On  day  zero,  PMEFs  
were  seeded  on  TCPS  wells  or  poly-­‐‑D-­‐‑lysine/laminin-­‐‑coated  glass  coverslips  in  complete  
medium  containing  serum.  24  hours  later,  the  first  transfection  was  performed.  One  to  
four  additional  doses  were  then  administered  every  48  hours.  Beginning  48  hours  after  
administration  of  the  final  dose,  the  cells  were  cultured  for  a  minimum  of  10  additional  
days  before  assay  in  serum-­‐‑free  N3  neural  induction  medium  containing  FGF2,  which  




5.3.3 Serial Doses of Reprogramming Factors Generate Tuj1+ Cells  
One  dose  of  1.0  µμg  pmax-­‐‑BAM  neuronal  reprogramming  factors  in  p(CBA-­‐‑
ABOL)  polyplexes  produced  rare  and  isolated  Tuj1+  cells,  while  three  and  particularly  
five  doses  generated  networks  of  Tuj1+  cells  showing  varying  degrees  of  neuronal  and  
fibroblastic  morphologies  (Figure  36).  Neuron-­‐‑like  Tuj1+  processes  increased  in  length  
and  complexity  with  increased  culture  time  in  N3  medium.  Untransfected  PMEFs  were  
not  reactive  to  antibodies  against  Tuj1.  Automated  microscopy  and  image  analysis  of  
large  culture  regions  were  used  to  quantify  the  efficiency  of  Tuj1+  conversion  relative  to  
the  number  of  PMEFs  seeded  (Figure  36).  Five  doses  produced  significantly  more  Tuj1+  
cells  than  one  or  three  doses.  The  increase  in  efficiency  with  dose  is  visually  evident  in  
the  mosaic  images  of  24-­‐‑well  plates.  When  three  or  five  doses  of  pmax-­‐‑BAM  factors  
were  delivered  to  normal  human  dermal  fibroblasts,  a  small  number  of  MAP2+  cells  
were  detectable.  While  efficient  reprogramming  of  adult  human  cells  likely  requires  the  
addition  of  NeuroD1  or  other  additional  factors,  this  result  suggests  that  the  nonviral  




Figure  36.  Reprogramming  Efficiency  following  Multiple  Serial  Doses  
(a)  Tuj1  stain  of  cells  transfected  with  one  to  five  doses  of  1.0  µμg  pmax-­‐‑BAM  factors  in  
p(CBA-­‐‑ABOL)  polyplexes  after  a  minimum  of  14  days  in  N3  medium  following  
transfection.  (200  µμm  scale  bars)  (b)  Large  mosaic  images  of  the  entire  culture  area  (2.5  
mm  scale  bar)  acquired  for  image  analysis-­‐‑based  quantification  of  the  number  of  Tuj1+  
cells  normalized  to  the  number  of  PMEFs  seeded  (c),  after  a  minimum  of  10  days  in  N3  
following  transfection.  Letters  (x,y)  not  shared  between  columns  denote  significant  
comparisons  by  Tukey  post-­‐‑hoc  tests  of  a  one-­‐‑way  ANOVA  (P  <  0.05).  Error  bars  




Figure  37.  Generation  of  MAP2+  Human  Cells  
While  less  efficient,  the  reprogramming  of  human  dermal  fibroblasts  to  MAP2+  neuronal  
cells  has  been  accomplished  with  nonviral  delivery  of  BAM  factors  to  normal  human  
dermal  fibroblasts  
  
5.3.4 Induced Neuronal Cells Express Pan-Neuronal Proteins 
After  confirming  the  feasibility  of  nonviral  neuronal  transdifferentiation  using  
the  BAM  factors,  we  added  an  additional  set  of  plasmids  to  give  the  best  chance  of  
producing  NiNs  with  active  membrane  properties.  The  CMV  promoter  is  generally  
inactive  in  cortical  neurons  [247],  and  it  is  not  known  if  or  at  what  point  this  silencing  
could  occur  during  neuronal  transdifferentiation.  We  therefore  added  a  parallel  plasmid  
cocktail  with  serial  transfections  of  2.0  µμg  pUNO-­‐‑AM/pmax-­‐‑B  factors,  which  utilize  the  
EF1α/HTLV  promoter  for  Ascl1  and  Myt1l  expression  instead  of  the  CMV  promoter  in  
pmax-­‐‑BAM  plasmids,  and  would  potentially  take  advantage  of  increased  expression  
levels  with  2.0  µμg  of  plasmid  compared  to  the  1.0  µμg  dose.    
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Distal  enrichment  of  tau  (Figure  38),  characteristic  of  neurons,  was  visible  for  a  
subset  of  Tuj1+  cells  (center  and  right  panels).  Tuj1+  cells  with  fibroblastic  morphologies  
were  not  tau+  (red  cells,  left  panel).  Tuj1+  cells  with  neuronal  morphology  were  also  
reactive  to  MAP2  antibodies  (second  row).  Synaptophysin  punctae  were  visible  in  a  
subset  of  Tuj1+  cells,  a  protein  characteristic  of  synaptic  vesicles  (third  row).  Synapsin-­‐‑
RFP  was  also  visible  in  long,  branching  processes.  Synapsin-­‐‑RFP+  cells  were  less  
common  than  any  of  those  detected  by  immunofluorescence.  Though  less  prevalent,  
synapsin-­‐‑RFP+  processes  were  present  at  sufficient  densities  and  lengths  to  intersect  
with  neighboring  cells  (fourth  row),  particularly  for  those  transfected  with  the  pUNO-­‐‑
AM/pmax-­‐‑B  cocktail  (right  panel).  A  worst  case  estimate  of  synapsin-­‐‑RFP+  cells  counted  
compared  to  Tuj1+  cells  quantified  in  Figure  38  provides  that  approximately  0.1%  -­‐‑  1%  of  





Figure  38.  Immunofluorochemistry  and  Synapsin  Reporter  Activity  in  NiNs  
Generated  with  p(CBA-­‐‑ABOL)/DNA  Polyplexes    
All  scale  bars  are  50  µμm.  Tau  stain  (first  row):  three  doses  of  1.0  µμg  pmax-­‐‑BAM  factors,  ≥  
10  days  in  N3  medium,  on  TCPS.  MAP2  stain  (second  row):  three  doses  of  1.0  µμg  pmax-­‐‑
BAM  factors  (left  panel),  or  2.0  µμg  pUNO-­‐‑AM/pmax-­‐‑B  factors  (center  and  right  panels),  
16  days  in  N3,  on  poly-­‐‑D-­‐‑lysine/laminin-­‐‑coated  coverslips.  Synaptophysin  stain  (third  
row):  five  (left  and  center  panels)  or  three  (right  panel)  doses  of  1.0  µμg  pmax-­‐‑BAM  
factors,  17  days  in  N3,  on  PDL/laminin-­‐‑coated  coverslips.  Expression  of  RFP  under  
control  of  the  synapsin  promoter  (fourth  row):  three  doses  of  1.0  µμg  pmax-­‐‑BAM  factors  
(left  and  center  panels),  or  2.0  µμg  pUNO-­‐‑AM/pmax-­‐‑B  factors  (right  panel),  ≥  10  days  in  
N3,  on  PDL/laminin-­‐‑coated  coverslips.  Synapsin-­‐‑RFP  images  have  not  been  pseudo-­‐‑
colored  red,  in  order  to  maximize  visual  contrast  for  thin  cellular  processes.  Arrows  
indicate  synapsin-­‐‑RFP+  cell  bodies.    
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5.3.5 Microfluidic Nanomanufacturing Improves the Efficiency of 
Nonviral Neuronal Cellular Reprogramming 
To  test  the  potential  of  microfluidic  nanomanufactured  polyplexes  to  enhance  
the  efficiency  of  nonviral  neuronal  reprogramming,  0.5  µμg  doses  of  pUNO-­‐‑BAM  factor  
genes  were  delivered  to  passage  two  ATCC  PMEF  cells.  Since  we  had  seen  that  
reprogramming  factors  driven  by  the  EF1α/HTLV  promoter  tend  to  generate  more  
mature  NiNs  in  greater  quantities,  we  used  strictly  pUNO  constructs  throughout  the  
testing  of  MAC  p(CBA-­‐‑ABOL)  polyplexes  (Figure  39).  This  required  the  cloning  of  
pUNO-­‐‑Brn2  by  excising  the  Brn2  coding  region  from  pmax-­‐‑Brn2  and  substituting  it  in  
place  of  Ascl1  in  pUNO-­‐‑Ascl1.  Prior  to  use,  pUNO-­‐‑Brn2  sequence  and  activity  was  
validated  by  sequencing,  immunocytochemistry,  and  Western  blot  (Figure  39).    
  
  
Figure  39.  Schematic  of  pUNO-­‐‑BAM  Factors  and  Validtion  of  pUNO-­‐‑Brn2  Activity  
  
There  was  reason  to  believe  that  MAC  polyplex  assembly  would  improve  
nonviral  neuronal  transdifferentiation.  In  all  of  our  experiments,  we  delivered  the  BAM  
factors  each  on  a  separate  plasmid.  Previous  reports  have  clearly  demonstrated  the  
importance  of  co-­‐‑expression  of  all  three  BAM  factors  to  produce  iNs  with  mature  
  166  
electrophysiological  phenotypes  [6],  which  we  expected  to  occur  for  a  subset  of  cells  
transfected  with  our  system.  Figure  40  below  illustrates  the  variability  in  co-­‐‑expression  
of  GFP,  RFP,  and  luciferase  reporter  constructs  co-­‐‑delivered  within  p(CBA-­‐‑ABOL)  
polyplexes  to  PMEF  cells.  While  many  cells  express  both  fluorescent  reporters,  the  levels  
of  expression  vary  significantly  and  some  cells  appear  positive  for  only  one  transgene.  
When  extrapolated  to  the  case  of  BAM  factor  expression,  it  is  no  surprise  that  there  
exists  significant  variability  in  the  resultant  downstream  responses,  namely  neuronal  
protein  expression  and  electrophysiological  capacity,  given  the  variability  in  BAM  factor  
co-­‐‑expression  the  cells  would  have  encountered  during  conversion.  It  follows  that  even  
a  modest  increase  in  transfection  levels  achieved  through  the  use  of  microfluidic  
nanomanufacturing  could  yield  a  nonlinear  improvement  in  neuronal  conversion.  In  
addition  to  improving  transfection  efficiency,  MAC  assembly  might  offer  benefits  in  
terms  of  co-­‐‑transfection  of  multiple  constructs.  MAC  particles  tend  to  have  more  
uniform  physical  properties,  so  it  stands  to  reason  that  their  compositional  uniformity  




Figure  40.  Co-­‐‑transfection  of  GFP,  RFP,  and  Luciferase  Reporter  Constructs  Delivered  
by  p(CBA-­‐‑ABOL)  Polyplexes  to  PMEF  Cells    
Delivery  of  fluorescent  reporter  constructs  illustrates  the  expected  variability  in  cellular  
co-­‐‑expression  of  BAM  factors  during  nonviral  neuronal  reprogramming.  
  
Quantifying  the  efficiency  of  MAC  particle  mediated  nonviral  reprogramming  
was  performed  as  previously  described.  The  gross  conversion  efficiency  measured  by  
the  percent  Tuj1+  cells  was  determined  as  before  by  automated  microscopy  and  image  
cytometry  of  entire  culture  wells.  Single  and  repeated  transfections  of  PMEFs  were  
performed,  along  with  bulk  controls,  and  assayed  10  days  after  the  final  transfection.  In  
the  case  of  single  transfections,  we  found  that  1.2  ±  0.6  percent  of  cells  were  converted  
with  bulk  nanoparticles,  while  8.1  ±  0.8  percent  were  converted  with  MAC  polyplexes  
(Figure  41).  Due  to  the  increased  susceptibility  of  ATCC  PMEFs  to  cytotoxicity,  the  
efficiency  of  conversion  mediated  by  serial  transfections  exhibited  significant  variability.  
Conversion  efficiencies  as  high  as  21  percent  were  recorded,  which  represents  in  
improvement  upon  the  maximum  achieved  in  prior  nonviral  reports,  but  the  variability  
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precluded  the  establishment  of  statistical  significance.  However,  the  improvement  in  
neuronal  conversion  efficiency  derived  from  the  use  of  microfluidic  nanomanufactured  
p(CBA-­‐‑ABOL)  BAM  factor  polyplexes  in  place  of  bulk  prepared  particles  is  evident  in  
the  single  dose  experiments.    
  
  
Figure  41.  Enhancement  of  Cellular  Reprogramming  with  Nanomanufactured  
Polyplexes  
Using  microfluidic  nanomanufactured  complexes  to  deliver  the  BAM  factors,  we  are  
able  to  improve  the  efficiency  of  nonviral  neuronal  reprogramming,  achieving  a  6-­‐‑fold  




5.3.6 Substrate Topography Improves the Efficiency of Nonviral 
Neuronal Cellular Reprogramming 
To  assess  the  potential  of  cell-­‐‑substrate  interactions  to  influence  the  process  of  
nonviral  neuronal  transdifferentiation,  we  applied  the  reprogramming  protocol  on  
multi-­‐‑architecture  (MARC)  chips  fabricated  from  PDMS  containing  17  distinct  
topographies  consisting  of  micro-­‐‑,  nano-­‐‑,  and  hierarchical  combination  pattern  features  
(Table  3).  
Table  3:  Multi-­‐‑Architecture  (MARC)  Chip  Topographies  
ID  #   Pattern  Description  
1   250  nm  lines,  250  nm  space,  250  nm  depth  
  
2   250  nm  lines,  250  nm  space,  150  nm  depth  
  
3   460  nm  lines,  70  nm  space  
  
4   2  µμm  lines,  2  µμm  space  
  
5   1  µμm  lines,  2  µμm  space  
  
6   2  µμm  lines,  1  µμm  space  
  
7   2  µμm  lines  ⊥  250  nm  line  
  
8   2  µμm  lines  //  250  nm  line  
  
9   2  µμm  lines  250  nm  pillar  
  
10   1  µμm  pitch  microlens  concave  
  
11   1  µμm  pitch  microlens  convex  
  
12   1.8  µμm  diameter,  2  µμm  pitch  microlens  concave  
  
13   1.8  µμm  diameter,  2  µμm  pitch  microlens  convex  
  
14   2  µμm  pillars,  12  µμm  pitch  
  
15   1  µμm  holes,  9  µμm  pitch  
  
16   250  nm  pillars  
  
17   Control  –  no  pattern  –  plain  PDMS  
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First,  we  tested  whether  any  of  the  patterns  would  result  in  increased  
transfection  efficiency  using  p(CBA-­‐‑ABOL)  polyplexes.  We  delivered  0.25  cm-­‐‑2  doses  of  
pmax-­‐‑GFP  to  PMEF  cells  seeded  on  MARC  chips  and  quantified  transfection  efficiency  
by  image  cytometry  after  24  hours.  We  found  no  significant  difference  in  the  fraction  of  
cells  that  were  GFP+  amongst  the  different  patterned  regions.  Image  cytometry  was  used  
for  quantification,  instead  of  flow  cytometry,  because  it  is  not  straightforward  to  isolate  
cells  from  separate  patterned  regions  on  the  MARC  chip.  We  next  delivered  single  0.25  
cm-­‐‑2  doses  of  pUNO-­‐‑BAM  factors  in  p(CBA-­‐‑ABOL)  polyplexes  to  PMEFs  on  MARC  
chips  to  screen  for  influence  on  the  reprogramming  process.  After  transfection  and  
maturation,  cells  were  stained  for  Tuj1  and  quantified  by  image  cytometry.  PMEFs  
cultured  on  flat  PDMS  were  converted  to  Tuj1+  cells  at  a  rate  of  0.8  ±  0.4  percent.  The  
majority  of  patterns  tested  did  not  yield  a  significant  effect  on  the  reprogramming  
efficiency  in  either  direction.  However,  we  identified  five  patterns  that  did  result  in  a  
significantly  higher  rate  of  conversion  to  Tuj1+  cells  (Figures  42  and  43).  These  patterns  
included  2  µμm  pillars  with  12  µμm  pitch,  1  µμm  holes  with  9  µμm  pitch,  2  µμm  lines  with  
hierarchical  perpendicular  250  nm  lines,  2  µμm  lines  with  hierarchical  parallel  250  nm  
lines,  and  2  µμm  lines  with  hierarchical  250  nm  pillars.  Interestingly,  isolation  of  the  
components  of  the  hierarchical  patterns  did  not  yield  the  same  effects.  Microgratings  
(patterns  4  and  5)  or  nanogratings  (patterns  1  and  2)  alone  are  insufficient  to  improve  the  
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conversion  efficiency.  However,  their  hierarchical  combination  results  in  a  significant  
increase  in  the  production  of  Tuj1+  NiNs.      
  
  
Figure  42.  Tuj1  Immunostaining  of  PMEFs  Reprogrammed  on  MARC  Chips  with  
pUNO-­‐‑BAM  Factors  Delivered  by  p(CBA-­‐‑ABOL)  Polyplexes    
PMEFs  cultured  on  flat  PDMS  were  converted  to  Tuj1+  cells  at  a  rate  of  0.8  ±  0.4  percent.  
Five  patterns  resulted  in  a  significantly  higher  rate  of  conversion  to  Tuj1+  cells.  These  
patterns  included  2  µμm  pillars  with  12  µμm  pitch,  1  µμm  holes  with  9  µμm  pitch,  2  µμm  lines  
with  hierarchical  perpendicular  250  nm  lines,  2  µμm  lines  with  hierarchical  parallel  250  
nm  lines,  and  2  µμm  lines  with  hierarchical  250  nm  pillars.  Interestingly,  isolation  of  the  
components  of  the  hierarchical  patterns  did  not  yield  the  same  effects.  Microgratings  or  
nanogratings  alone  are  insufficient  to  improve  the  conversion  efficiency.  However,  their  












Figure  43.  Enhancement  of  Cellular  Reprogramming  with  Substrate  Topography    
Quantification  of  the  generation  of  Tuj1+  cells  on  distinct  MARC  chip  patterns  following  
normalization  to  the  transfection  efficiency  measured  for  each  pattern.  
  
5.3.7 Nonvirally-Induced Neuronal Cells Exhibit Electrophysiological 
Function 
Given  the  increased  heterogeneity  in  maturity  and  completeness  of  NiNs  
compared  to  conventional  iNs,  we  expected  that  upstream  markers  of  neurogenesis,  
such  as  tau  [6]  or  MAP2  promoter  activity  [230],  would  likely  be  less  useful  in  NiNs  for  
predicting  active  membrane  properties.  Accordingly,  we  transduced  NiNs  with  a  
lentiviral  reporter  driving  expression  of  RFP  under  the  control  of  the  highly  neuron-­‐‑
specific  synapsin  I  promoter  [248,  249],  in  order  to  help  us  identify  the  most-­‐‑mature  
NiNs  for  electrophysiological  characterization.  This  lentivirus  may  have  a  natural  
tropism  for  excitatory  cortical  neurons  [246],  which  are  similar  to  the  predominant  
subtype  generated  by  ectopic  BAM  expression  in  PMEFs  [6].  
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The  presence  of  synapsin-­‐‑RFP  in  long  processes  of  NiNs  was  used  to  identify  
cells  for  electrophysiological  recording.  Twelve  out  of  thirteen  synapsin-­‐‑RFP+  cells  
produced  with  three  doses  of  1.0  µμg  pmax-­‐‑BAM  factors  fired  single  action  potentials  in  
response  to  depolarizing  current  injection  as  shown  in  (Figure  44).  These  cells  had  an  
average  resting  membrane  potential  of  -­‐‑46.3  ±  2.2  mV  (mean  ±  SEM,  n  =  12),  and  an  
average  input  resistance  of  1.7  ±  0.3  GΩ  (mean  ±  SEM,  n  =  11).  Twelve  out  of  thirteen  
synapsin-­‐‑RFP+  cells  produced  with  three  doses  of  2.0  µμg  pUNO-­‐‑AM/pmax-­‐‑B  factors  
fired  at  least  one  action  potential  in  response  to  depolarizing  current  injection.  Further,  
5/13  of  these  cells  fired  multiple  action  potentials  as  shown  in  Figure  44,  and  7/13  fired  
single  action  potentials.  One  cell  was  observed  firing  spontaneous  trains  of  action  
potentials  (Figure  44,  0  pA),  and  rebound  action  potentials  were  also  recorded.  These  
cells  had  an  average  resting  membrane  potential  of  -­‐‑41.7  ±  2.4  mV  (mean  ±  SEM,  n  =  12),  
and  an  average  input  resistance  of  1.5  ±  0.2  GΩ  (mean  ±  SEM,  n  =  12).  Results  are  for  
recordings  with  freely-­‐‑fluctuating  resting  membrane  potentials,  though  maintaining  the  
cells  at  ~  -­‐‑65  mV  with  holding  current  between  recordings  did  occasionally  result  in  
more-­‐‑clearly  defined  trains  of  action  potentials.  Qualitatively,  we  observed  that  cells  
firing  trains  of  action  potentials  tended  to  be  larger  and  expressed  synapsin-­‐‑RFP  more-­‐‑




Figure  44.  Electrophysiological  Activity  of  NiNs  
Current  clamp  in  the  whole-­‐‑cell  configuration  of  synapsin-­‐‑RFP+  NiNs  generated  with  
p(CBA-­‐‑ABOL)/DNA  polyplexes.  (a)  and  (b)  are  traces  of  cells  that  received  three  doses  
of  1.0  µμg  pmax-­‐‑BAM  factors,  after  16-­‐‑17  days  of  culture  in  N3  medium,  on  poly-­‐‑D-­‐‑
lysine/laminin-­‐‑coated  coverslips.  (c)  and  (d)  are  traces  of  cells  that  received  three  doses  




Our  aim  in  this  study  was  to  demonstrate  nonviral  direct  neuronal  
transdifferentiation  in  an  effort  to  bring  cellular  reprogramming  one  step  closer  to  viable  
clinical  translation.  We  hypothesized  that  multiple  doses  of  reprogramming  factors  
would  be  required  to  generate  non-­‐‑virally-­‐‑induced  neuronal  cells  (NiNs)  efficiently.  We  
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used  the  three  neuronal  reprogramming  factors  Brn2,  Ascl1,  and  Myt1l  (BAM)  in  
separate  nonviral  plasmids.  Accordingly,  we  expect  the  proportion  of  cells  that  receive  
and  express  all  three  transgenes  to  be  lower  than  that  of  those  expressing  only  one  or  
two  [250].  The  fraction  of  cells  co-­‐‑expressing  all  three  can  be  roughly  estimated  by  
considering  the  fraction  of  cells  positive  for  a  single  reporter,  and  raising  it  to  the  power  
n  =  number  of  transgenes  that  must  be  co-­‐‑expressed.  This  worst-­‐‑case  is  mitigated  
somewhat  by  our  inclusion  of  all  three  factors  in  the  same  polyplexes,  such  that  they  are  
co-­‐‑delivered,  but  it  is  helpful  to  realize  the  large  benefit  high  transfection  efficiencies  
have  on  co-­‐‑expression  of  multiple  plasmids.  Previous  reports  have  clearly  demonstrated  
the  importance  of  co-­‐‑expression  of  all  three  BAM  factors  to  produce  iNs  with  mature  
electrophysiological  phenotypes  [6],  which  we  expected  to  occur  for  a  subset  of  cells  
transfected  with  our  system.  Poly(CBA-­‐‑ABOL)  is  a  highly-­‐‑efficient  and  non-­‐‑toxic  gene  
carrier  that  is  rapidly  degraded  upon  delivery  to  the  reducing  intracellular  environment,  
for  favorable  unpacking  [22].  In  our  hands,  p(CBA-­‐‑ABOL)  outperforms  most  
commercially-­‐‑available  transfection  reagents  in  vitro.  The  high  efficiency  and  low  
cytotoxicity  of  this  gene  carrier  is  key  to  the  success  of  the  current  study,  as  serial  
multiple-­‐‑plasmid  transfections  are  helpful  for  efficient  NiN  generation.  
Optimization  of  PMEF  transfection  demonstrated  that  p(CBA-­‐‑ABOL)  polyplexes  
are  nontoxic  for  doses  that  elicit  robust  transgene  expression.  A  2.0  µμg  dose  was  
identified  as  the  highest  dose  suitable  for  serial  delivery  without  toxicity  concern.  
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Poly(CBA-­‐‑ABOL)  is  more  efficient  and  less  toxic  than  Lipofectamine  2000,  which  we  
deemed  to  be  inappropriate  for  multiple  dose  delivery  due  to  its  compounding  toxicity.  
Maintenance  of  high  transfection  efficiencies  upon  administration  of  a  second  dose  is  
likely  due  to  re-­‐‑transfection  of  fibroblasts  silencing  the  transgenes,  as  well  as  from  
transfection  of  newly-­‐‑divided  PMEFs  replacing  those  lost  to  toxicity.  The  increase  in  
expression  levels  for  2.0  µμg  compared  to  1.0  µμg  is  important,  particularly  if  there  is  a  
threshold  level  of  reprogramming  factor  that  must  be  expressed  in  a  given  cell  to  induce  
transdifferentiation  [251,  252].    
Using  1.0  µμg  of  pmax-­‐‑BAM  factors,  we  observed  dramatic  ectopic  expression  of  
BAM  factor  mRNA  and  endogenous  activation  of  Ascl1,  but  no  upregulation  of  MAP2  
or  Tuj1  mRNA.  However,  the  presence  of  Tuj1  and  MAP2  at  the  protein  level  highlights  
the  necessity  of  FACS  enrichment  or  single-­‐‑cell  PCR  [253]  when  attempting  to  analyze  
NiN  mRNA  amidst  a  background  population  of  unconverted  cells.  The  exogenous  BAM  
factors  were  silenced  to  a  large  extent  by  day  10  in  N3  medium,  supporting  the  use  of  
this  technique  as  a  transient  expression  system.  Integration  of  nonviral  DNA  vectors  
occurs  rarely  [237,  239,  254],  but  direct  neuronal  transdifferentiation  is  superior  to  iPSC  
systems  in  this  regard  in  that  sporadic  BAM  factor  reactivation  would  lead  to  growth  
arrest,  rather  than  cell  proliferation.  
The  morphological  heterogeneity  of  Tuj1+  cells  generated  by  our  technique  is  
further  confirmation  of  Tuj1+  as  an  early  or  promiscuous  marker  of  induced  
  177  
neurogenesis  [252].  However,  a  subset  of  these  cells  have  more  complete  neuronal  
morphologies  and  phenotypes,  and  increasing  the  number  of  Tuj1+  cells  is  therefore  
likely  predictive  of  an  increased  number  of  more-­‐‑mature  NiNs  at  downstream  analysis  
points.  The  nonlinear  improvement  in  the  efficiency  of  Tuj1  induction  with  an  increasing  
number  of  serial  transfections  may  be  a  consequence  of  the  re-­‐‑transfection  of  individual  
cells  that  did  not  initially  express  sufficient  transcription  factor  to  surpass  the  threshold  
required  for  transdifferentiation,  and  also  of  the  potential  continued  proliferation  and  
subsequent  transfection  of  unconverted  PMEFs.    
In  accordance  with  the  mixture  of  fibroblastic  and  neuron-­‐‑like  Tuj1+  cell  
morphologies,  immunofluorochemistry  revealed  a  similar  heterogeneity  in  the  
expression  of  pan-­‐‑neuronal  markers.  Delivering  separate  transcription  factors  with  both  
pmax-­‐‑BAM  and  pUNO-­‐‑BAM  plasmids  resulted  in  some  more-­‐‑mature  NiNs  that  
expressed  MAP2,  distal  tau  enrichment,  Tuj1,  synaptophysin  punctae,  and  had  synapsin  
promoter  activity,  as  well  as  some  less-­‐‑mature  cells  that  expressed  only  subsets  of  these  
markers.  These  less-­‐‑complete  neuron-­‐‑like  cells  may  have  received  an  inappropriate  
timing,  amount,  or  mixture  of  transcription  factors,  or  may  have  been  in  the  process  of  
becoming  fully-­‐‑reprogrammed  NiNs.  Though  heterogeneous  on  the  population  level,  
the  presence  of  non-­‐‑virally-­‐‑induced  markers  of  maturing  neuronal  cells  (synapsin  
promoter  activity,  synaptophysin  punctae)  foreshadowed  the  neuron-­‐‑like  
electrophysiological  properties  exhibited  by  these  cells.  
  178  
The  synapsin-­‐‑RFP  reporter  was  excellent  at  predicting  which  cells  would  fire  
action  potentials,  with  24/26  patched  cells  firing.  These  cells  had  heterogeneous  resting  
membrane  potentials,  action  potential  thresholds,  action  potential  amplitudes,  and  
number  of  action  potentials.  We  observed  action  potentials  after  hyperpolarization,  and  
spontaneous  action  potentials  for  NiNs  generated  with  2.0  µμg  pUNO-­‐‑AM/pmax-­‐‑B  
factors.  These  heterogeneous  active  membrane  properties  are  again  likely  indicative  of  
the  disparate  combinations  of  BAM  factors  the  cells  receive  during  nonviral  
transdifferentiation,  producing  NiNs  in  different  stages  of  maturity  and  completion.  
NiNs  generated  with  pmax-­‐‑BAM  factors  were  electrophysiologically  similar  to  
iNs  produced  with  lentiviral  transduction  of  Ascl1  only  [6].  Ascl1  is  the  only  member  of  
the  BAM  factors  that  is  able  to  generate  cells  with  active  membrane  responses  on  its  
own.  As  such,  if  a  population  of  cells  tends  to  receive  a  supra-­‐‑threshold  dose  of  only  one  
of  the  transcription  factors,  Ascl1  cells  may  be  the  only  ones  detected  as  synapsin-­‐‑RFP+.  
pmax-­‐‑BAM  vectors  may  be  silenced  before  an  expression  time  has  been  reached  that  is  
sufficient  for  Brn2  or  Myt1l  to  act,  or  the  more-­‐‑prevalent  pmax-­‐‑Ascl1  transcript  may  
have  out-­‐‑competed  pmax-­‐‑Brn2  and  -­‐‑Myt1l  for  translational  machinery  [255].  The  2.0  µμg  
dose  of  pUNO-­‐‑AM/pmax-­‐‑B  factors  may  have  elicited  higher  (or  more  balanced)  overall  
expression  levels  compared  to  1.0  µμg  of  pmax-­‐‑BAM  factors.  The  use  of  separate  
plasmids  would  allow  simple  alteration  of  BAM  plasmid  ratios  to  correct  such  an  
imbalance,  if  necessary.  
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It  is  now  established  that  functional  NiNs  can  be  produced  by  nonviral  gene  
delivery  methods,  and  that  the  transfection  process  plays  a  large  role  in  the  efficiency  of  
reprogramming.  Furthermore,  it  has  already  been  demonstrated  that  microfluidic  
nanomanufactured  particles  are  capable  of  transfecting  a  greater  number  of  PMEF  cells  
than  bulk-­‐‑prepared  particles,  while  also  producing  much  higher  overall  transgene  
expression  levels.  It  was  natural  to  combine  these  two  capabilities  to  improve  the  
transdifferentiation  of  fibroblasts  to  functional  neuronal  cells.  Some  groups  have  
generated  polycistronic  BAM  expression  constructs,  which  certainly  increase  the  
likelihood  of  co-­‐‑expression  within  cells  and  likely  increase  the  reprogramming  
efficiency.  However,  such  approaches  prevent  the  straightforward  substitution  of  factors  
and  adjustment  of  their  ratios.  As  the  field  expands  and  new  factors  continue  to  emerge  
to  direct  transdifferentiation  toward  specific  neuronal  subtypes,  the  facile  substitution  
and  adjustment  of  factors  will  remain  necessary,  at  least  in  the  preliminary  stages  of  
optimization.  Even  with  these  limitations,  we  were  able  to  increase  the  conversion  
efficiency  of  a  single  dose  by  more  than  four  times,  and  achieve  greater  than  twenty  
percent  conversion  with  serial  dosing.  
In  addition  to  their  genetic  programs,  cells  respond  to  topographical  cues  from  
their  extracellular  microenvironment  during  development  and  maintenance.  Contact  
guidance  is  a  mechanism  by  which  physical  stimuli  induce  cellular  responses.  Neurons  
migrate  along  tracks  of  radial  glia  during  development,  while  axon  regeneration  
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following  peripheral  nerve  injury  takes  places  along  tracks  created  by  Schwann  cells  
[256].  The  effects  of  substrate  topography,  including  isotropic  pits  and  pillars,  
anisotropic  gratings,  and  random  and  aligned  electrospun  fibers,  on  the  rate  and  fate  of  
neuron  progenitor  and  stem  cell  differentiation  have  also  been  studied  [257].  It  has  
recently  been  shown  that  the  incorporation  of  substrate  topography  into  the  tissue  
culture  polystyrene  used  for  lentiviral  neuronal  transdifferentiation  can  improve  the  
yield  and  purity  of  the  iNs  produced  [258].  They  found  that  5  µμm  gratings  improved  
both  of  these  parameters.  However,  in  vivo  cells  experience  a  wide  variety  of  features  
that  range  from  the  microscale  to  nanoscale,  and  studying  a  limited  range  of  microscale  
patterns  is  unlikely  to  capture  the  full  range  of  influence.  Topography  feature  size  affects  
progenitor  and  stem  cell  differentiation,  cell  morphology,  and  neurite  length,  alignment,  
and  branching  [257].  We  found,  by  testing  17  distinct  patterns  simultaneously  in  the  
same  culture,  that  the  inclusion  of  both  microscale  and  nanoscale  features  into  the  same  
substrate  was  necessary  to  achieve  the  greatest  improvement  in  reprogramming  
efficiency.  Further,  both  isotropic  and  anisotropic  patterns  demonstrated  ability  to  
improve  nonviral  neuronal  transdifferentiation.  
These  results  are  the  first  example  of  nonviral  direct  neuronal  
transdifferentiation.  We  believe  this  method  will  prove  useful  in  the  nonviral  production  
of  subtype-­‐‑specific  neuronal  cells,  as  well  as  provide  an  accessible  means  of  generating  
iNs  without  lentivirus.  Lentiviral  protocols  have  demonstrated  that  adult  human  cells  
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may  be  intrinsically  more  resistant  to  neuronal  transdifferentiation  than  are  embryonic  
mouse  cells,  and  as  such  our  nonviral  approach  can  benefit  from  further  increases  in  
efficiency  as  it  is  deployed  in  human  cells.  The  effectiveness  of  the  nonviral  technique  
will  undoubtedly  improve  as  polycistronic  vectors  for  iN  generation  become  more  
readily  available  [230,  232],  which,  by  removing  redundant  plasmid  backbone  sequences  
will  increase  the  effective  dose  of  each  factor,  and  ensure  co-­‐‑expression  of  all  factors  in  
transfected  cells.  Work  is  underway  to  modify  these  polycistronic  vectors  for  nonviral  
use  in  adult  human  cells  to  generate  human  NiNs  at  a  sufficient  density  to  allow  study  
of  their  synaptic  properties,  their  designation  as  “fully-­‐‑mature”  iNs  [252],  and  to  achieve  
a  therapeutic  efficiency.  The  recent  discovery  that  small  molecules  can  greatly  boost  the  
efficiency  of  neuronal  transdifferentiation  is  also  expected  to  help  reach  this  goal  [259].  
Subtype-­‐‑specific  human  NiN  generation  will  likely  require  a  longer  pulse  of  ectopic  
expression  [171],  which  will  further  rely  on  the  unique  non-­‐‑toxicity  of  p(CBA-­‐‑ABOL).  
Though  the  non-­‐‑integrative  requirement  for  ex  vivo  generation  of  non-­‐‑proliferative  
therapeutic  NiNs  is  relaxed  compared  to  iPSCs,  mRNA  vectors  will  be  of  interest,  but  
may  need  to  be  delivered  even  more  frequently  to  maintain  sufficient  expression  levels  
given  their  significantly  shorter  intracellular  half-­‐‑lives.  
When  the  scalability  of  p(CBA-­‐‑ABOL)  synthesis  is  taken  together  with  successful  
demonstration  of  iMN  [231]  and  iDA  [171]  engraftment  and  iDA  functional  
improvement  in  animal  models  of  Parkinson’s  [172,  229],  the  goal  of  cell  replacement  
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therapies  using  iNs  for  a  number  of  neurodegenerative  diseases  seems  attainable.  For  
example,  if  this  nonviral  method  is  modified  with  a  different  TF  cocktail  to  produce  
functional  dopaminergic  neurons  with  five  1  µμg  doses  at  a  7.5%  efficiency,  only  ~  0.5%  of  
a  typical  p(CBA-­‐‑ABOL)  synthesis  and  ~  1%  of  a  Plasmid  Giga  Kit  product  would  be  
required  to  generate  enough  neurons  to  produce  phenotype  correction  in  a  Parkinsonian  
rat  [172].  The  benefit-­‐‑to-­‐‑risk  ratio  of  neuroprotective  AAV  gene  therapy  to  combat  PD  is  
already  deemed  high  enough  to  warrant  clinical  trials  [260],  so  the  introduction  of  an  
ethically  and  technically  viable  autologous  nonviral  source  of  neuronal  cells  should  be  of  
great  therapeutic  value.  The  reduced  risk  of  insertion  mutagenesis  with  this  nonviral  
approach  should  lower  the  entry  barrier  for  a  variety  of  neurological  diseases  even  
further.  Further,  our  demonstration  of  NiN  generation  is  suggestive  of  the  feasibility  of  




6. Conclusions and Future Perspectives 
6.1 Conclusions 
  This  dissertation  describes  efforts  to  extend,  evaluate,  improve,  and  apply  a  
reliable  and  scalable  microfluidic  nanomanufacturing  platform  to  generate  polymer-­‐‑
nucleic  acid  nanocomplexes  with  better-­‐‑controlled  characteristics  and  improved  
functional  performance.  Through  these  results,  we  have  contributed  to  the  improvement  
of  nonviral  gene  transfer  and  cellular  reprogramming  by:  1)  selecting  and  synthesizing  a  
promising  polymeric  gene  carrier  while  optimizing  its  delivery  strategy  to  facilitate  
serial  dosing  without  compounding  cytotoxicity,  2)  implementing  emulsion-­‐‑based  
microfluidic  nanomanufacturing  techniques  to  improve  the  physicochemical  
characteristics  and  functional  performance  of  the  chosen  nanoparticles,  and  3)  applying  
these  more  potent  nanoparticles  to  increase  the  efficiency  of  nonviral  cellular  
reprogramming  of  fibroblasts  to  functional  induced  neurons.    
We  first  attempted  to  improve  upon  the  modestly  successful  high  molecular  
weight  chitosan  carrier  system  that  has  been  used  previously.  However,  efforts  to  solve  
the  known  issue  of  overly  stable  binding  through  payload  substitution,  adjustment  of  
molecular  weight  and  charge  density,  and  the  addition  of  the  ternary  anionic  component  
PGA  all  proved  inadequate  to  significantly  improve  transfection  levels.  We  
subsequently  pivoted  our  efforts  to  an  alternative  carrier  system  -­‐‑  a  bioreducible  linear  
poly(amido  amine)  able  to  give  sustained,  robust  transgene  expression  through  serial  
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dosing.  Poly(CBA-­‐‑ABOL)  possesses  an  inherent  degradative  response  mechanism  to  
changes  encountered  in  the  redox  environment  while  transitioning  from  the  
extracellular  space  to  the  cytoplasmic  domain.  It  is  designed  to  unpack  efficiently  within  
cells,  and  to  break  down  quickly  to  minimize  associated  sequelae.  Following  selection  
and  synthesis  of  this  promising  carrier,  we  showed  that  it  forms  polyplexes  of  
appropriate  size  and  charge,  dissociates  readily  upon  challenge  with  intracellular  
concentrations  of  reducing  agents,  and  transfects  cells  efficiently.  We  also  demonstrated  
its  ability  to  achieve  modest  levels  of  transfection  in  vivo,  and  show  that  its  favorable  
cytotoxicity  profiles  allows  for  repeated  dosing  in  order  to  sustain  high  transgene  
expression  levels.      
Next,  we  reported  the  benefits  of  applying  a  microfluidic  nanomanufacturing  
approach  to  better  control  the  preparation  of  polyplexes  and  to  produce  more  uniform  
and  more  potent  delivery  systems.  While  polymer-­‐‑DNA  nanocomplexes  have  been  
synthesized  by  microfluidics,  to  our  knowledge  this  is  the  first  example  of  the  
production  of  polymer-­‐‑RNA  nanocomplexes  with  a  droplet-­‐‑based  microfluidic  
nanomanufacturing  approach,  as  well  as  the  first  time  that  QD-­‐‑FRET  has  been  used  in  
combination  with  flow  cytometry  to  quantify  the  intracellular  unpacking  of  polymer-­‐‑
DNA  nanocomplexes.  We  have  demonstrated  that  nanomanufactured  polyplexes  
exhibit  significant  and  consistent  decreases  in  size,  zeta  potential,  and  polydispersity  
relative  to  complexes  synthesized  by  traditional  bulk  methods.  Both  DNA-­‐‑  and  RNA-­‐‑
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loaded  nanocomplexes  exhibit  increased  colloidal  and  binding  stability,  as  quantified  by  
fluorescence-­‐‑based  competitive  binding  assays.  Transfection  was  significantly  improved  
in  a  broad  range  of  cell  types,  in  terms  of  both  the  number  of  cells  transfected  and  gross  
transgene  expression.  We  ascribed  this  improvement  in  part  to  a  more  gradual  release  of  
nucleic  acids  offered  by  the  more  stable  microfluidic  nanomanufactured  nanocomplexes,  
evidenced  by  the  retarded  decline  of  intracellular  QD-­‐‑FRET  emission.    
The  increased  transfection  efficiency  and  diminished  toxicity  of  p(CBA-­‐‑ABOL)  
nanomanufactured  particles  are  especially  advantageous  in  applications  requiring  high  
levels  of  transgene  expression  and  repeated  administration.  One  such  application  is  the  
nonviral  direct  cellular  reprogramming  of  fibroblasts  to  neurons.  In  an  effort  to  address  
the  lack  of  a  safe  and  ethical  source  of  therapeutic  cells  to  treat  neurodegenerative  
diseases,  we  developed  a  nonviral  transfection  strategy  to  deliver  genes  encoding  the  
transcription  factors  necessary  to  convert  fibroblasts  directly  to  functional  neuronal  cells.  
Nonviral  cellular  reprogramming  strategies  eliminate  the  integration  of  viral  DNA  
sequences  and  represent  a  potentially  safer  alternative  to  viral  transdifferentiation  
methods.  Our  method  produced  neuronal  cells  with  appropriate  morphological  
changes,  activation  and  expression  of  endogenous  neuronal  markers,  and  
electrophysiological  function.  Delivery  of  the  reprogramming  factors  with  microfluidic  
nanomanufactured  particles  significantly  improved  the  efficiency  of  this  nonviral  
neuronal  transdifferentiation,  which  is  a  critical  parameter  in  the  effort  to  generate  a  
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sufficient  supply  cells  for  potential  transplantation  given  the  postmitotic,  non-­‐‑
proliferative  nature  of  neurons.  To  achieve  the  primary  goal  of  sustained  and  robust  
transgene  expression,  this  work  endeavored,  through  optimization  of  polymer-­‐‑nucleic  
acid  nanocomplex  formulation  and  application,  to  alleviate  the  paucity  of  uniform,  
potent,  biocompatible,  and  reproducibly  generated  gene  carriers  that  are  able  to  satisfy  
the  contrary  requirements  of  adequate  nucleic  acid  protection  and  efficient  release.  
6.2 Future Perspectives  
By  validating  the  merits  of  microfluidic  nanomanufacturing  with  a  range  of  
carriers,  nucleic  acid  payloads,  and  cell  types,  we  have  provided  justification  for  the  
further  translation  of  the  platform.  Due  to  the  role  of  physical  particle  properties  in  
uptake,  endocytosis,  circulatory  retention,  and  toxicity,  the  development  of  precise  
structure-­‐‑function  correlations  requires  a  reliable  technique  to  produce  uniform  
particles.  The  increased  consistency  of  nanomanufactured  particles,  and  subsequent  
reduced  variances  in  cellular  and  systemic  processing,  has  the  potential  provide  more  
accurate  mechanistic  and  pharmacodynamic  data  for  the  rational  design  of  better  gene  
carriers.  Furthermore,  nonviral  gene  delivery  will  continue  to  demand  more  
sophisticated  delivery  systems,  such  as  multi-­‐‑functional  particles  endowed  with  
targeting,  imaging  and  environmental-­‐‑sensitive  functionalities.  Better  control  of  the  self-­‐‑
assembly  of  these  types  of  particles  will  be  even  more  critical.  We  have  not  explicitly  
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addressed  the  scale-­‐‑up  issue,  however  the  microfluidics  approach  is  certainly  scalable  
using  arrayed  channel  designs  and  parallel  chips.    
Our  protocol  for  nonviral  neuronal  cellular  reprogramming  is  expected  to  be  
readily  adaptable  to  other  direct  transdifferentiation  strategies  as  new  reprogramming  
factors  are  identified.  The  capacity  of  our  carrier  system  to  deliver  a  variety  of  nucleic  
acid  payloads  provides  the  opportunity  to  deliver  alternative  payloads  including  
mRNA,  siRNA,  and  protein  factors  should  they  eventually  prove  superior  to  plasmid  
DNA  in  some  applications.  Safe  and  efficient  cellular  reprogramming  may  represent  the  
most  realistic  treatment  on  the  horizon  for  neurodegenerative  disease  in  the  near-­‐‑term.  
Further  development  of  the  physical  culture  conditions  and  nonviral  carrier  systems  
used  to  transfer  reprogramming  factors  promises  to  not  only  continue  to  add  to  our  
collective  understanding  of  transdifferentiation  processes,  but  also  move  the  technology  
closer  to  successful  translation.  If  in  situ  transdifferentiation  proves  necessary,  the  many  
years  of  engineering  spent  developing  nonviral  carriers  for  in  vivo  delivery  will  provide  
an  excellent  starting  point.  Whether  the  future  calls  for  in  vivo  or  ex  vivo  nonviral  
cellular  reprogramming,  there  will  be  a  demand  for  a  reproducible  and  scalable  
platform  to  produce  uniform  and  potent  delivery  systems.  Microfluidic  
nanomanufacturing  of  polymer-­‐‑nucleic  acid  nanocomplexes  represents  an  important  
step  forward  in  addressing  this  critical  need.  
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